

CITATION REPORT

List of articles citing

Oral sildenafil in the treatment of erectile dysfunction.
Sildenafil Study Group

DOI: 10.1056/nejm199805143382001

New England Journal of Medicine, 1998, 338, 1397-404.

Source: <https://exaly.com/paper-pdf/29448379/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1999	Relaxation of corpus cavernosum and raised intracavernous pressure by berberine in rabbit. 1998 , 125, 1677-84		36
1998	Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men. 1998 , 15, 821-5		92
1997	Sildenafil: a revolutionary therapy?. 1998 , 15, 897-9		1
1996	La médicalisation de la sexualité: Aspects sociologiques et historiques. 1998 , 8, 383-390		3
1995	Sildenafil. 1998 , 36, 270-270		
1994	Phytothérapie in Japan. 1998 , 38, 278-290		
1993	Viagra: Facts, fiction and furore. 1998 , 15, 195-196		
1992	Oral sildenafil in erectile dysfunction. 1998 , 352, 1557		4
1991	Acute myocardial infarction associated with sildenafil. 1998 , 352, 1937		3
1990	Sildenafil: medical advance or media event?. 1998 , 351, 1599-600		25
1989	Acute myocardial infarction associated with sildenafil. 1998 , 352, 957-8		91
1988	Blue-chip technology. 1998 , 352, S2		
1987	Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. 1998 , 20, 1033-48		90
1986	SILDENAFIL, A TYPE-5 CGMP PHOSPHODIESTERASE INHIBITOR, SPECIFICALLY AMPLIFIES ENDOGENOUS cGMP-DEPENDENT RELAXATION IN RABBIT CORPUS CAVERNOSUM SMOOTH MUSCLE IN VITRO. 1998 , 160, 257-261		119
1985	Evaluation and nonsurgical management of erectile dysfunction. 1998 , 25, 647-59, ix		17
1984	An open trial of oral sildenafilin antidepressant-induced sexual dysfunction. 1998 , 67, 328-31		100
1983	Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. 1998 , 249, 612-7		124

1982	New insights into erectile dysfunction: a practical approach. 1998 , 105, 135-44		67
1981	Pupil-sparing third nerve palsy associated with sildenafil citrate (Viagra). 1998 , 126, 476-7		73
1980	Combination therapy using oral alpha-blockers and intracavernosal injection in men with erectile dysfunction. 1998 , 52, 739-43		67
1979	Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). 1998 , 52, 963-6		151
1978	Epstein-Barr virus in action in vivo. <i>New England Journal of Medicine</i> , 1998 , 338, 1461-3	59.2	25
1977	A pill for impotence. <i>New England Journal of Medicine</i> , 1998 , 338, 1458-9	59.2	30
1976	Influenza immunization for children. <i>New England Journal of Medicine</i> , 1998 , 338, 1459-61	59.2	32
1975	Sildenafil in the treatment of erectile dysfunction. <i>New England Journal of Medicine</i> , 1998 , 339, 699; author reply 701-2	59.2	20
1974	Commentary: pharmacological agents for erectile dysfunction and the human sexual response cycle. 1998 , 24, 309-12		8
1973	Fluvoxamine-induced erectile dysfunction responding to sildenafil. 1998 , 24, 313-7		22
1972	Opportunities for the treatment of erectile dysfunction by modulation of the NO axis--alternatives to sildenafil citrate. 1998 , 14, 187-202		11
1971	Enhanced external counterpulsation as a new treatment modality for patients with erectile dysfunction. 1998 , 61, 168-71		12
1970	Integrating Viagra Into Cognitive-Behavioral Couples Sex Therapy. 1998 , 23, 302-308		17
1969	NO skeletal muscle derived relaxing factor in Duchenne muscular dystrophy. 1998 , 95, 14592-3		16
1968	Erectile dysfunction: a multifaceted disorder. 1998 , 33, 65-74, 77-8, 83-9; discussion 89-90		2
1967	When patients request the impotence pill. 1998 , 104, 55-8, 61-2, 65-6		13
1966	Viagra: on release. Evidence on the effectiveness of sildenafil is good. 1998 , 317, 759-60		8
1965	Oral medications in the management of erectile dysfunction. 1998 , 11, 307-14		5

1964	KEEDB erster deutschsprachig validierter Fragebogen zur Erfassung der männlichen sexuellen Funktion. 1998 , 29, 300-305		13
1963	Facts and Ideas from Anywhere. 1998 , 11, 161-170		
1962	Guest Editor's Note. 1998 , 23, 185-186		0
1961	The Pharmacologic Management of Erectile Dysfunction: Sildenafil Citrate (Viagra). 1998 , 23, 207-216		3
1960	Viagra Beware the quick fix. 1998 , 169, 504-504		
1959	Viagra: What Every Physician Should Know. 1998 , 77, 783-786		13
1958	Sildenafil induced priapism. 1999 , 40, 215-7		18
1957	Update in general internal medicine. 1999 , 131, 199-206		3
1956	Predictors of sexual health in women after a breast cancer diagnosis. 1999 , 17, 2371-80		278
1955	Prospective pilot study of sildenafil for treatment of postradiotherapy erectile dysfunction in patients with prostate cancer. 1999 , 17, 3444-9		67
1954	Learning the regulation of peripheral blood flow. 1999 , 277, S164-73		8
1953	Basic Bibliographies. 1999 , 34, 1005-1008		
1952	Acute renal failure in a young man, 9 days after a 5-h persisting erection following Viagra: is there a causal relationship?. 1999 , 14, 2045-7		8
1951	What is causing your patient's sexual dysfunction? Uncovering a connection with hypertension and antihypertensive therapy. 1999 , 106, 149-52, 155-7		12
1950	Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. 1999 , 13, F101-7		74
1949	New options for the prevention of influenza. <i>New England Journal of Medicine</i> , 1999 , 341, 1387-8	59.2	12
1948	Inhaled nitric oxide: a premature remedy for chronic lung disease?. 1999 , 103, 667-70		8
1947	Direct sale of sildenafil (Viagra) to consumers over the Internet. <i>New England Journal of Medicine</i> , 1999 , 341, 1389-92	59.2	64

1946	Sildenafil (Viagra) for the treatment of erectile dysfunction in men with diabetes. 1999 , 25, 79-80, 83-4, 87 passim	6
1945	Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. 1999 , 99, 168-77	260
1944	Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. 1999 , 281, 421-6	440
1943	Sildenafil (Viagra) and ophthalmology. 1999 , 117, 518-9	32
1942	Treatment of erectile dysfunction in men with diabetes. 1999 , 281, 465-6	14
1941	Urology. 1999 , 281, 495-6	2
1940	Effectiveness of treatment for impotence in diabetic men. 1999 , 16, 1048-9	3
1939	Sexual dysfunction in women with diabetes mellitus: Addressing impaired arousal. 1999 , 14, 385-397	7
1938	Caution recommended. 1999 , 25, 2-5	5
1937	Phenelzine-induced sexual dysfunction treated with sildenafil. 1999 , 25, 131-5	8
1936	Assessment and management of erectile dysfunction in men with diabetes. 1999 , 25, 65-73; quiz 75	15
1935	Sildenafil (Viagra [®]) and erectile dysfunction. 1999 , 3, 99-102	
1934	Higher post-absorptive C-peptide levels in Type 1 diabetic patients without renal complications. 1999 , 16, 1048	23
1933	Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. 1999 , 22, 385-92	118
1932	Neuropeptides and sexual behaviour. 1999 , 23, 1127-42	138
1931	Progress in Interventional Cardiology. 1999 , 12, 95-98	1
1930	Intracavernosal self-injection therapy in men with erectile dysfunction: satisfaction and attrition in 119 patients. 1999 , 11, 145-51	22
1929	The process of care model for evaluation and treatment of erectile dysfunction. The Process of Care Consensus Panel. 1999 , 11, 59-70; discussion 70-4	122

1928	Intracavernosal therapy for erectile failure--impact of treatment and reasons for drop-out and dissatisfaction. 1999 , 11, 287-99	40
1927	Time dependent patient satisfaction with sildenafil for erectile dysfunction (ED) after nerve-sparing radical retropubic prostatectomy (RRP). 1999 , 11 Suppl 1, S15-22	80
1926	Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. 1999 , 11, 319-26	1970
1925	Naturalizing Myths of Aging: Reading Popular Culture. 1999 , 4, 79-109	2
1924	Acute myocardial infarction following sildenafil citrate (Viagra) intake in a nitrate-free patient. 1999 , 22, 762-3	26
1923	Socio-épidémiologie de l'impuissance masculine: Évolution des conceptions nosographiques et des données épidémiologiques. 1999 , 9, 177-190	4
1922	Use of oral sildenafil (Viagra) in the treatment of erectile dysfunction. 1999 , 25, 90-4	4
1921	[Erectile function after treatment of prostatic carcinoma]. 1999 , 175, 44-5	11
1920	Multiple Sclerosis: Symptomatic Treatment. 1999 , 1, 221-238	2
1919	Pharmacy continuing education available on the Internet. 1999 , 19, 909-21	3
1918	Erectile dysfunction and sildenafil citrate and cardiologists. 1999 , 83, 576-82, A7	60
1917	Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. 1999 , 83, 3C-12C	384
1916	Effects of sildenafil citrate on human hemodynamics. 1999 , 83, 13C-20C	280
1915	Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. 1999 , 83, 21C-28C	222
1914	Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. 1999 , 83, 29C-34C	157
1913	Overall cardiovascular profile of sildenafil citrate. 1999 , 83, 35C-44C	244
1912	Cardiovascular effects of sildenafil citrate and recommendations for its use. 1999 , 84, 11N-17N	70
1911	A new era in the treatment of erectile dysfunction. 1999 , 84, 18N-23N	21

1910	Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. 1999 , 57, 965-73	110
1909	Molecular mechanisms of the effects of sildenafil (VIAGRA). 1999 , 34, 305-18	53
1908	Urology. 1999 , 188, 198-201	1
1907	Randomized trial of sildenafil for the treatment of erectile dysfunction in spinal cord injury. Sildenafil Study Group. 1999 , 46, 15-21	130
1906	SSRI-induced sexual dysfunction treated with sildenafil. 1999 , 9, 180-182	8
1905	Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. 1999 , 162, 722-5	134
1904	Annual cost of erectile dysfunction to UK Society. 1999 , 16, 699-709	27
1903	Treatment of secondary progressive multiple sclerosis: current recommendations and future prospects. 1999 , 12, 267-77	6
1902	Sildenafil. 1999 , 1, 137-47	16
1901	Sildenafil. 1999 , 25, 271-9	11
1900	Emerging pharmacological therapies for erectile dysfunction. 1999 , 9, 1689-1696	3
1899	Psychosocial side effects of sildenafil therapy for erectile dysfunction. 1999 , 25, 145-50	21
1898	Medical treatment of erectile dysfunction. 1999 , 31, 388-98	24
1897	Sildenafil Citrate, a Selective Phosphodiesterase Type 5 Inhibitor:. 1999 , 10, 97-104	91
1896	Retinal side-effects of sildenafil. 1999 , 353, 375	77
1895	Erectile dysfunction in spina bifida is treatable. 1999 , 354, 125-6	40
1894	Male impotence. 1999 , 354, 1713-8	66
1893	Possible interaction between sildenafil and HIV combination therapy. 1999 , 353, 840	24

1892	ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. 1999 , 33, 273-82	336
1891	Advances in the diagnosis and management of impotence. 1999 , 45, 1-20	3
1890	Sildenafil (Viagra) and ophthalmology. 1999 , 44, 153-62	136
1889	EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. 1999 , 53, 793-9	326
1888	Sildenafil citrate (Viagra) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. 1999 , 53, 800-5	90
1887	Efficacy of oral sildenafil in patients with erectile dysfunction after radiotherapy for carcinoma of the prostate. 1999 , 53, 775-8	105
1886	The Internet and patient education--resources and their reliability: focus on a select urologic topic. 1999 , 53, 1117-20	74
1885	Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dysfunction. 1999 , 53, 1112-6	88
1884	Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. 1999 , 54, 346-51	804
1883	Viagra--after one year. 1999 , 54, 12-7	55
1882	Treatment of erectile dysfunction with sildenafil citrate (Viagra) after radiation therapy for prostate cancer. 1999 , 54, 308-12	66
1881	Oral pharmacotherapy for erectile dysfunction: current perspectives. 1999 , 54, 392-400	21
1880	Sex inventories: can questionnaires replace erectile dysfunction testing?. 1999 , 54, 719-23	50
1879	Sildenafil citrate (Viagra) after radical retropubic prostatectomy: con. 1999 , 54, 587-9	13
1878	Indications and early results of sildenafil (Viagra) in erectile dysfunction. 1999 , 54, 1073-7	43
1877	Posttraumatic erectile potential of spinal cord injured men: how physiologic recordings supplement subjective reports. 1999 , 80, 1268-72	39
1876	Male infertility and erectile dysfunction in spinal cord injury: a review. 1999 , 80, 1331-9	64
1875	Pharmacotherapeutic advances in the treatment of erectile dysfunction. 1999 , 74, 709-21	43

1874	THE EFFECT OF SILDENAFIL ON APOMORPHINE-EVOKED INCREASES IN INTRACAVERNOUS PRESSURE IN THE AWAKE RAT. 1999 , 161, 1707-1712	50
1873	Erectile dysfunction in the aging man. 1999 , 83, 1267-78	22
1872	SILDENAFIL CITRATE AFTER RADICAL RETROPUBIC PROSTATECTOMY. 1999 , 162, 1614-1617	112
1871	POTENTIATION OF ERECTILE RESPONSE AND cAMP ACCUMULATION BY COMBINATION OF PROSTAGLANDIN E 1 AND ROLIPRAM, A SELECTIVE INHIBITOR OF THE TYPE 4 PHOSPHODIESTERASE (PDE 4). 1999 , 162, 1848-1855	29
1870	Viagra and Cardiovascular Disease. 1999 , 4, 259-267	12
1869	Assessment of the aging man. 1999 , 83, 1131-49	3
1868	A comparison of patient and partner responses to a brief sexual function questionnaire. 1999 , 162, 1999-2002	20
1867	Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction. 1999 , 162, 726-30; discussion 730-1	36
1866	Re: Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting. 1999 , 162, 168-9	1
1865	THE CAUSES OF PATIENT DROPOUT FROM PENILE SELF-INJECTION THERAPY FOR IMPOTENCE. 1999 , 162, 1291-1294	60
1864	Sildenafil: a review of its use in erectile dysfunction. 1999 , 57, 967-89	138
1863	Endogenous nitric oxide synthesis: biological functions and pathophysiology. 1999 , 31, 577-96	574
1862	Treatment of erectile dysfunction with sildenafil. 1999 , 53, 19-24	95
1861	Dehydroepiandrosterone in the treatment of erectile dysfunction: a prospective, double-blind, randomized, placebo-controlled study. 1999 , 53, 590-4; discussion 594-5	78
1860	Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. 1999 , 53, 481-6	240
1859	Oral sildenafil may reverse secondary ejaculatory dysfunction during infertility treatment. 1999 , 72, 1144-5	17
1858	Sildenafil citrate (Viagra) treatment of sexual dysfunction in a schizophrenic patient. 1999 , 14, 353-5	12
1857	Sildenafil and sexual dysfunction associated with antidepressants. 1999 , 25, 259-64	9

1856	Acute myocardial infarction after the use of sildenafil. <i>New England Journal of Medicine</i> , 1999 , 341, 700	59.2	55
1855	Sildenafil and erectile dysfunction. 1999 , 22, 486-92		19
1854	Ways to minimize adverse drug reactions. Individualized doses and common sense are key. 1999 , 106, 163-8, 171-2		37
1853	Erectile dysfunction in patients with diabetes. 1999 , 60, 638-44		28
1852	Sildenafil: desired and undesired effects. 1999 , 60, 158-9		2
1851	Chapter 31. To Market, To Market - 1998. 1999 , 317-338		16
1850	SILDENAFIL-ORAL MEDICATION FOR ERECTILE DYSFUNCTION-A REVIEW. 1999 , 55, 233-236		2
1849	The epidemiology, anatomy, physiology, and treatment of erectile dysfunction in chronic renal failure patients. 1999 , 6, 296-309		14
1848	Drugs acting on the cerebral and peripheral circulations. 1999 , 22, 221-223		
1847	Diabetic Autonomic Neuropathy. 1999 , 12, 142-154		
1846	Pain: cause of agitation in elderly individuals with dementia. 1999 , 156, 1662-3		26
1845	Organische Chemie 1998, Teil II. 1999 , 47, 275-285		
1844	Olanzapine-induced tardive dystonia. 1999 , 156, 1662		56
1843	The diffusion of a novel therapy into clinical practice: the case of sildenafil. 2000 , 160, 3401-5		21
1842	Relative Efficacy of Sildenafil Compared to Other Treatment Options for Erectile Dysfunction. 2000 , 93, 962-965		1
1841	Reply. 2000 , 93, 1039-1040		
1840	Serum ionized magnesium in type 2 diabetes. 2000 , 93, 1038-40		3
1839	Initial results utilizing combination therapy for patients with a suboptimal response to either alprostadil or sildenafil monotherapy. 2000 , 38, 30-4		45

1838	AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. 2000 , 37, 50-5	161
1837	Gamma-hydroxybutyric acid in the right hands. 2000 , 93, 1037-8	
1836	Science, art and drug discovery: a personal perspective. 2000 , 99, 255-260	55
1835	Science, art and drug discovery: a personal perspective. 2000 , 99, 255	33
1834	Sildenafil in the treatment of sexual dysfunction in spinal cord-injured male patients. 2000 , 38, 184-93	67
1833	Reply. 2000 , 93, 1038	0
1832	The use of sildenafil in heart disease. 2000 , 61, 526-7	3
1831	Cost utility analysis of sildenafil compared with papaverine-phentolamine injections. 2000 , 320, 1165-8	48
1830	Viagra and HAART. 2000 , 93, 1037	
1829	The economics of Viagra. 2000 , 19, 147-57	30
1828	Pelvic Arterial Insufficiency and What to Do About It. 2000 , 12, 85-93	
1827	Cardiovascular pharmacology: new drugs and new indications. 2000 , 13, 5-13	1
1826	Andrology. 2000 , 10, 611-2	
1825	Quality-of-life after penile prosthesis placed at radical prostatectomy. 2000 , 15, 651-661	5
1824	Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. 2000 , 92, 1702-12	177
1823	Male sexual dysfunction--the new millennium. 2000 , 10, 313-7	3
1822	Sildenafil can increase the response to inhaled nitric oxide. 2000 , 92, 1827-9	54
1821	Safety of sildenafil. 2000 , 10, 613-5	2

1820	Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. 2000 , 18, 1865-9	77
1819	Clinical experience with intraurethral alprostadil (MUSE) in the treatment of men with erectile dysfunction. A retrospective study. Medicated urethral system for erection. 2000 , 38, 671-6	38
1818	Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. 2000 , 15, 305-8	113
1817	Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction. 2000 , 86, 469-73	31
1816	Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. 2000 , 50, 99-107	137
1815	Non-surgical management of erectile dysfunction. 2000 , 52, 253-60	16
1814	New therapies for erectile dysfunction. 2000 , 23 Suppl 2, 87-8	
1813	Central mechanisms in the control of penile erection: current theory and research. 2000 , 24, 503-5	13
1812	Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. 2000 , 24, 561-9	94
1811	Quality of life in patients with spinal cord injury receiving Viagra (sildenafil citrate) for the treatment of erectile dysfunction. 2000 , 38, 363-70	80
1810	Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction. 2000 , 12, S75-S80	52
1809	Role of alpha adrenergic receptors in erectile function. 2000 , 12, S48-S63	47
1808	Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. 2000 , 12, 165-8	43
1807	Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. 2000 , 12, 177-82	47
1806	Measurement of erectile dysfunction in population-based studies: the use of a single question self-assessment in the Massachusetts Male Aging Study. 2000 , 12, 197-204	126
1805	Medical and surgical advances in the radical prostatectomy patient. 2000 , 12 Suppl 4, S47-52	4
1804	Opportunities and challenges in oral therapy. 2000 , 12 Suppl 4, S59-61	3
1803	Sildenafil citrate: current clinical experience. 2000 , 12 Suppl 4, S62-6	3

1802	Apomorphine: an update of clinical trial results. 2000 , 12 Suppl 4, S67-73	50
1801	Developmental status of topical therapies for erectile and ejaculatory dysfunction. 2000 , 12 Suppl 4, S80-5	17
1800	Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. 2000 , 12, 305-11	715
1799	Inhibition of neuroeffector transmission in human vas deferens by sildenafil. 2000 , 131, 871-4	41
1798	Proceedings of the Symposium Paracrine Interactions of Testicular Somatic Cells□ 2000 , 32, 41-64	4
1797	In vitro effects of sildenafil and phentolamine, drugs used for erectile dysfunction, on human sperm motility. 2000 , 182, 1093-5	24
1796	Comparison of responses to siguazodan, rolipram, and zaprinast in the feline pulmonary vascular bed. 2000 , 406, 233-8	9
1795	Introduction. 2000 , 86, 1-2	2
1794	Sexual intercourse and stable angina pectoris. 2000 , 86, 35F-37F	26
1793	Evaluating the cardiovascular tolerance for sex. 2000 , 86, 51F-56F	29
1792	Cardiovascular risk and sildenafil. 2000 , 86, 57F-61F	65
1791	Importance of asking questions about erectile dysfunction. 2000 , 86, 1210-3, A5	32
1790	Assessing sexual functioning in patients with chronic disorders by using a generic health-related quality of life questionnaire. 2000 , 9, 1081-92	19
1789	Age, libido, and male sexual function. 2000 , 10, 9-13	2
1788	New treatment for erectile dysfunction. 2000 , 2, 206-10	2
1787	Sexual side effects of antidepressant drugs. 2000 , 2, 223-7	11
1786	Current status of penile prosthesis implantation. 2000 , 1, 291-6	10
1785	Oral and injectable medications for the treatment of erectile dysfunction. 2000 , 1, 307-12	6

1784	Initial clinical experience with the selective phosphodiesterase-I isoenzyme inhibitor vinpocetine in the treatment of urge incontinence and low compliance bladder. 2000 , 18, 439-43	44
1783	Profil des patients ayant une dysfonction sexuelle masculine ^ l'Hopital g�n�ral de Yaounde. 2000 , 10, 215-219	
1782	Erektile Dysfunktion nach radikaler Prostatektomie. 2000 , 16, 279-283	
1781	Incidence of erectile dysfunction after open abdominal aortic aneurysm repair. 2000 , 14, 13-9	37
1780	Acute priapism associated with the use of sildenafil in a patient with sickle cell trait. 2000 , 95, 1878-1879	31
1779	A single tube multiplex PCR method to detect the common alpha + thalassemia alleles. 2000 , 95, 1879-1879	22
1778	Clinical assessment of sildenafil in the treatment of neurogenic male sexual dysfunction: After the hype. 2000 , 15, 101-105	18
1777	Erectile dysfunction. 2000 , 11, 29-35	
1776	Erectile dysfunction: diagnosis and management with newer oral agents. 2000 , 13, 356-60	3
1775	The cost-effectiveness of sildenafil. 2000 , 132, 933-7	56
1774	Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiology Studies. 41-62	
1773	Erectile dysfunction. 2000 , 173, 492-7	8
1772	Viagra and Beyond: Where Sex Educators and Therapists Fit in From a Multidisciplinary Perspective. 2000 , 25, 17-24	7
1771	Sexual Function and Infertility Following Spinal Cord Injury. 2000 , 11, 141-156	23
1770	Sympathetic activation by sildenafil. 2000 , 102, 3068-73	101
1769	Progress in Erectile Dysfunction and Hormone Function. 2000 , 3, 169-175	
1768	Gene expression of the phosphodiesterases 3A and 5A in human corpus cavernosum penis. 2000 , 38, 108-14	26
1767	Acute, Symptomatic Atrial Fibrillation after Sildenafil Citrate Therapy in a Patient with Hypertrophic Obstructive Cardiomyopathy. 2000 , 320, 69-71	6

1766	Effects of sildenafil (Viagra) administration on seminal parameters and post-ejaculatory refractory time in normal males. 2000 , 15, 131-4		104
1765	Sildenafil: a urologist's view. 2000 , 16 Suppl 1, s48-58		4
1764	End-stage renal disease and erectile dysfunction. Is there any hope?. 2000 , 15, 1525-8		37
1763	Hemodynamic effects of sildenafil in men with severe coronary artery disease. <i>New England Journal of Medicine</i> , 2000 , 342, 1622-6	59.2	257
1762	Increased glomerular filtration rate in kidney-transplant recipients who take sildenafil. <i>New England Journal of Medicine</i> , 2000 , 342, 1679-80	59.2	12
1761	Vascular Reconstruction in the Resection of Soft Tissue Sarcomas. 2000 , Volume 13, 0067-0084		
1760	Die Prävalenz von männlichen Erektionsstörungen in Deutschland heute und in der Zukunft - The prevalence of male erectile dysfunction in Germany today and in the future -. 2000 , 31, 302-307		3
1759	Valuing the effects of sildenafil in erectile dysfunction. Strong assumptions are required to generate a QALY value. 2000 , 320, 1156-7		10
1758	Sexology and the pharmaceutical industry: The threat of co-optation. 2000 , 37, 273-283		61
1757	Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. 2000 , 143, 143-54		101
1756	Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. 2000 , 102, 275-7		85
1755	Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. 2000 , 102, 2516-21		77
1754	The neurobiology of sexual function. 2000 , 57, 1012-30		304
1753	Chapter VIII The nitric oxide system in the urogenital tract. 2000 , 267-314		4
1752	A study using Viagra in a mental health practice. 2000 , 26, 41-50		16
1751	UK management guidelines for erectile dysfunction. 2000 , 321, 499-503		67
1750	Erectile dysfunction in cyclic GMP-dependent kinase I-deficient mice. 2000 , 97, 2349-54		170
1749	Relation between psychosocial risk factors and incident erectile dysfunction: prospective results from the Massachusetts Male Aging Study. 2000 , 152, 533-41		89

1748	Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. 2000 , 268, 628-35	141
1747	Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. 2000 , 30, 328-38	604
1746	Diagnosis and treatment of erectile dysfunction. 2000 , 109 Suppl 9A, 3S-12S; discussion 29S-30S	53
1745	Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Araliaceae) as an adaptogen: a closer look. 2000 , 72, 345-93	194
1744	Pharmacotherapy for erectile dysfunction. 2000 , 21, 484-9	95
1743	Sildenafil: clinical toxicology profile. 2000 , 38, 645-51	35
1742	Erectile dysfunction: a review of a common problem in rapid evolution. 2000 , 7, 124-129	4
1741	Acute myocardial infarction associated with Sildenafil (Viagra) ingestion. 2000 , 18, 353-5	7
1740	Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels. 2000 , 70, 1327-31	33
1739	Sildenafil effects on sexual and cardiovascular responses in women with spinal cord injury. 2000 , 55, 812-5	159
1738	Effects of sildenafil on human penile blood vessels. 2000 , 56, 539-43	35
1737	Side-effect profile of sildenafil citrate (Viagra) in clinical practice. 2000 , 56, 474-6	111
1736	Sildenafil in the treatment of erectile dysfunction after radical prostatectomy. 2000 , 56, 631-4	123
1735	Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. 2000 , 56, 641-6	121
1734	Asian sildenafil efficacy and safety study (ASSESS-1): a double-blind, placebo-controlled, flexible-dose study of oral sildenafil in Malaysian, Singaporean, and Filipino men with erectile dysfunction. The Assess-1 Study Group. 2000 , 56, 635-40	47
1733	Relationship between patient self-assessment of erectile function and the erectile function domain of the international index of erectile function. 2000 , 56, 477-81	114
1732	Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. 2000 , 56, 906-11	95
1731	Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. 2000 , 55, 146-50	109

1730	Role of Viagra after radical prostatectomy. 2000 , 55, 241-5	167
1729	Intracavernous alprostadil alfadex (EDEX/VIRIDAL) is effective and safe in patients with erectile dysfunction after failing sildenafil (Viagra). 2000 , 55, 477-80	70
1728	INCIDENCE OF ERECTILE DYSFUNCTION IN MEN 40 TO 69 YEARS OLD: LONGITUDINAL RESULTS FROM THE MASSACHUSETTS MALE AGING STUDY. 2000 , 163, 460-463	790
1727	LACK OF DIAGNOSTIC TOOLS TO PROVE ERECTILE DYSFUNCTION: CONSEQUENCES FOR REIMBURSEMENT?. 2000 , 163, 91-94	16
1726	[The family doctor and well-being medications]. 2000 , 25, 1-3	1
1725	Economic cost of male erectile dysfunction using a decision analytic model: for a hypothetical managed-care plan of 100,000 members. 2000 , 17, 77-107	36
1724	Sildenafil in the Treatment of Sexual Dysfunction Induced by Selective Serotonin Reuptake Inhibitors. 2000 , 13, 321-335	14
1723	Pharmacotherapy in the treatment of male sexual dysfunction. 2000 , 37, 226-243	19
1722	The cAMP signaling pathway as a therapeutic target in lymphoid malignancies. 2000 , 37, 39-51	65
1721	Soluble guanylate cyclase. 2000 , 4, 735-749	15
1720	Visual Side Effects Possibly Associated with Viagra. 2000 , 19, 21-25	3
1719	EFFICACY, SAFETY AND PATIENT ACCEPTANCE OF SILDENAFIL CITRATE AS TREATMENT FOR ERECTILE DYSFUNCTION. 2000 , 164, 1192-1196	99
1718	SWITCHING FROM INTRACAVERNOUS PROSTAGLANDIN E1 INJECTIONS TO ORAL SILDENAFIL CITRATE IN PATIENTS WITH ERECTILE DYSFUNCTION: RESULTS OF A MULTICENTER EUROPEAN STUDY. 2000 , 164, 708-711	33
1717	SILDENAFIL VERSUS INTRACAVERNOUS INJECTION THERAPY: EFFICACY AND PREFERENCE IN PATIENTS ON INTRACAVERNOUS INJECTION FOR MORE THAN 1 YEAR. 2000 , 164, 1197-1200	52
1716	EFFECT OF SILDENAFIL CITRATE ON POST-RADICAL PROSTATECTOMY ERECTILE DYSFUNCTION. 2000 , 164, 1935-1938	53
1715	EFFECT OF THE PLANT-EXTRACT OSTHOLE ON THE RELAXATION OF RABBIT CORPUS CAVERNOSUM TISSUE IN VITRO. 2000 , 163, 1975-1980	48
1714	ERECTILE DYSFUNCTION IN PATIENTS WITH SPINA BIFIDA IS A TREATABLE CONDITION. 2000 , 164, 958-961	66
1713	Biopsychosocial aspects of prostate cancer. 2000 , 41, 85-94	98

1712	Should patients be given an initial low test dose of sildenafil?. 2000 , 23, 1-9	9
1711	Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. 2000 , 118, 253-7	161
1710	Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk?. 2000 , 56, 302-6	436
1709	Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. 2000 , 36, 25-31	146
1708	Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. 2000 , 36, 845-51	250
1707	Erectile dysfunction. <i>New England Journal of Medicine</i> , 2000 , 342, 1802-13	59.2 1134
1706	Cyclic nucleotide phosphodiesterases. 2001 , 108, 671-80	328
1705	A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction. 2001 , 24, 255-65	3
1704	Leptin in nonalcoholic steatohepatitis: is it one of the 2001 , 96, 2519-2520	2
1703	Prevention and management of erectile dysfunction following radical prostatectomy. 2001 , 28, 613-27	88
1702	Efectividad del tratamiento con sildenafil en pacientes con disfunci3n er3ctil e hipertensi3n arterial. 2001 , 18, 65-71	
1701	Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis. 2001 , 16, 1818-22	72
1700	Seizures, hormones and sexuality. 2001 , 10, 319-40	70
1699	Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. 2001 , 108, 623-628	124
1698	Relationship between patient self-assessment of erectile dysfunction and the sexual health inventory for men. 2001 , 23, 1707-19	97
1697	VIAGRA : IS IT A WONDER DRUG ?. 2001 , 57, 44-6	1
1696	PHARMACOLOGICAL THERAPY OF ERECTILE DYSFUNCTION. 2001 , 57, 47-51	
1695	Subjective visual halos after sildenafil (Viagra) administration: Electroretinographic evaluation. 2001 , 108, 877-81	51

1694	Preliminary observations of sildenafil treatment for erectile dysfunction in dialysis patients. 2001 , 37, 134-137	47
1693	Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. 2001 , 14, 70-3	139
1692	Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. 2001 , 69, 2249-56	48
1691	Practice patterns in the diagnosis and treatment of erectile dysfunction among family practice physicians. 2001 , 57, 146-50	23
1690	Combination of phentolamine and L-arginine or sildenafil synergistically improves neurogenic relaxation of rabbit corpus cavernosum smooth muscle. 2001 , 57, 585-9	20
1689	Sildenafil citrate effectively reverses sexual dysfunction induced by three-dimensional conformal radiation therapy. 2001 , 57, 769-73	45
1688	Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. 2001 , 57, 960-5	90
1687	Efficacy, safety, and use of sildenafil in urologic practice. 2001 , 57, 1141-4	53
1686	Analysis of the consistency of intraurethral prostaglandin E(1) (MUSE) during at-home use. 2001 , 58, 262-6	35
1685	Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. 2001 , 58, 441-5	37
1684	Penile prosthesis implantation. 2001 , 28, 355-61, x	42
1683	CLINICAL EFFICACY OF SILDENAFIL IN PATIENTS ON CHRONIC DIALYSIS. 2001 , 165, 819-821	58
1682	Neurologic erectile dysfunction. 2001 , 28, 289-308	54
1681	Sexualidad en pacientes que han sufrido un infarto. 2001 , 27, 516-520	2
1680	Psychogenic erectile dysfunction. Classification and management. 2001 , 28, 269-78	115
1679	SILDENAFIL VERSUS THE VACUUM ERECTION DEVICE: PATIENT PREFERENCE. 2001 , 166, 1779-1781	34
1678	Oral drug therapy for erectile dysfunction. 2001 , 28, 321-34	71
1677	DIRECT EFFECTS OF SELECTIVE TYPE 5 PHOSPHODIESTERASE INHIBITORS ALONE OR WITH OTHER VASODILATORS ON THE ERECTILE RESPONSE IN CATS. 2001 , 165, 1004-1009	11

1676	LONG-TERM EFFICACY OF SILDENAFIL AND TACHYPHYLAXIS EFFECT. 2001 , 166, 927-931	80
1675	Disfunci3 sexual en la hipertensi3 y beneficios del tratamiento con sildenafilo. 2001 , 18, 59-62	
1674	IMPROVEMENT IN EMOTIONAL WELL-BEING AND RELATIONSHIPS OF USERS OF SILDENAFIL. 2001 , 166, 1774-1778	69
1673	Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. 2001 , 56, M113-9	58
1672	[Results after treatment with sildenafil citrate in 100 patients with erectile dysfunction]. 2001 , 25, 335-40	
1671	Expression of different phosphodiesterase genes in human cavernous smooth muscle. 2001 , 165, 280-3	63
1670	Potassium channel openers: therapeutic potential in cardiology and medicine. 2001 , 2, 1995-2010	18
1669	The role of nitric oxide in penile erection. 2001 , 2, 95-107	46
1668	Sildenafil overdose in a female patient. 2001 , 39, 423-4	5
1667	Relapse prevention strategies and techniques with erectile dysfunction. 2001 , 27, 1-8	29
1666	Efficacy and safety of sildenafil citrate in the treatment of men with mild to moderate erectile dysfunction. 2001 , 178, 325-30	22
1665	Sildenafil: efficacy and safety in daily clinical experience. 2001 , 40, 176-80	18
1664	Prognostic factors for response to sildenafil in patients with erectile dysfunction. 2001 , 40, 641-6; discussion 647	76
1663	. 2001 ,	0
1662	Central modulation of the NO/cGMP pathway affects the MPOA-induced intracavernous pressure response. 2001 , 281, R269-78	33
1661	Erectile Dysfunction in Chronic Peritoneal Dialysis Patients: Incidence and Treatment with Sildenafil. 2001 , 21, 355-359	16
1660	Vaginal physiological changes in a model of sexual arousal in anesthetized rats. 2001 , 281, R140-9	67
1659	Modulation of human platelet aggregation by the phosphodiesterase type 5 inhibitor sildenafil. 2001 , 37, 413-21	53

1658	Modern pharmacotherapy for erectile dysfunction: evolving concepts with central and peripheral acting agents. 2001 , 11, 625-30	2
1657	Determination of sildenafil citrate in plasma by high-performance liquid chromatography and a case for the potential interaction of grapefruit juice with sildenafil citrate. 2001 , 23, 21-6	38
1656	Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. 2001 , 158, 1623-30	209
1655	Psychological testing and psychological assessment: A review of evidence and issues.. 2001 , 56, 128-165	855
1654	Sexual aspects of headache. How sexual function relates to headaches and their causes and treatment. 2001 , 109, 81-4, 87-8, 92	7
1653	How Should Erectile Dysfunction in Diabetes be Managed?. 258-277	0
1652	Does sildenafil also improve breathing?. 2001 , 120, 305-6	21
1651	Managing treatment-emergent sexual dysfunction associated with serotonergic antidepressants: before and after sildenafil. 2001 , 7, 92-108	19
1650	AUTONOMIC DISORDERS. 2001 , 7, 220-233	5
1649	Phosphodiesterase isoenzymes as pharmacological targets in the treatment of male erectile dysfunction. 2001 , 19, 14-22	60
1648	Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. 2001 , 19, 40-5	15
1647	Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. 2001 , 19, 46-50	76
1646	Sildenafil citrate for the treatment of erectile dysfunction in men with Type II diabetes mellitus. 2001 , 44, 1296-301	135
1645	Orale Therapie der erektilen Dysfunktion mit Apomorphin SL. 2001 , 41, 372-378	1
1644	Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction. 2001 , 156, 86-91	6
1643	Engineering of cells and tissues for treatment of erectile dysfunction. 2001 , 19, 67-73	2
1642	Key issues from the clinical trials of apomorphine SL. 2001 , 19, 25-31	34
1641	Bladder, Bowel, and Sexual Dysfunction in Multiple Sclerosis. 2001 , 3, 207-214	18

1640	The impact of the new sexual pharmaceuticals on sex therapy. 2001 , 3, 195-201	26
1639	The interface of psychiatric disorders and diabetes mellitus. 2001 , 3, 243-50	4
1638	Management of erectile dysfunction following radical prostatectomy. 2001 , 2, 495-503	56
1637	Neurogenic erectile dysfunction. 2001 , 11, 285-94	13
1636	Sildenafil citrate (Viagra) and erectile dysfunction following external beam radiotherapy for prostate cancer: a randomized, double-blind, placebo-controlled, cross-over study. 2001 , 51, 1190-5	85
1635	Sildenafil inhibits gastroduodenal motility. 2001 , 15, 157-61	29
1634	Viagra: are anaesthetists rising to the challenge?. 2001 , 56, 91-3	
1633	Phentolamine mesylate relaxes rabbit corpus cavernosum by a nonadrenergic, noncholinergic mechanism. 2001 , 15, 1-7	7
1632	Prevalence and determinants of erectile dysfunction in hemodialysis patients. 2001 , 59, 2259-66	133
1631	Current treatments and emerging therapeutic approaches in male erectile dysfunction. 2001 , 88 Suppl 3, 11-7	21
1630	Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. 1999 , 83, 269-73	117
1629	Treating men with predominantly nonpsychogenic erectile dysfunction with intracavernosal vasoactive intestinal polypeptide and phentolamine mesylate in a novel auto-injector system: a multicentre double-blind placebo-controlled study. 1999 , 83, 274-9	30
1628	A dose-escalation study to assess the efficacy and safety of sildenafil citrate in men with erectile dysfunction. 2001 , 87, 75-81	54
1627	The Dutch cohort of sildenafil users: baseline characteristics. 2001 , 87, 648-53	5
1626	Neurosexology. 2001 , 8, 2-24	31
1625	Effect of sildenafil, a phosphodiesterase-5 inhibitor, on oesophageal peristalsis and lower oesophageal sphincter function in cats. 2001 , 13, 325-31	32
1624	Sexuality rehabilitation. 2001 , 92, 1008-12	124
1623	The cardiovascular response to sexual activity: do we know enough?. 2001 , 24, 271-5	13

1622	Evaluation of side effects of sildenafil in group of young healthy volunteers. 2001 , 32, 705-8	12
1621	Sildenafil test: changes in the diagnostic and therapeutic management of erectile dysfunction. 2001 , 33, 387-9	6
1620	Sildenafil (Viagra): is there an influence on psychological performance?. 2001 , 32, 409-12	29
1619	Sexual Rehabilitation for Men with Spinal Cord Injury: Preliminary Report on a Behavioral Strategy. 2001 , 19, 149-157	11
1618	Efficacy results and quality-of-life measures in men receiving sildenafil citrate for the treatment of erectile dysfunction. 2001 , 10, 359-69	63
1617	Effects of sildenafil on esophageal motility of normal subjects. 2001 , 46, 2301-6	31
1616	Synergistic effects of sildenafil on relaxation of rabbit and rat cavernosal smooth muscles when combined with various vasoactive agents. 2001 , 88, 596-601	1
1615	Effects of the specific phosphodiesterase inhibitors on alloxan-induced diabetic rabbit cavernous tissue in vitro. 2001 , 13, 24-30	8
1614	On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. 2001 , 13, 2-9	175
1613	Evaluation of oral ro70-0004/003, an alpha1A-adrenoceptor antagonist, in the treatment of male erectile dysfunction. 2001 , 13, 157-61	17
1612	Sildenafil improves nocturnal penile erections in organic impotence. 2001 , 13, 125-9	21
1611	ASSESS-3: a randomised, double-blind, flexible-dose clinical trial of the efficacy and safety of oral sildenafil in the treatment of men with erectile dysfunction in Taiwan. 2001 , 13, 221-9	38
1610	The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. 2001 , 13, 192-9	257
1609	Assessment of the efficacy and safety of Viagra (sildenafil citrate) in men with erectile dysfunction during long-term treatment. 2001 , 13, 261-7	54
1608	The history of erectile dysfunction management. 2001 , 13 Suppl 3, S3-7	18
1607	Characterising the benefit of apomorphine SL (Uprima) as an optimised treatment for representative populations with erectile dysfunction. 2001 , 13 Suppl 3, S35-9	15
1606	The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. 2001 , 13, 282-90	192
1605	Effects of oral phentolamine, taken before sleep, on nocturnal erectile activity: a double-blind, placebo-controlled, crossover study. 2001 , 13, 303-8	12

1604	Erectile dysfunction in a primary care setting: results of an observational, no-control-group, prospective study with sildenafil under routine conditions of use. 2001 , 13, 338-47	31
1603	Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double-blind, cross-over, placebo-controlled study. 2001 , 108, 623-8	36
1602	Phosphodiesterase 5 inhibitors and nitrenergic transmission-from zaprinast to sildenafil. 2001 , 411, 1-10	68
1601	Effect of sildenafil on non-adrenergic non-cholinergic neurotransmission in bovine penile small arteries. 2001 , 412, 155-69	29
1600	FR226807: a potent and selective phosphodiesterase type 5 inhibitor. 2001 , 428, 295-302	17
1599	Sex, the heart, and sildenafil. 2001 , 26, 388-415	4
1598	Autonomic dysreflexia and foot and ankle surgery. 2001 , 40, 172-7	3
1597	Erectile dysfunction in uremic dialysis patients: diagnostic evaluation in the sildenafil era. 2001 , 38, S115-7	17
1596	The rise and fall of Viagra. 2001 , 6, 704-706	1
1595	Pharmacotherapy or psychotherapy?: effective treatment for FSD related to unresolved childhood sexual abuse. 2001 , 27, 421-5	20
1594	Use of sildenafil in penile implant patients. 2001 , 66, 149-51	5
1593	Are adverse effects of sildenafil also caused by inhibition of diamine oxidase?. 2001 , 67, 59-61	7
1592	Is the sildenafil product information adequate to facilitate informed therapeutic decisions?. 2001 , 35, 337-42	
1591	Sexuality in the older person. 2001 , 30, 121-4	49
1590	Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. 2001 , 38, 940-6	30
1589	Anterior ischemic optic neuropathy associated with viagra. 2001 , 21, 22-5	82
1588	Leptin in nonalcoholic steatohepatitis: is it one of the "hits"?. 2001 , 96, 2519-20	3
1587	Hemorrhoidal bleeding associated with sildenafil. 2001 , 96, 2518-9	13

1586	The management of erectile dysfunction. 2001 , 9, 35-47	1
1585	An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. 2001 , 56, S1-S88	443
1584	Comparison of FDA reports of patient deaths associated with sildenafil and with injectable alprostadil. 2001 , 35, 285-8	9
1583	Quality of partnership in patients with erectile dysfunction after sildenafil treatment. 2001 , 34, 91-5	57
1582	[Interaction between sildenafil and antihypertensive drugs: what is evidence-based?]. 2001 , 126, 1144-9	7
1581	Efficacy of sildenafil citrate for the treatment of erectile dysfunction in men taking serotonin reuptake inhibitors. 2001 , 158, 1926-8	67
1580	Effect of sildenafil on ocular haemodynamics. 2001 , 15, 507-10	40
1579	Sexuelle Störungen - Erscheinungsformen, Ursachen, Behandlungsangebote. 2001 , 2, 246-251	1
1578	Erectile dysfunction. 2001 , 86, 2391-4	23
1577	Male Sexuality After Fifty. 2001 , 12, 29-37	9
1576	FSD partner issues: expanding sex therapy with sildenafil. 2002 , 28 Suppl 1, 195-204	18
1575	Review of patients with erectile dysfunction attending the Maudsley psychosexual clinic in 1999: The impact of sildenafil. 2002 , 17, 171-185	3
1574	MUSE: clinical experience. 2002 , 18, 64-7	8
1573	Pharmacotherapy of erectile dysfunction. 2002 , 17, 389-400	0
1572	Male Sexual Behavior. 2002 , 3-137	82
1571	Is sildenafil citrate an alternative agent in the evaluation of penile vascular system with color Doppler ultrasound?. 2002 , 68, 255-60	8
1570	Penile arteries and erection. 2002 , 39, 283-303	85
1569	Interaction of sildenafil with cAMP-mediated vasodilation in vivo. 2002 , 40, 763-7	24

1568	Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. 2002 , 50, 758-64	132
1567	Combined oral therapy with sildenafil and doxazosin for the treatment of non-organic erectile dysfunction refractory to sildenafil monotherapy. 2002 , 14, 50-3	51
1566	Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction. 2002 , 14, 54-9; discussion 60	19
1565	New treatments for pulmonary arterial hypertension. 2002 , 165, 1209-16	101
1564	Sildenafil reverses O ₂ constriction of the rabbit ductus arteriosus by inhibiting type 5 phosphodiesterase and activating BK(Ca) channels. 2002 , 52, 19-24	36
1563	Management of erectile dysfunction by combination therapy with testosterone and sildenafil in recipients of high-dose therapy for haematological malignancies. 2002 , 29, 607-10	43
1562	Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. 2002 , 14, 38-43	34
1561	Evaluation of health-related quality of life in patients treated for erectile dysfunction with viagra (sildenafil citrate) using SF-36 score. 2002 , 48, 15-21	23
1560	Protein and Amino Acid Metabolism. 2002 , 331-363	4
1559	American association of clinical endocrinologists meeting, may 2002. 2002 , 25, 1464-71	2
1558	Review: Modern treatment of erectile dysfunction. 2002 , 2, 255-261	4
1557	The pathophysiology of erectile dysfunction related to endothelial dysfunction and mediators of vascular function. 2002 , 7, 213-25	160
1556	Cardiovascular safety in erectile dysfunction treatment. 2002 , 2, 301-304	5
1555	Schedule 11 Impact on treating erectile dysfunction. 2002 , 2, 315-318	3
1554	Sildenafil for male erectile dysfunction: a systematic review and meta-analysis. 2002 , 162, 1349-60	184
1553	[Nitroxidergic (nitrenergic) nerve and erectile dysfunction]. 2002 , 119, 21-8	1
1552	Neurogenic Bladder, Neurogenic Bowel, and Sexual Dysfunction in People With Spinal Cord Injury. 2002 , 82, 601-612	170
1551	Bladder and sexual dysfunction. 2002 , 833-852	

1550	The hemodynamics of erection and the pharmacotherapies of erectile dysfunction. 2002 , 4, 252-64	5
1549	Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. 2002 , 15, 271-8	63
1548	Sexual dysfunction in neurologic disease. 2002 , 25, 126-32	11
1547	Intracavernous injection as an option for aging men with erectile dysfunction. 2002 , 5, 177-180	
1546	Sildenafil induces retinal vasodilatation in healthy subjects. 2002 , 86, 156-8	44
1545	Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. 2002 , 287, 719-25	132
1544	Therapeutic options in female sexual dysfunction. 2002 , 42, 479-87; quiz 487-8	9
1543	Sildenafil citrate for the sexual dysfunction in antidepressant-treated male patients with posttraumatic stress disorder. A preliminary pilot open-label study. 2002 , 71, 173-6	9
1542	Sildenafil-nitric oxide donor combination promotes ventricular tachyarrhythmias in the swine right ventricle. 2002 , 282, H1787-92	9
1541	Disfunzione erettile. 2002 , 3, 223-238	1
1540	Erectile dysfunction and depression: category or dimension?. 2002 , 28, 175-81	28
1539	Biological factors in human sexuality. 2002 , 39, 15-21	49
1538	Sexual dysfunction: overview of prevalence, etiological factors, and treatments. 2002 , 39, 73-8	169
1537	Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses. 2002 , 168, 1332-1336	429
1536	Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. 2002 , 77, 276-82	46
1535	Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. 2002 , 106, 1097-103	150
1534	Management of Erectile Dysfunction. 2002 , 10, 431-452	5
1533	Vardenafil. 2002 , 19, 228-229	

1532	A Prospective Study Comparing Paroxetine Alone Versus Paroxetine Plus Sildenafil in Patients With Premature Ejaculation. 2002 , 168, 2486-2489	140
1531	[Erectile dysfunction]. 2002 , 26, 667-90	5
1530	[Prevalence erectile dysfunction in patients with hypertension]. 2002 , 119, 521-6	17
1529	Sublingual apomorphine for the treatment of erectile dysfunction. 2002 , 11, 295-302	16
1528	SSRI sexual dysfunction: a female perspective. 2002 , 28 Suppl 1, 143-53	22
1527	Economic aspects of medical erectile dysfunction therapies. 2002 , 3, 257-63	10
1526	Current oral treatments for erectile dysfunction. 2002 , 3, 1613-29	8
1525	Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. 2002 , 59, 747-52	58
1524	Effects of various nitric oxide donating agents on the contractility and cyclic nucleotide turnover of human seminal vesicles in vitro. 2002 , 59, 958-62	28
1523	Quality control in the screening of erectile dysfunction--results of a survey. 2002 , 60, 125-9	9
1522	Type 5 phosphodiesterase expression in the human vagina. 2002 , 60, 191-5	125
1521	Introduction. The management of erectile dysfunction (ED). 2002 , 60, 1-3	4
1520	Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. 2002 , 60, 4-11	117
1519	The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. 2002 , 60, 12-27	130
1518	Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction. 2002 , 60, 28-38	133
1517	Efficacy and safety of sildenafil citrate (Viagra) in black and Hispanic American men. 2002 , 60, 39-48	31
1516	Efficacy and safety of sildenafil citrate (Viagra) in men with erectile dysfunction and spinal cord injury: a review. 2002 , 60, 49-57	49
1515	Topical alprostadil cream for the treatment of erectile dysfunction: a combined analysis of the phase II program. 2002 , 60, 1077-82	18

1514	[When and why to use penile prostheses: seven years of experience]. 2002 , 36, 69-73	1
1513	The Role of Apomorphine SL in the Treatment of Erectile Dysfunction. 2002 , 1, 4-11	4
1512	Patient Choice is Critical in Managing Erectile Dysfunction. 2002 , 1, 33-37	10
1511	What Do Patients Expect from Erectile Dysfunction Therapy?. 2002 , 1, 4-11	16
1510	Oral Agents: First-Line Therapy for Erectile Dysfunction. 2002 , 1, 12-18	22
1509	Spinal cord injury medicine. 3. Rehabilitation outcomes. 2002 , 83, S65-71, S90-8	25
1508	Cardiologists' discussions about sexuality with patients with chronic coronary artery disease. 2002 , 144, 239-42	46
1507	[Efficacy and safety of sildenafil in men with type 2 diabetes mellitus and erectile dysfunction]. 2002 , 119, 121-4	8
1506	The placebo effect and randomized trials: analysis of alternative medicine. 2002 , 29, 135-55, x	8
1505	Diagnostic Steps In The Evaluation Of Patients With Erectile Dysfunction. 2002 , 168, 615-620	60
1504	Immunolocalization of Multidrug Resistance Protein 5 in the Human Genitourinary System. 2002 , 167, 2271-2275	50
1503	Dietary supplements and other alternative medicines for erectile dysfunction. What do I tell my patients?. 2002 , 29, 11-22, vii	10
1502	RE: LONG-TERM EFFICACY OF SILDENAFIL AND TACHYPHYLAXIS EFFECT. 2002 , 168, 206-206	4
1501	The placebo effect and randomized trials: analysis of conventional medicine. 2002 , 29, 125-33, ix-x	21
1500	Clinical safety profile of sildenafil in Singaporean men with erectile dysfunction: pre-marketing experience (ASSESS-I evaluation). 2002 , 30, 137-43	7
1499	Neurologic, psychological, and aggressive disturbances with sildenafil. 2002 , 36, 1129-34	76
1498	The enhancement of vaginal vasocongestion by sildenafil in healthy premenopausal women. 2002 , 11, 357-65	80
1497	Sildenafil in the cardiologist's office: patients' attitudes and physicians' practices toward discussions about sexual functioning. 2002 , 97, 79-82	7

1496	Sildenafil and T-1032, phosphodiesterase type 5 inhibitors, showed a different vasorelaxant property in the isolated rat aorta. 2002 , 440, 45-52	28
1495	The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. 2002 , 440, 141-57	55
1494	The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. 2002 , 450, 93-109	73
1493	Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. 2002 , 456, 91-8	22
1492	Potassium channels and erectile dysfunction. 2002 , 38, 61-71	60
1491	Guidelines on erectile dysfunction. 2002 , 41, 1-5	79
1490	Switching from long-term treatment with self-injections to oral sildenafil in diabetic patients with severe erectile dysfunction. 2002 , 41, 387-91	38
1489	Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. 2002 , 41, 382-6	57
1488	Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. 2002 , 41, 608-13; discussion 613	67
1487	In vitro effects of a novel class of nitric oxide (NO) donating compounds on isolated human erectile tissue. 2002 , 42, 523-8	37
1486	Viagra (sildenafil citrate) and ophthalmology. 2002 , 21, 485-506	104
1485	A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. 2002 , 17, 279-84	62
1484	Apomorphine, systèmes dopaminergiques centraux et contrôle de l'érection. 2002 , 12, 156-166	2
1483	Etiology and treatment of erectile failure in diabetes mellitus. 2002 , 2, 501-9	44
1482	Combination therapy for erectile dysfunction: where we are and what's in the future. 2002 , 3, 467-70	11
1481	Topical agents and erectile dysfunction: is there a place?. 2002 , 3, 471-6	8
1480	Vasoconstriction and vasodilation in erectile physiology. 2002 , 3, 477-83	7
1479	Phosphodiesterase inhibitors cause relaxation of the internal anal sphincter in vitro. 2002 , 45, 530-6	29

1478	Randomized, double-blind, placebo-controlled trial of sildenafil (Viagra) for erectile dysfunction after rectal excision for cancer and inflammatory bowel disease. 2002 , 45, 727-32	90
1477	Introduction. 2002 , 53, 1S-3S	3
1476	Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. 2002 , 53 Suppl 1, 5S-12S	245
1475	The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. 2002 , 53 Suppl 1, 21S-30S	92
1474	The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers. 2002 , 53 Suppl 1, 31S-36S	17
1473	The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. 2002 , 53 Suppl 1, 37S-43S	39
1472	A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction. 2002 , 53 Suppl 1, 45S-52S	46
1471	The effects of sildenafil on human sperm function in healthy volunteers. 2002 , 53 Suppl 1, 53S-60S	39
1470	Onset and duration of action of sildenafil for the treatment of erectile dysfunction. 2002 , 53 Suppl 1, 61S-65S	68
1469	Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil. 2002 , 53 Suppl 1, 13S-20S	92
1468	The clinical studies of sildenafil for the ageing male. 2002 , 25, 28-33	21
1467	Oral sildenafil (Viagra) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital. 2002 , 2, 4	12
1466	Effect of Sildenafil on hypertensive lower oesophageal sphincter. 2002 , 32, 682-5	31
1465	Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients. 2002 , 9, 308-15	16
1464	Erosion of a penile prosthesis due to an indwelling urethral catheter as a late complication. 2002 , 9, 525-7	9
1463	Usefulness of power Doppler ultrasonography in evaluating erectile dysfunction. 2002 , 89, 779-82	13
1462	Efficacy and safety of sildenafil for treating erectile dysfunction in patients on dialysis. 2002 , 90, 442-5	28
1461	Sildenafil influences lower urinary tract symptoms. 2002 , 90, 836-9	212

1460	Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy. 2002 , 14 Suppl 1, S38-42	79
1459	Erectile dysfunction in the 21st century: whom we can treat, whom we cannot treat and patient education. 2002 , 14 Suppl 1, S29-34	21
1458	IC351 (tadalafil, Cialis): update on clinical experience. 2002 , 14 Suppl 1, S57-64	82
1457	Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. 2002 , 14, 178-88	25
1456	The International Index of Erectile Function (IIEF): a state-of-the-science review. 2002 , 14, 226-44	718
1455	The use of the simplified International Index of Erectile Function (IIEF-5) as a diagnostic tool to study the prevalence of erectile dysfunction. 2002 , 14, 245-50	265
1454	The effect of sildenafil on electrostimulation-induced erection in the rat model. 2002 , 14, 251-5	11
1453	Did men with erectile dysfunction discuss their condition with partner and physicians? A survey of men attending a free call information service. 2002 , 14, 256-8	39
1452	Incidence and determinants of sildenafil (dis)continuation: the Dutch cohort of sildenafil users. 2002 , 14, 259-65	69
1451	Long-term safety and efficacy of oral phentolamine mesylate (Vasomax) in men with mild to moderate erectile dysfunction. 2002 , 14, 266-70	28
1450	Efficacy and safety of flexible-dose oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction in Brazilian and Mexican men. 2002 , 14 Suppl 2, S27-32	23
1449	Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. 2002 , 14 Suppl 2, S33-41	14
1448	Efficacy and safety of oral sildenafil citrate (Viagra) in the treatment of male erectile dysfunction in Colombia, Ecuador, and Venezuela: a double-blind, multicenter, placebo-controlled study. 2002 , 14 Suppl 2, S42-7	14
1447	Comparison of the efficacy and safety of sildenafil citrate (Viagra) and oral phentolamine for the treatment of erectile dysfunction. 2002 , 14 Suppl 2, S48-53	9
1446	Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus. 2002 , 14, 466-71	84
1445	High dose sildenafil citrate as a salvage therapy for severe erectile dysfunction. 2002 , 14, 533-8	48
1444	KMUP-1 relaxes rabbit corpus cavernosum smooth muscle in vitro and in vivo: involvement of cyclic GMP and K(+) channels. 2002 , 135, 1159-66	38
1443	NO as a signalling molecule in the nervous system. 2002 , 135, 1079-95	376

1442	Effects of sildenafil on erectile activity in mice lacking neuronal or endothelial nitric oxide synthase. 2002 , 136, 693-700	46
1441	Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. 2002 , 137, 295-310	134
1440	The clinical safety of viagra. 2002 , 962, 378-88	33
1439	Receiving the torch in the era of sexology's renaissance. 2002 , 31, 1-6	12
1438	The effects of yohimbine plus L-arginine glutamate on sexual arousal in postmenopausal women with sexual arousal disorder. 2002 , 31, 323-32	60
1437	Sexual function assessment and the role of vasoactive drugs in female sexual dysfunction. 2002 , 31, 439-43	27
1436	Sexual Functioning After Treatment for Early Stage Prostate Cancer. 2002 , 20, 239-260	4
1435	How to use nitrates. 2002 , 16, 511-4	13
1434	Prevalence and determinants of erectile dysfunction in patients on peritoneal dialysis. 2003 , 35, 553-6	25
1433	The nature of sexual desire: a clinician's perspective. 2003 , 32, 279-85	164
1432	Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. 2003 , 12, 363-71	49
1431	Sildenafil, a phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats. 2003 , 48, 2064-8	23
1430	[How effective are PDE-5 inhibitors?]. 2003 , 42, 553-8	4
1429	Erectile dysfunction in the cardiac patient. 2003 , 4, 466-71	16
1428	Tadalafil in the treatment of erectile dysfunction. 2003 , 4, 472-8	13
1427	Immunocytochemical distribution of nitric oxide synthase in the human seminal vesicle: a light and electron microscopical study. 2003 , 31, 262-6	23
1426	Erforschung der Epidemiologie von männlichen Sexualstörungen in Deutschland. 2003 , 19, 55-63	2
1425	A comparative study of Ferula hermonis root extracts and sildenafil on copulatory behaviour of male rats. 2003 , 74, 242-6	40

1424	Pro-erectile effect of vardenafil: in vitro experiments in rabbits and in vivo comparison with sildenafil in rats. 2003 , 44, 731-6	21
1423	Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. 2003 , 188, 286-93	64
1422	Overview of phosphodiesterase 5 inhibition in erectile dysfunction. 2003 , 92, 9M-18M	160
1421	The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips. 2003 , 462, 155-60	8
1420	Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. 2003 , 9, 9-15	27
1419	Phosphodiesterase inhibitors are neuroprotective to cultured spinal motor neurons. 2003 , 71, 485-95	57
1418	Erectile dysfunction after surgical treatment. 2003 , 26, 137-40	16
1417	Sildenafil citrate does not affect QT intervals and QT dispersion: an important observation for drug safety. 2003 , 8, 14-7	10
1416	Preference for oral sildenafil or intracavernosal injection in patients with erectile dysfunction already using intracavernosal injection for > 1 year. 2003 , 92, 277-80	12
1415	The downside of Viagra: women's experiences and concerns. 2003 , 25, 697-719	77
1414	Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. 2003 , 36, 529-35	118
1413	Activation and potentiation of the NO/cGMP pathway by NG-hydroxyl-L-arginine in rabbit corpus cavernosum under normoxic and hypoxic conditions and ageing. 2003 , 138, 63-70	22
1412	The efficacy and safety of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two phase 2 studies in mild-to-moderate and severe ED. 2003 , 15, 10-7	31
1411	Inflatable penile prosthesis: site-specific malfunction analysis. 2003 , 15, 22-5	15
1410	A double-blind, randomised- placebo, controlled, parallel group, multicentre, flexible-dose escalation study to assess the efficacy and safety of sildenafil administered as required to male outpatients with erectile dysfunction in Korea. 2003 , 15, 80-6	34
1409	A baseline-controlled, open-label, flexible dose-escalation study to assess the safety and efficacy of sildenafil citrate (Viagra) in patients with erectile dysfunction. 2003 , 15 Suppl 1, S19-24	11
1408	Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. 2003 , 15 Suppl 1, S25-9	20
1407	Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in Nigerian men. 2003 , 15 Suppl 1, S15-8	7

1406	Effect of sildenafil on nocturnal erections of potent men. 2003 , 15, 117-21	18
1405	Vardenafil enhances clitoral and vaginal blood flow responses to pelvic nerve stimulation in female dogs. 2003 , 15, 137-41	28
1404	Sildenafil does not improve sexual function in men without erectile dysfunction but does reduce the postorgasmic refractory time. 2003 , 15, 225-8	63
1403	Cross-cultural adaptation and validation of the English version of the International Index of Erectile Function (IIEF) for use in Malaysia. 2003 , 15, 329-36	40
1402	What to learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical experience. 2003 , 15, 412-7	23
1401	Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E(1) intracavernosal injection therapy to oral sildenafil citrate. 2003 , 15, 444-9	17
1400	Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey. 2003 , 15 Suppl 5, S13-9	15
1399	Sex coaching for physicians: combination treatment for patient and partner. 2003 , 15 Suppl 5, S67-74	70
1398	Sildenafil citrate for treatment of erectile dysfunction in men with type 1 diabetes: results of a randomized controlled trial. 2003 , 26, 279-84	124
1397	MALE AND FEMALE SEXUAL FUNCTION AND DYSFUNCTION; ANDROLOGY. 2003 , 170, 677-684	3
1396	Expression of guanylyl cyclase B in the human corpus cavernosum penis and the possible involvement of its ligand C-type natriuretic polypeptide in the induction of penile erection. 2003 , 169, 1918-22	28
1395	Optimizing treatment for diabetes mellitus induced erectile dysfunction. 2003 , 170, S35-8; discussion S39	45
1394	Implications of diabetes mellitus in urology. 2003 , 30, 1-12	70
1393	Deciphering erectile dysfunction drug trials. 2003 , 170, 353-8	49
1392	Comparison of satisfaction rates and erectile function in patients treated with sildenafil, intracavernous prostaglandin E1 and penile implant surgery for erectile dysfunction in urology practice. 2003 , 170, 159-63	130
1391	Tratamiento sintomático de las complicaciones de la esclerosis múltiple. tratamiento rehabilitador. 2003 , 8, 5202-5206	
1390	Erectile dysfunction in early, middle, and late adulthood: symptom patterns and psychosocial correlates. 2003 , 29, 381-99	33
1389	Time course of the interaction between tadalafil and nitrates. 2003 , 42, 1855-60	138

1388	Stimulation of the nitric oxide-guanosine 3', 5'-cyclic monophosphate pathway by sildenafil: Effect on rectal muscle tone, distensibility, and perception in health and in irritable bowel syndrome. 2003 , 98, 2253-2260	4
1387	Female sexual dysfunction: potential for pharmacotherapy. 2003 , 63, 1445-57	38
1386	A classification based on peak systolic velocity and end diastolic velocity predicts sildenafil citrate success. 2003 , 37, 502-6	9
1385	Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. 2003 , 24, 2206-12	55
1384	What's new in sex therapy? From stagnation to fragmentation. 2003 , 18, 95-106	17
1383	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. 2003 , 108, 239-44	124
1382	Should the patient with coronary artery disease use sildenafil?. 2003 , 6, 161-5	11
1381	Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. 2003 , 312, 1202-8	89
1380	Sildenafil in erectile dysfunction: a critical review. 2003 , 19, 241-62	77
1379	Non erectile dysfunction application of sildenafil. 2003 , 28, 325-33	10
1378	Genetic risk factors for erectile dysfunction and genetic determinants of drug response--on the way to improve drug safety?. 2003 , 28, 304-13	14
1377	Appropriate use of exercise testing prior to administration of drugs for treatment of erectile dysfunction. 2003 , 28, 291-7	4
1376	Effects of various nitric oxide-donating drugs on adrenergic tension of human seminal vesicles in vitro. 2003 , 61, 479-83	37
1375	Phosphodiesterases as therapeutic targets. 2003 , 61, 685-91	43
1374	Treatment responsiveness of the Self-Esteem And Relationship questionnaire in erectile dysfunction. 2003 , 61, 888-92	88
1373	Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. 2003 , 61, 8-14	123
1372	Efficacy of sildenafil in an open-label study as a continuation of a double-blind study in the treatment of erectile dysfunction after radiotherapy for prostate cancer. 2003 , 62, 116-20	38
1371	ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction. 2003 , 62, 152-7	42

1370	Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial. 2003 , 62, 121-5; discussion 125-6	250
1369	Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. 2003 , 62, 519-23; discussion 523-4	55
1368	Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double-blind, placebo-controlled trial. 2003 , 62, 400-3	76
1367	Factors influencing the outcomes of penile prosthesis surgery at a teaching institution. 2003 , 62, 918-21	87
1366	Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. 2003 , 25, 2724-37	66
1365	Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH ₂ induces penile erection via brain and spinal melanocortin receptors. 2003 , 118, 755-62	62
1364	[Use of oral sildenafil (Viagra) in pulmonary hypertension after cardiac pediatric surgery]. 2003 , 22, 140-3	5
1363	Erectile dysfunction: etiology and treatment in young and old patients. 2003 , 19, 539-51	17
1362	Prevalence of sexual disorders in those young males who later become drug abusers. 2003 , 29, 149-56	20
1361	Androgens and cardiovascular disease. 2003 , 24, 313-40	579
1360	Salvage of sildenafil failures referred from primary care physicians. 2003 , 170, 2356-8	74
1359	Current and future trends in the oral pharmacotherapy of male erectile dysfunction. 2003 , 12, 1521-33	10
1358	Erectile dysfunction: current concepts and future directions. 2003 , 49, 7-17	
1357	Long-term use of sildenafil. 2003 , 4, 397-405	89
1356	New achievements and pharmacotherapeutic approaches to impotence in the elderly. 2003 , 15, 222-33	2
1355	Andropause: symptom management for prostate cancer patients treated with hormonal ablation. 2003 , 8, 474-87	77
1354	Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. 2003 , 26, 1093-9	164
1353	Review of tadalafil in the treatment of erectile dysfunction. 2003 , 4, 2049-56	16

1352	Stimulation of the nitric oxide-guanosine 3', 5'-cyclic monophosphate pathway by sildenafil: effect on rectal muscle tone, distensibility, and perception in health and in irritable bowel syndrome. 2003 , 98, 2253-60	22
1351	Isoform-specific regulation of adenylyl cyclase: a potential target in future pharmacotherapy. 2003 , 7, 441-51	23
1350	The pharmacology of nitric oxide in the peripheral nervous system of blood vessels. 2003 , 55, 271-324	247
1349	Effect of sildenafil on arterial stiffness and wave reflection. 2003 , 8, 243-8	67
1348	Therapies for neurologic erectile dysfunction. 2003 , 3, 641-8	
1347	Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. 2003 , 41, 734-43	42
1346	Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. 2003 , 289, 56-64	148
1345	Erectile dysfunctions. 2003 , 2, 350-6	2
1344	Phosphodiesterase 5 inhibitors in male sexual dysfunction. 2003 , 13, 405-10	13
1343	Cognitive changes predict continued recovery of erectile functioning versus relapse after discontinuation of sildenafil treatment for male erectile dysfunction. 2003 , 65, 709-18	20
1342	Chapter 14 Complications of Multiple Sclerosis: Fatigue; Spasticity; Ataxia; Pain; and Bowel, Bladder, and Sexual Dysfunction. 2003 , 27, 217-227	1
1341	Neurochemical aspects of the sexual response cycle. 2003 , 8, 211-6	27
1340	Evaluation of the effects of sildenafil citrate (Viagra) on canine renal artery, carotid and aortic blood flow with the aid of color Doppler sonography. 2003 , 71, 103-7	8
1339	Oral agents for erectile dysfunction. 2003 , 64, 292-5	
1338	Selective phosphodiesterase type-5 inhibitor treatment of serotonergic reuptake inhibitor antidepressant-associated sexual dysfunction: a review of diagnosis, treatment, and relevance. 2003 , 8, 194-202	11
1337	American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem--2003 update. 2003 , 9, 77-95	60
1336	. 2003 ,	19
1335	Effects of sildenafil on retinal blood flow and flicker-induced retinal vasodilatation in healthy subjects. 2003 , 44, 4872-6	42

1334	Effect of sildenafil in cavernous arteries of patients with erectile dysfunction. 2003 , 29, 320-6	0
1333	Recent advances in the treatment of erectile dysfunction in patients with diabetes mellitus. 2003 , 9, 52-63	10
1332	Sexual health. 2004 , 61-80	
1331	[Cardiac rehabilitation and resuming sexual activity]. 2004 , 62, 162-8	1
1330	Emerging oral drugs for erectile dysfunction. 2004 , 9, 179-189	4
1329	[Erectile dysfunction. Are interdisciplinary diagnosis and therapy necessary?]. 2004 , 129, 131-6	8
1328	Heart Disease and Erectile Dysfunction. 2004 ,	
1327	The assessment of sexual functions in women with male partners complaining of erectile dysfunction: does treatment of male sexual dysfunction improve female partner's sexual functions?. 2004 , 30, 333-41	114
1326	Erectile dysfunction after open versus angioplasty aortoiliac procedures: a questionnaire survey. 2004 , 38, 157-65	16
1325	Review: PDE-5 inhibitors in summary. 2004 , 4, 383-386	3
1324	Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial. 2004 , 164, 514-20	65
1323	Effect of sildenafil citrate on retinal functions: preliminary report on Humphrey visual field analysis. 2004 , 73, 28-30	5
1322	Erectile dysfunction: a need for greater awareness. 2004 , 124, 214-6	3
1321	Central Nervous Sequelae of Local Muscle Pain. 2004 , 12, 101-109	3
1320	The patient's self-evaluation better predicts the degree of erectile dysfunction than the response to intracavernous alprostadil testing. 2004 , 72, 216-20	1
1319	A 66-year-old man with sexual dysfunction. 2004 , 291, 2994-3003	19
1318	Tadalafil: A Comprehensive Update. 2004 , 2, 225-246	
1317	Erectile dysfunction: management update. 2004 , 170, 1429-37	70

1316	Impact of erectile dysfunction and its subsequent treatment with sildenafil: qualitative study. 2004 , 328, 1037	96
1315	Erectile dysfunction: an underdiagnosed condition associated with multiple risk factors. 2004 , 20, 603-6	22
1314	Treatment of erectile dysfunction. 2004 , 15, 215-21	7
1313	Treatment of primary pulmonary hypertension with oral sildenafil. 2004 , 71, 192-4	22
1312	A novel therapy with testosterone and sildenafil for erectile dysfunction in patients on renal dialysis or after renal transplantation. 2004 , 30, 88-90	39
1311	Influence of sildenafil on gastric sensorimotor function in humans. 2004 , 287, G988-92	47
1310	Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. 2004 , 93, 796-801	36
1309	Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double-blind, 12-week, flexible-dose, placebo-controlled erectile dysfunction clinical trial. 2004 , 94, 1301-9	59
1308	The etiology of erectile dysfunction and contributing factors in different age groups in Turkey. 2004 , 11, 525-9	37
1307	Erectile dysfunction in hemodialysis patients with diabetes mellitus: association with age and hemoglobin A1c levels. 2004 , 11, 530-4	19
1306	Sublingual sildenafil in the treatment of erectile dysfunction: faster onset of action with less dose. 2004 , 11, 989-92	17
1305	Clinical application of prognostic factors for patients with organic causes of erectile dysfunction on 100 mg of sildenafil citrate. 2004 , 11, 1104-9	5
1304	Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase testosterone levels. 2004 , 61, 382-6	95
1303	Comparative effects of sildenafil, phentolamine, yohimbine and L-arginine on the rabbit corpus cavernosum. 2004 , 18, 187-94	10
1302	Systemic and splanchnic haemodynamic effects of sildenafil in an in vivo animal model of cirrhosis support for a risk in cirrhotic patients. 2004 , 24, 63-8	30
1301	Kidney disease quality of life of Japanese dialysis patients who desire administration of sildenafil and the treatment of erectile dysfunction using sildenafil. 2004 , 8, 340-6	10
1300	Phosphodiesterase-5 inhibitors and migraine. 2004 , 44, 925-6	14
1299	Update on oral treatments for male erectile dysfunction. 2004 , 18, 267-74	25

1298	Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis. 2004 , 9, 228-33	5
1297	Challenges in the assessment of erectile dysfunction and treatment with oral therapies: review with case examples. 2004 , 16, 428-40	
1296	Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. 2004 , 16, 21-9	62
1295	A comparative, crossover study of the efficacy and safety of sildenafil and apomorphine in men with evidence of arteriogenic erectile dysfunction. 2004 , 16, 2-7	34
1294	Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. 2004 , 16, 51-9	95
1293	Rechallenge prior sildenafil nonresponders. 2004 , 16, 64-8	30
1292	NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. 2004 , 16, 195-200	20
1291	Effects of sildenafil on ocular perfusion demonstrated by color Doppler ultrasonography. 2004 , 16, 244-8	25
1290	Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. 2004 , 16, 135-42	67
1289	Characteristics of photoreceptor PDE (PDE6): similarities and differences to PDE5. 2004 , 16 Suppl 1, S28-33	125
1288	Erectile dysfunction in men with obstructive sleep apnea syndrome: a randomized study of the efficacy of sildenafil and continuous positive airway pressure. 2004 , 16, 256-60	38
1287	A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats. 2004 , 16, 479-85	20
1286	Core document on erectile dysfunction: key aspects in the care of a patient with erectile dysfunction. 2004 , 16 Suppl 2, S26-39	16
1285	Sildenafil citrate significantly improves nocturnal penile erections in sildenafil non-responding patients with psychogenic erectile dysfunction. 2004 , 16, 552-6	9
1284	Cardiovascular effects of sildenafil in hypertensive men with erectile dysfunction and different alleles of the type 5 cGMP-specific phosphodiesterase (PDE5). 2004 , 16, 412-7	12
1283	Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. 2004 , 1, 292-300	95
1282	Does sildenafil enhance quality of nocturnal erections in healthy young men? A NPT-RigiScan study. 2004 , 1, 314-7	7
1281	Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. 2004 , 1, 322-36	29

1280	Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. 2004 , 1, 161-7	38
1279	Efficacy and safety of on-demand oral tadalafil in the treatment of men with erectile dysfunction in Taiwan: a randomized, double-blind, parallel, placebo-controlled clinical study. 2004 , 1, 201-8	23
1278	Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebo-controlled study. 2004 , 18, 205-10	49
1277	The enhancing effects of manualized treatment for erectile dysfunction among men using sildenafil: A preliminary investigation. 2004 , 35, 55-73	18
1276	T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs. 2004 , 485, 283-8	5
1275	Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil. 2004 , 504, 1-6	34
1274	A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. 2004 , 45, 499-507; discussion 507-9	76
1273	Efficacy of vardenafil in men with erectile dysfunction: a flexible-dose community practice study. 2004 , 46, 73-9	30
1272	Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window. 2004 , 46, 357-60; discussion 360-1	51
1271	Efficacy and treatment satisfaction with on-demand tadalafil (Cialis) in men with erectile dysfunction. 2004 , 46, 362-9; discussion 369	48
1270	Efficacy of sildenafil citrate in treatment of erectile dysfunction: effect of type 2 diabetes. 2004 , 46, 503-9	32
1269	The influence of sildenafil on random skin flap survival in rats: an experimental study. 2004 , 57, 769-72	75
1268	Relaxant action of sildenafil citrate (Viagra) on human myometrium of pregnancy. 2004 , 191, 315-21	26
1267	The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment. 2004 , 33, 19-30	74
1266	Seeking help for erectile dysfunction after treatment for prostate cancer. 2004 , 33, 443-54	38
1265	Psychotherapy for erectile dysfunction: now more relevant than ever. 2004 , 23, 131-4	33
1264	Therapy of ED: PDE-5 Inhibitors. 2004 , 23, 135-41	24
1263	Development and initial validation of a new preference-based disease-specific health-related quality of life instrument for erectile function. 2004 , 13, 349-59	27

1262	[Treatment of achalasia]. 2004 , 116, 296-304	2
1261	Longitudinal assessment of changes in sexual function and bother in patients treated with external beam radiotherapy or brachytherapy, with and without neoadjuvant androgen ablation: data from CaPSURE. 2004 , 60, 1066-75	21
1260	Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone. 2004 , 22, 261-6	48
1259	[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors]. 2004 , 43, 820-8	9
1258	Impact of diabetes mellitus on the severity of erectile dysfunction and response to treatment: analysis of data from tadalafil clinical trials. 2004 , 47, 1914-23	132
1257	Erectile dysfunction in the cardiac patient. 2004 , 30, 50-4	6
1256	The impact of erectile dysfunction and its treatment with phosphodiesterase type-5 (PDE5) inhibitors in patients with diabetes. 2004 , 21, 225-230	0
1255	The PsychoedPlusMed approach to erectile dysfunction treatment: the impact of combining a psychoeducational intervention with sildenafil. 2004 , 30, 305-14	40
1254	Clinical efficacy and safety of sildenafil in elderly patients with erectile dysfunction. 2004 , 50, 255-60	15
1253	[The influence of technical products on sexual activity and gender relations: oral contraceptive, condom, oral treatments of sexual disorders]. 2004 , 52, 377-87	16
1252	Ultrastructural changes of corpora cavernosa in men with erectile dysfunction and chronic renal failure. 2004 , 24, 488-91	18
1251	Erectile dysfunction: etiology, evaluation, and treatment options. 2004 , 88, 387-416, xi	8
1250	Prevention and treatment of erectile dysfunction using lifestyle changes and dietary supplements: what works and what is worthless, part I. 2004 , 31, 249-57	19
1249	Efficacy of Vardenafil in Men with Erectile Dysfunction: A Flexible-Dose Community Practice Study. 2004 ,	
1248	Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. 2004 , 172, 1935-40	133
1247	New approaches for persistent pulmonary hypertension of newborn. 2004 , 31, 591-611	56
1246	Concomitant use of sildenafil and a vacuum entrapment device for the treatment of erectile dysfunction. 2004 , 171, 292-5	34
1245	New phosphodiesterase inhibitors in the treatment of erectile dysfunction. 2004 , 5, 2241-9	11

1244	New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88	69
1243	Future options for combination therapy in the management of erectile dysfunction in older men. 2004 , 21, 555-64	26
1242	Management of Prostate Cancer. 2004 ,	2
1241	Sildenafil. 2004 ,	
1240	The discovery and development of Viagra® (sildenafil citrate). 2004 , 1-13	4
1239	Beyond Sexual Mechanics and Hydraulics: Humanizing the Discourse Surrounding Erectile Dysfunction. 2004 , 44, 215-242	13
1238	Diagnosis and treatment of pulmonary arterial hypertension. 2004 , 22, 441-52, vii	5
1237	Treatment Options for Erectile Dysfunction in Patients Failing Oral Drug Therapy. 2004 , 2, 75-83	11
1236	Epilepsy and erectile dysfunction: a review. 2004 , 13, 453-9	52
1235	Efficacy and safety of sildenafil citrate in hemodialysis patients. 2004 , 36, 56-8	8
1234	Female sexual dysfunction after radical cystectomy: a new outcome measure. 2004 , 63, 1153-7	87
1233	Histopathological effects of sildenafil citrate on rat corpus cavernosum. 2004 , 106, 37-45	6
1232	Visual short-term effects of Viagra: double-blind study in healthy young subjects. 2004 , 137, 842-9	50
1231	Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. 2004 , 17, 139-45	52
1230	Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking-induced endothelial dysfunction. 2004 , 17, 1040-4	38
1229	Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. 2004 , 110, 3149-55	143
1228	Nitric oxide release from human corpus cavernosum induced by a purified scorpion toxin. 2004 , 63, 184-9	31
1227	Effect of acute in vivo sildenafil citrate and in vitro 8-bromo-cGMP treatments on semen parameters and sperm function. 2004 , 81, 1026-33	40

1226	Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. 2004 , 125, 580-6	100
1225	Efficacy of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in remission from depression. 2004 , 19, 191-9	32
1224	Sildenafil citrate ingestion in a pediatric patient. 2004 , 20, 314-5	8
1223	Economic analysis of sildenafil citrate (Viagra) add-on to treat erectile dysfunction associated with selective serotonin reuptake inhibitor use. 2004 , 11, 9-12	22
1222	Understanding erectile dysfunction medication preference studies. 2004 , 14, 367-73	30
1221	Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. 2005 ,	
1220	Physiology and Pharmacology of Erectile Dysfunction. 2005 , 1-24	1
1219	Fluvoxamine affects sildenafil kinetics and dynamics. 2005 , 25, 589-92	8
1218	Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. 2005 , 112, 2980-5	260
1217	Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. 2005 , 108, 331-8	39
1216	Gene transfer of vasoactive intestinal polypeptide into the penis improves erectile response in the diabetic rat. 2005 , 95, 890-4	31
1215	In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit. 2005 , 96, 164-8	16
1214	Phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 96, 257-80	153
1213	Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD[P]H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. 2005 , 96, 423-7	97
1212	Pelvic floor exercises for erectile dysfunction. 2005 , 96, 595-7	42
1211	An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy. 2005 , 96, 1323-32	78
1210	Past, present, and future: a 7-year update of Viagra (sildenafil citrate). 2005 , 59, 680-91	61
1209	Possible role of sildenafil in inhibiting rat vas deferens contractions by influencing the purinergic system. 2005 , 12, 829-34	6

1208	Tunica albuginea overlapping: a novel technique for the treatment of erectile dysfunction. 2005 , 37, 180-4	6
1207	An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. 2005 , 59, 85-93	23
1206	A study of the management of erectile dysfunction in general practice. 2005 , 30, 297-304	
1205	Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. 2005 , 11, 214-22	728
1204	Post-marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. 2005 , 17, 71-5	9
1203	Sildenafil in the treatment of erectile dysfunction in men with diabetes: demand, efficacy and patient satisfaction. 2005 , 17, 264-9	17
1202	Efficacy of sildenafil as the first-step therapeutic tool for Japanese patients with erectile dysfunction. 2005 , 17, 339-42	4
1201	Why do patients with heart failure suffer from erectile dysfunction? A critical review and suggestions on how to approach this problem. 2005 , 17 Suppl 1, S25-36	44
1200	A multidisciplinary approach to assess erectile dysfunction in high-risk cardiovascular patients. 2005 , 17 Suppl 1, S37-43	8
1199	A 6-month study of the efficacy and safety of tadalafil in the treatment of erectile dysfunction: a randomised, double-blind, parallel-group, placebo-controlled study in Australian men. 2005 , 59, 143-9	14
1198	Characteristics of sildenafil erections in healthy young men. 2005 , 7, 395-8	7
1197	The effects of sildenafil on ocular blood flow. 2005 , 83, 355-9	34
1196	Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. 2005 , 47, 80-5; discussion 85-6	239
1195	Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. 2005 , 47, 87-91	94
1194	Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. 2005 , 47, 518-22; discussion 522-3	68
1193	An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. 2005 , 47, 846-54; discussion 854	44
1192	The efficacy and safety of PDE5 inhibitors. 2005 , 7, 47-56	28
1191	Symptomatic therapy and neurorehabilitation in multiple sclerosis. 2005 , 4, 643-52	160

1190	Vascular aetiology of erectile dysfunction. 2005 , 28 Suppl 2, 35-9	11
1189	The therapeutic dilemma: how to use tadalafil. 2005 , 28 Suppl 2, 74-80	36
1188	The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. 2005 , 2, 532-40; discussion 540-2	174
1187	Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial. 2005 , 2, 685-98	22
1186	Sexual intercourse attempt patterns with two dosing regimens of tadalafil in men with erectile dysfunction: results from the SURE study in 14 European countries. 2005 , 2, 668-74	11
1185	Efficacy of sildenafil citrate in men with erectile dysfunction following radical prostatectomy: a systematic review of clinical data. 2005 , 2, 658-67	75
1184	Current perspectives on the clinical assessment and diagnosis of female sexual dysfunction and clinical studies of potential therapies: a statement of concern. 2005 , 2 Suppl 3, 146-53	36
1183	Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 2, 848-55	30
1182	A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. 2005 , 2, 53-7	20
1181	Sildenafil citrate response correlates with the nature and the severity of penile vascular insufficiency. 2005 , 2, 104-8	24
1180	Superoxide anion production in the rat penis impairs erectile function in diabetes: influence of in vivo extracellular superoxide dismutase gene therapy. 2005 , 2, 187-97; discussion 197-8	99
1179	Invited Comment on Bivalacqua T. et al. Superoxide Anion Production in the Rat Penis Impairs Erectile Function in Diabetes: Influence of In Vivo Extracellular Superoxide Dismutase Gene Therapy. 2005 , 2, 197-198	3
1178	Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. 2005 , 2, 341-6	26
1177	Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. 2005 , 2, 415-25; discussion 425-7	80
1176	Use of a visual analog scale to assess pain of injection with intracavernous injection therapy. 2005 , 2, 428-31	7
1175	Nitric oxide and penile erectile function. 2005 , 106, 233-66	163
1174	Effects of sildenafil on major arterial blood flow using duplex sonography. 2005 , 33, 173-5	3
1173	Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. 2005 , 23, 385-92	37

1172	Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. 2005 , 23, 374-84	25
1171	Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries--immunohistochemical distribution and functional significance. 2005 , 23, 405-10	29
1170	[Therapy for organic erectile dysfunction]. 2005 , 44, 1160-6	2
1169	Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. 2005 , 62, 1198-220	188
1168	Optimization of purine based PDE1/PDE5 inhibitors to a potent and selective PDE5 inhibitor for the treatment of male ED. 2005 , 15, 2365-9	22
1167	Hypogonadism in the man with erectile dysfunction: what to look for and when to treat. 2005 , 6, 476-81	17
1166	Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries. 2005 , 37, 785-9	2
1165	Indirect comparison of interventions using published randomised trials: systematic review of PDE-5 inhibitors for erectile dysfunction. 2005 , 5, 18	43
1164	Prevention and Treatment of Erectile Dysfunction Utilizing Lifestyle Changes and Dietary Supplements. 2005 , 339-378	
1163	Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. 2005 , 11, 674-80	12
1162	Therapie der erektilen Dysfunktion. 2005 , 341-352	
1161	Bibliography. 2005 , 649-682	
1160	Urologic Diseases in Elderly Men. 2005 , 48, 236	2
1159	Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. 2005 , 31, 342-53; discussion 354-5	10
1158	Effect of sildenafil citrate on the cardiovascular system. 2005 , 38, 1303-11	8
1157	Clinical experience with the Mentor Alpha-1 inflatable penile prosthesis: report on 65 patients. 2005 , 39, 69-72	12
1156	Endothelial nitric oxide synthase gene therapy for erectile dysfunction. 2005 , 11, 4059-67	24
1155	Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans. 2005 , 112, 2642-9	142

1154	Urologic complications of diabetes. 2005 , 28, 177-85	211
1153	Oral sildenafil for treatment of severe pulmonary hypertension in an infant. 2005 , 88, 109-12	24
1152	A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. 2005 , 76, 700-5	90
1151	[Management of erectile dysfunction in the cardiac patient]. 2005 , 130, 2899-903	3
1150	Clinical and duplex US assessment of effects of sildenafil on cavernosal arteries of the penis: comparison with intracavernosal injection of vasoactive agents--initial experience. 2005 , 237, 986-91	16
1149	PDE5 Inhibitors may help some women with sexual problems. 2005 , 20, 65-69	2
1148	Erectile dysfunction: anatomical parameters, etiology, diagnosis, and therapy. 2005 , 51, 15-31	23
1147	Cardiovascular system as a 'core' of sexual life. 2005 , 6, 2223-30	2
1146	Interruption of homologous desensitization in cyclic guanosine 3',5'-monophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. 2005 , 65, 11129-35	30
1145	Erectile Dysfunction. 2005 , 23, 105-113	5
1144	Effects of phosphodiesterase type 5 inhibitor sildenafil on retinal function in isolated superfused retina. 2005 , 21, 305-14	13
1143	Erectile dysfunction in spinal cord injury: a cost-utility analysis. 2005 , 37, 358-64	22
1142	Integrating medication, realistic expectations, and therapeutic interventions in the treatment of male sexual dysfunction. 2005 , 31, 319-28	47
1141	Developing an open relationship with the drug industry. 2005 , 366, 1062-4	10
1140	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72	4
1139	Disfunci3 er3til: objetivos e intervenciones en la consulta de enfermer3. 2005 , 15, 43-49	0
1138	Correlation between voiding and erectile function in patients with symptomatic benign prostatic hyperplasia. 2005 , 68, 178-82	6
1137	Psychosocial evaluation and combination treatment of men with erectile dysfunction. 2005 , 32, 431-45, vi	30

1136	Treatment of erectile dysfunction following therapy for clinically localized prostate cancer: patient reported use and outcomes from the Surveillance, Epidemiology, and End Results Prostate Cancer Outcomes Study. 2005 , 174, 646-50; discussion 650	98
1135	Disfunci3 sexual en la hipertensi3 arterial. 2005 , 22, 59-72	0
1134	Oral Pharmacotherapy for Male Sexual Dysfunction. 2005 ,	
1133	Pharmacology of Phosphodiesterase Inhibitors. 2005 , 43-63	2
1132	Prescribing for erectile dysfunction: A Delphi based consensus study. 2005 , 20, 181-194	2
1131	A review of hypogonadism and erectile dysfunction among HIV-infected men during the pre- and post-HAART eras: diagnosis, pathogenesis, and management. 2005 , 19, 655-71	58
1130	Effects of combined treatment with sildenafil and itraconazole on the cardiovascular system in telemetered conscious dogs. 2005 , 28, 177-86	3
1129	The supraspinal network in the control of erection. 2005 , 9, 941-54	3
1128	Is it necessary to use sexual health inventory for men (SHIM) routinely?. 2005 , 51, 207-12	
1127	Sildenafil citrate (Viagra) enhances vasodilatation in fetal growth restriction. 2005 , 90, 2550-5	124
1126	Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. 2005 , 6, 75-84	43
1125	Phosphodiesterase 5 inhibitors for erectile dysfunction. 2005 , 39, 1286-95	61
1124	Effects of short-term moderate exercise training on sexual function in male patients with chronic stable heart failure. 2005 , 101, 83-90	52
1123	Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension. 2005 , 100, 267-73	129
1122	Sildenafil potentiates nitric oxide mediated inhibition of human platelet aggregation. 2005 , 337, 382-5	30
1121	The possible role of the NO-cGMP pathway in nociception: different spinal and supraspinal action of enzyme blockers on rat dorsal horn neurones. 2005 , 117, 358-367	30
1120	Melanocortinerbic control of penile erection. 2005 , 26, 1972-7	21
1119	Aggressive behavior increases after termination of chronic sildenafil treatment in mice. 2005 , 83, 683-8	29

1118	Effects of sildenafil citrate on ejaculation latency, detumescence time, and refractory period: placebo-controlled, double-blind, crossover laboratory setting study. 2005 , 65, 347-52	15
1117	Efficacy, safety, and treatment satisfaction of tadalafil versus placebo in patients with erectile dysfunction evaluated at tertiary-care academic centers. 2005 , 65, 353-9	53
1116	Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. 2005 , 65, 755-9	35
1115	Management of erectile dysfunction after radical prostatectomy. 2005 , 66, 923-9	19
1114	The efficacy of tadalafil in improving sexual satisfaction and overall satisfaction in men with mild, moderate, and severe erectile dysfunction: a retrospective pooled analysis of data from randomized, placebo-controlled clinical trials. 2005 , 21, 1701-9	14
1113	[Sensitivity to change and minimally important difference of the Spanish version of the life-satisfaction questionnaire LISAT-8 in male patients with erectile dysfunction]. 2005 , 124, 165-71	6
1112	Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy. 2005 , 26, 757-60	39
1111	A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. 2005 , 65, 1621-50	133
1110	Treatment for erectile dysfunction based on patient-reported outcomes: to every man the PDE5 inhibitor that he finds superior. 2005 , 65, 2245-51	24
1109	Quality-of-Life Utility Values for Erectile Function and Sildenafil Treatment. 2005 , 25, 99-105	19
1108	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. 2005 , 4, 531-40	18
1107	Male erectile dysfunction: Chemical pharmacology of penile erection. 2005 , 2, 31-36	8
1106	Strategies in the oral pharmacotherapy of male erectile dysfunction viewed from bench and bedside (Part I). 2005 , 2, 87-94	2
1105	PDE-5 inhibitors: current status and future trends. 2005 , 32, 511-25, viii	25
1104	Safety and tolerability of oral erectile dysfunction treatments in the elderly. 2005 , 22, 323-38	5
1103	Aging in the Hypothalamic-Pituitary-Testicular Axis. 2006 , 2697-2728	5
1102	[Tadalafil vs sildenafil patient preference in Spanish men with erectile dysfunction: results from an International Multicentric Study]. 2006 , 30, 67-79	7
1101	Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. 2006 , 4, 293-300	41

1100	Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials. 2006 , 22, 2111-20	24
1099	Neurobiology of Male Sexual Behavior. 2006 , 1729-1824	29
1098	Combined angiopoietin-1 and vascular endothelial growth factor gene transfer restores cavernous angiogenesis and erectile function in a rat model of hypercholesterolemia. 2006 , 13, 705-15	73
1097	Hypertension and Erectile Dysfunction. 2006 , 13, 7-11	
1096	Sildenafil effects on sexual function in asymptomatic volunteers: a controlled study. 2006 , 32, 37-42	
1095	Effects of sildenafil citrate (Viagra) on renal arteries: an evaluation with Doppler ultrasound. 2006 , 77, 170-2	4
1094	The Role of Erection Hardness in Determining Erectile Dysfunction (ED) Treatment Outcome. 2006 , 5, 767-772	5
1093	Partner Satisfaction and Successful Treatment Outcomes for Men with Erectile Dysfunction (ED). 2006 , 5, 779-785	8
1092	Role of nitric oxide in the relaxation elicited by sildenafil in penile resistance arteries. 2006 , 175, 1164-70	11
1091	Brain processing of audiovisual sexual stimuli inducing penile erection: a positron emission tomography study. 2006 , 176, 679-83	30
1090	Evaluation and medical management of erectile dysfunction. 2006 , 81, 385-90	17
1089	An overview of the diagnosis and treatment of erectile dysfunction. 2006 , 66, 2339-55	17
1088	Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. 2006 , 117, 1077-83	253
1087	Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. 2006 , 27, 165-75	39
1086	Correlation of improved erectile function and rate of successful intercourse with improved emotional well-being assessed with the Self-Esteem And Relationship questionnaire in men treated with sildenafil for erectile dysfunction and stratified by age. 2006 , 22, 939-48	20
1085	Does testosterone have a role in erectile function?. 2006 , 119, 373-82	74
1084	Cardiovascular risk among men seeking help for erectile dysfunction. 2006 , 16, 85-90	31
1083	Sildenafil improves sexual functioning in premenopausal women with type 1 diabetes who are affected by sexual arousal disorder: a double-blind, crossover, placebo-controlled pilot study. 2006 , 85, 1496-501	86

1082	Subcellular localization and regulation of type-1C and type-5 phosphodiesterases. 2006 , 341, 837-46	39
1081	1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction. 2006 , 49, 5093-109	16
1080	Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. 2006 , 166, 231-3	67
1079	The role of nitric oxide in erectile dysfunction: implications for medical therapy. 2006 , 8, 53-62	112
1078	Phosphodiesterase type 5 inhibitor sildenafil citrate does not potentiate the vasodilative properties of nebivolol in rat aorta. 2006 , 78, 1103-7	6
1077	Non-responders to phosphodiesterase type 5 inhibitors: is there a second chance?. 2006 , 3, 342-349	5
1076	Vasodilatory factors in treatment of older men with symptomatic benign prostatic hyperplasia. 2006 , 67, 225-31	7
1075	Effect of Epimedium brevicornum Maxim extract on elicitation of penile erection in the rat. 2006 , 67, 631-5	17
1074	Changes in clitoral blood flow in premenopausal women affected by type 1 diabetes after single 100-mg administration of sildenafil. 2006 , 68, 161-5	42
1073	An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. 2006 , 68, 386-91	48
1072	Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction. 2006 , 68, 397-401	12
1071	Efficacy of sildenafil citrate in treatment of erectile dysfunction: impact of associated premature ejaculation and low desire. 2006 , 68, 642-7	17
1070	A prospective study of the beneficial effects of dose optimization and customized instructions on patient satisfaction with sildenafil citrate (Viagra) for erectile dysfunction. 2006 , 68, 38-46	17
1069	Introduction. 2006 , 68, 1-5	0
1068	Efficacy and safety of tadalafil 5, 10, and 20 mg in Japanese men with erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled study. 2006 , 68, 845-51	18
1067	Erection hardness: a unifying factor for defining response in the treatment of erectile dysfunction. 2006 , 68, 17-25	53
1066	Research instruments for the diagnosis and treatment of patients with erectile dysfunction. 2006 , 68, 6-16	46
1065	Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). 2006 , 68, 26-37	41

1064	Sexual function after surgery for prostate or bladder cancer. 2006 , 13, 179-87	17
1063	A Randomised, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy and Safety of Tadalafil Administered On-Demand to Men with Erectile Dysfunction in Korea. 2006 , 47, 852	3
1062	. 2006 ,	
1061	Multiple sclerosis. 616-635	
1060	Effect of sildenafil citrate on postprandial gallbladder motility. 2006 , 99, 208-11	2
1059	The PDE-5 inhibitors and psychiatry. 2006 , 12, 46-9	1
1058	Effects of tadalafil on myocardial blood flow in patients with coronary artery disease. 2006 , 17, 493-9	8
1057	Androgens and male sexual dysfunction. 2006 , 13, 267-271	
1056	Management of the cardinal features of andropause. 2006 , 13, 145-60	19
1055	Management of sildenafil treatment failures. 2006 , 16, 449-59	33
1054	Effectiveness of sildenafil in treating erectile dysfunction in PTSD patients: a double-blind, placebo-controlled crossover study. 2006 , 26, 426-30	8
1053	Use of Sildenafil in the Treatment of Erectile Dysfunction in Patients With Spinal Cord Injury. 2006 , 16, 40-43	3
1052	Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. 2006 , 38, 61-8	49
1051	Physician-rated patient preference and patient- and partner-rated preference for tadalafil or sildenafil citrate: results from the Canadian 'Treatment of Erectile Dysfunction' observational study. 2006 , 98, 623-9	22
1050	Efficacy and safety of on-demand tadalafil for the treatment of erectile dysfunction in South-East Asian men. 2006 , 13, 721-7	12
1049	Sexuality and seeking medical help for erectile dysfunction in young adults with spina bifida. 2006 , 13, 1323-6	20
1048	Comparison of phosphodiesterase type 5 (PDE5) inhibitors. 2006 , 60, 967-75	113
1047	Diabetic neuropathy - a further indication for phosphodiesterase type 5 inhibitors?. 2006 , 60, 1026-7	0

1046	Efficacy and safety of on demand tadalafil in the treatment of East and Southeast Asian men with erectile dysfunction: a randomized double-blind, parallel, placebo-controlled clinical study. 2006 , 8, 685-92	22
1045	Regaining of morning erection and sexual confidence in patients with erectile dysfunction. 2006 , 8, 703-8	2
1044	Effects of sildenafil citrate on defibrillation efficacy. 2006 , 17, 292-5	14
1043	Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study. 2006 , 23, 121-8	50
1042	The effect of sildenafil on segmental oesophageal motility and gastro-oesophageal reflux. 2006 , 24, 1029-36	20
1041	Penile duplex pharmaco-ultrasonography of cavernous arteries in men with erectile dysfunction and generalized atherosclerosis. 2006 , 29, 496-501	16
1040	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702	366
1039	Late-stage clinical development in lower urogenital targets: sexual dysfunction. 2006 , 147 Suppl 2, S153-9	10
1038	Effects of sildenafil on blue-on-yellow and white-on-white Humphrey perimetry in 3 months regular use. 2006 , 20, 810-3	6
1037	Can self-administered questionnaires supplant objective testing of erectile function? A comparison between the International Index Of Erectile Function and objective studies. 2006 , 18, 126-9	16
1036	Efficacy of sildenafil in male dialysis patients with erectile dysfunction unresponsive to erythropoietin and/or testosterone treatments. 2006 , 18, 61-8	12
1035	Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. 2006 , 18, 229-35	49
1034	Outcome analysis of sildenafil citrate for erectile dysfunction of Japanese patients. 2006 , 18, 302-5	5
1033	Gene and protein expression profiles of prostaglandin E2 receptor subtypes in the human corpus cavernosum. 2006 , 18, 275-81	4
1032	Inventories for male and female sexual dysfunctions. 2006 , 18, 236-50	109
1031	Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil. 2006 , 18, 251-7	16
1030	Gene transfer for the therapy of erectile dysfunction: progress in the 21st century. 2006 , 18, 19-25	17
1029	Effect of sildenafil on ocular hemodynamics in 3 months regular use. 2006 , 18, 282-6	17

1028	Epimedium brevicornum Maxim extract relaxes rabbit corpus cavernosum through multitargets on nitric oxide/cyclic guanosine monophosphate signaling pathway. 2006 , 18, 335-42	31
1027	Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. 2006 , 18, 400-4	63
1026	Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. 2006 , 18, 550-8	17
1025	A meta-regression analysis of treatment effect modifiers in trials with flexible-dose oral sildenafil for erectile dysfunction in broad-spectrum populations. 2006 , 18, 559-65	11
1024	Sildenafil citrate (Viagra) treatment for erectile dysfunction: An updated profile of response and effectiveness. 2006 , 18, 423-31	26
1023	Determination of changes in blood pressure during administration of sildenafil (Viagra) in patients with spinal cord injury and erectile dysfunction. 2006 , 44, 301-8	15
1022	A randomized, double-blind, placebo-controlled, cross-over study to assess the efficacy of tadalafil (Cialis) in the treatment of erectile dysfunction following three-dimensional conformal external-beam radiotherapy for prostatic carcinoma. 2006 , 66, 439-44	55
1021	Inhibitory effects of sildenafil on small intestinal motility and myoelectrical activity in dogs. 2006 , 51, 671-6	4
1020	A Combined-Constructionist Therapeutic Approach to Couples Experiencing Erectile Dysfunction: Part II. 2006 , 28, 403-418	6
1019	Phosphodiesterase-5 inhibitors and their hemodynamic effects. 2006 , 8, 345-51	23
1018	Sildenafil citrate induces migration of mouse aortic endothelial cells and proteinase secretion. 2006 , 11, 402-407	1
1017	Sildenafil citrate improves self-esteem, confidence, and relationships in men with erectile dysfunction: Results from an international, multi-center, double-blind, placebo-controlled trial. 2006 , 3, 521-9	71
1016	Treatment-seeking behavior of erectile dysfunction patients in Europe: Results of the Erectile Dysfunction Observational Study. 2006 , 3, 530-40	32
1015	Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. 2006 , 3, 650-661	45
1014	Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study. 2006 , 3, 716-722	33
1013	Subclinical erectile dysfunction: proposal for a novel taxonomic category in sexual medicine. 2006 , 3, 787-794	25
1012	Vardenafil improved erectile function in a "real-life" broad population study of men with moderate to severe erectile dysfunction in Australia and New Zealand. 2006 , 3, 892-900	4
1011	Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. 2006 , 3, 901-909	45

1010	Ca ²⁺ -activated K ⁺ (KCa) channels are involved in the relaxations elicited by sildenafil in penile resistance arteries. 2006 , 531, 232-7	22
1009	Can phosphodiesterase type 5 inhibitors cure erectile dysfunction?. 2006 , 49, 979-86	22
1008	Positive effect of counseling and dose adjustment in patients with erectile dysfunction who failed treatment with sildenafil. 2006 , 50, 134-40	54
1007	Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime. 2006 , 49, 900-7; discussion 907	16
1006	Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. 2006 , 50, 351-9	139
1005	Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. 2006 , 50, 1194-207; discussion 1207	74
1004	Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. 2006 , 97, 1778-84	63
1003	Treatment of erectile dysfunction with sildenafil citrate in renal allograft recipients: a randomized, double-blind, placebo-controlled, crossover trial. 2006 , 48, 128-33	45
1002	Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo-controlled, flexible-dose, two-way crossover trial. 2006 , 163, 494-9	53
1001	A double-blind, placebo-controlled, crossover study of sildenafil in obstructive sleep apnea. 2006 , 166, 1763-7	41
1000	[Erectile dysfunction in depression and under treatment with antidepressants -- current treatment options]. 2006 , 74, 71-6	3
999	Efficacy of sildenafil for Japanese patients with audio-visual sexual stimulation (AVSS) test by the RigiScan Plus. 2006 , 52, 163-8	1
998	Factors affecting sexuality in older Australian women: sexual interest, sexual arousal, relationships and sexual distress in older Australian women. 2006 , 9, 355-67	47
997	Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. 2006 , 12, 3467-84	47
996	Ion channel gene therapy for smooth muscle disorders: relaxing smooth muscles to treat erectile dysfunction. 2006 , 4, 89-95	7
995	Sildenafil citrate and fetal outcome in pregnant rats. 2006 , 21, 259-63	27
994	Detection of sildenafil analogues in herbal products for erectile dysfunction. 2006 , 69, 1951-8	30
993	Premature ejaculation: the scope of the problem. 2007 , 33, 151-70	19

992	Tadalafil is efficacious in Black American and Hispanic men with erectile dysfunction: results from multiple observations in men with erectile dysfunction in national tadalafil study in the US (MOMENTUS). 2007 , 19, 76-83	6
991	The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. 2007 , 19, 139-48	45
990	Early sildenafil dose optimization and personalized instruction improves the frequency, flexibility, and success of sexual intercourse in men with erectile dysfunction. 2007 , 19, 154-60	23
989	The association between intron 4 VNTR, E298A and IVF 23+10 G/T polymorphisms of ecNOS gene and sildenafil responsiveness in patients with erectile dysfunction. 2007 , 19, 149-53	31
988	Correlations between increased erection hardness and improvements in emotional well-being and satisfaction outcomes in men treated with sildenafil citrate for erectile dysfunction. 2007 , 19, 398-406	20
987	Recreational use of erectile dysfunction medication may decrease confidence in ability to gain and hold erections in young males. 2007 , 19, 591-6	25
986	Type 1 Diabetes in Adults. 2007 ,	0
985	Sildenafil in the treatment of erectile dysfunction. 2007 , 3, 295-303	2
984	Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection. 2007 , 50, 670-6	15
983	Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. 2007 , 19, 95-103	93
982	Sildenafil is well tolerated by erectile dysfunction patients taking antihypertensive medications, including those on multidrug regimens. 2007 , 2, 5-8	5
981	Chronic sildenafil in men with diabetes and erectile dysfunction. 2007 , 3, 451-64	24
980	Systems Biology. 2007 ,	4
979	Hemodynamic interaction between a daily dosed phosphodiesterase 5 inhibitor, tadalafil, and the alpha-adrenergic blockers, doxazosin and tamsulosin, in middle-aged healthy male subjects. 2007 , 47, 1303-10	16
978	Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?. 2007 , 116, 233-5	5
977	Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. 2007 , 79, 28-32	41
976	Treatment of erectile dysfunction: update. 2007 , 1, 126-38	5
975	Sildenafil citrate (Viagra) enhances vasodilatation by atrial natriuretic peptide in normal dogs. 2007 , 71, 1965-9	4

974 Sexual problems in medical patients. 221-244

973 A case of sensorineural deafness following ingestion of sildenafil. **2007**, 121, 395-7 40

972 Nitrate cessation profiles in men wishing to use sildenafil citrate. **2007**, 69, 946-9 2

971 Tadalafil (Cialis) and erectile dysfunction after radiotherapy for prostate cancer: an open-label extension of a blinded trial. **2007**, 70, 1190-3 27

970 Tratamiento sintomático de las complicaciones de la esclerosis múltiple. Tratamiento rehabilitador. **2007**, 9, 4886-4893

969 Sildenafil affects olfactory function. **2007**, 177, 258-61; discussion 261 17

968 Depression and erectile dysfunction. **2007**, 34, 565-74, vii 33

967 Re: Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial: K. T. McVary, W. Monnig, J. L. Camps, Jr., J. M. Young, L. J. Tseng and G. van den Ende. *J Urol* 2007, 177, 1071-1077. **2007**, 178, 1121-2, author reply 1122-3

966 Ventricular tachycardia after administration of sildenafil citrate: a case report. **2007**, 1, 65 4

965 Erectile Dysfunction. **2007**, 513-522

964 Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. **2007**, CD002187 50

963 The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. **2007**, 19, 253-64 107

962 Urogynecology in Primary Care. **2007**,

961 Vardenafil: a selective inhibitor of phosphodiesterase-5 for the treatment of erectile dysfunction. **2007**, 8, 965-74 16

960 [Acute myocardial infarction associated to the Sildenafil consumption. A case report and review of the literature]. **2007**, 31, 52-7 1

959 Sexual activity and chronic heart failure. **2007**, 82, 1203-10 31

958 [Oral sildenafil in neonatal medicine: "tested in adults also used in neonates"]. **2007**, 66, 167-76 7

957 Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?. **2007**, 19, 281-95 33

956	Management of sexual dysfunction due to antipsychotic drug therapy. 2007 , CD003546	19
955	Visual loss associated with erectile dysfunction drugs. 2007 , 42, 10-12	
954	Central corneal thickness measurement in glaucoma: why should we care?. 2007 , 42, 12-13	
953	Salvage strategies for nonresponders to phosphodiesterase-5 inhibitor treatment for erectile dysfunction in the aging male. 2007 , 3, 527-542	1
952	Pulmonary Hypertension. 2007 ,	
951	An Alternative dosing Regimen with Tadalafil 3 Times/Week in the Treatment of Erectile Dysfunction: Italian Data from the SURE Study. 2007 , 74, 30-36	
950	Comparison of the Efficacy, Safety and Patient Preference of the Phosphodiesterase Type 5 Inhibitors for the Patients with Erectile Dysfunction. 2007 , 48, 219	5
949	Molecular modeling studies of pyridopurinone derivatives--potential phosphodiesterase 5 inhibitors. 2007 , 26, 378-90	38
948	Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. 2007 , 6, 617-35	119
947	The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners. 2007 , 99, 376-82	21
946	Analysis of the efficacy and safety of sildenafil citrate in the geriatric population. 2007 , 100, 117-21	17
945	Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study. 2007 , 100, 122-9	33
944	Assessment of comparative treatment satisfaction with sildenafil citrate and penile injection therapy in patients responding to both. 2007 , 100, 1313-6	19
943	How long do patients with erectile dysfunction continue to use sildenafil citrate? Dropout rate from treatment course as outcome in real life. 2007 , 14, 339-42; discussion 343	23
942	Inhibitory effects of sildenafil on gastric motility and gastric slow waves in dogs. 2007 , 19, 218-24	4
941	Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study. 2007 , 61, 1850-62	27
940	The temporal relationship between erectile dysfunction and cardiovascular disease. 2007 , 61, 2019-25	88
939	Effect of sildenafil citrate (Viagra) on coronary flow in normal subjects. 2008 , 25, 72-6	3

938	Evaluation of an alternative dosing regimen with tadalafil, three times per week, for men with erectile dysfunction: SURE study in Italy. 2007 , 9, 395-402	6
937	Different hemodynamic responses by color Doppler ultrasonography studies between sildenafil non-responders and responders. 2007 , 9, 129-33	13
936	Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS). 2007 , 51, 541-50; discussion 550	44
935	Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. 2007 , 52, 990-1005	45
934	Blood pressure control and sildenafil--carrot stick or sword of Damocles?. 2007 , 100, 552-3	2
933	Is sex only for the healthy and wealthy?. 2007 , 4, 176-182	18
932	Quality of erection questionnaire correlates: change in erection quality with erectile function, hardness, and psychosocial measures in men treated with sildenafil for erectile dysfunction. 2007 , 4, 83-92	34
931	Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study. 2007 , 4, 137-144	9
930	Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. 2007 , 4, 166-175	36
929	Erectile dysfunction: monitoring response to treatment in clinical practice--recommendations of an international study panel. 2007 , 4, 448-64	59
928	Integrated sildenafil and cognitive-behavior sex therapy for psychogenic erectile dysfunction: a pilot study. 2007 , 4, 1117-25	63
927	The South Australian couples sildenafil study: double-blind, parallel-group randomized controlled study to examine the psychological and relationship consequences of sildenafil use in couples. 2007 , 4, 1126-35	22
926	Validation of the erection hardness score. 2007 , 4, 1626-34	180
925	Clinical application of CNS-acting agents in FSD. 2007 , 4 Suppl 4, 280-90	14
924	[Novel indications for phosphodiesterase type 5 inhibitors]. 2007 , 102, 617-30	4
923	Sildenafil combined with continuous positive airway pressure for treatment of erectile dysfunction in men with obstructive sleep apnea. 2007 , 39, 547-52	30
922	Phosphodiesterase type 5 inhibitors and endothelial function. 2007 , 4, 157-162	1
921	Off-line HPLC method combined to LC-MS for the determination of sildenafil and its active metabolite in post-mortem human blood according to confirmation criteria. 2008 , 178, 192-8	27

920	Integrating Sex Therapy Interventions with Couple Therapy. 2008 , 38, 139-149	26
919	Phosphodiesterase 5 inhibition in essential hypertension. 2008 , 10, 52-7	27
918	Chronic dosing of phosphodiesterase type 5 inhibitors. 2008 , 5, 65-69	
917	Short- and long-term effects of Ginkgo biloba extract on sexual dysfunction in women. 2008 , 37, 530-47	61
916	Mechanistic analysis of pH-dependent solubility and trans-membrane permeability of amphoteric compounds: application to sildenafil. 2008 , 352, 217-24	39
915	Yohimbine enhances the effect of sildenafil on erectile process in rats. 2008 , 20, 409-17	11
914	Effects of plant extract neferine on cyclic adenosine monophosphate and cyclic guanosine monophosphate levels in rabbit corpus cavernosum in vitro. 2008 , 10, 307-12	21
913	Global experiences with vardenafil in men with erectile dysfunction and underlying conditions. 2008 , 62, 1594-603	6
912	Expression of the PDE5 enzyme on human retinal tissue: new aspects of PDE5 inhibitors ocular side effects. 2008 , 22, 144-9	49
911	Bilateral cerebral hemispheric infarction associated with sildenafil citrate (Viagra) use. 2008 , 15, 306-8	12
910	Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. 2008 , 102, 829-34	10
909	Efficacy, tolerability and satisfaction with sildenafil citrate 100-mg titration compared with continued 50-mg dose treatment in men with erectile dysfunction. 2008 , 102, 1645-50	19
908	Medical treatments for benign prostatic hyperplasia and sexual function. 2008 , 102 Suppl 2, 8-12	6
907	Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. 2008 , 25, 37-44	101
906	Mechanisms of the relaxant effect of vardenafil in rat penile arteries. 2008 , 586, 283-7	18
905	Urologist practice patterns in the management of premature ejaculation: a nationwide survey. 2008 , 5, 199-205	28
904	Giving patients with erectile dysfunction the opportunity to try all three available phosphodiesterase type 5 inhibitors contributes to better long-term treatment compliance. 2008 , 5, 469-75	33
903	Pure hypertriglyceridemia might be associated with erectile dysfunction: a pilot study. 2008 , 5, 1230-1236	2

902	Efficient gene expression system using the RTP801 promoter in the corpus cavernosum of high-cholesterol diet-induced erectile dysfunction rats for gene therapy. 2008 , 5, 1355-64	14
901	Nitric oxide synthesis leads to vascular endothelial growth factor synthesis via the NO/cyclic guanosine 3',5'-monophosphate (cGMP) pathway in human corpus cavernosal smooth muscle cells. 2008 , 5, 1623-35	21
900	British Society for Sexual Medicine guidelines on the management of erectile dysfunction. 2008 , 5, 1841-65	98
899	Sexual attitude and perception on sexual relationship among long-term users of sildenafil. 2008 , 5, 2681-7	10
898	Sexual satisfaction among patients with erectile dysfunction treated with counseling, sildenafil, or both. 2008 , 5, 1720-6	33
897	An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. 2008 , 5, 2405-13	5
896	Relationship factors in the development and maintenance of ED: implications for treatment effectiveness. 2008 , 5, 1795-804	21
895	The erection hardness score and its relationship to successful sexual intercourse. 2008 , 5, 2374-80	58
894	Sexual counseling in elderly couples. 2008 , 5, 2027-43	33
893	Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. 2008 , 5, 2160-9	61
892	Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. 2008 , 5, 2672-80	60
891	Management of erectile impotence: use of inflatable prosthesis. 2008 , 5, 2494-7	2
890	The Good-Enough Sex Model: a case illustration. 2008 , 23, 227-234	20
889	Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. 2008 , 179, 1066-71	38
888	Sildenafil improves the alveolar-capillary function in heart failure patients. 2008 , 126, 68-72	13
887	Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. 2008 , 21, 516-21	7
886	Sexual problems in males with epilepsy--an interdisciplinary challenge!. 2008 , 17, 136-40	24
885	Sexuality: a quality-of-life issue for cancer survivors. 2008 , 24, 71-9	91

884	Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. 2008 , 1, 272-80	43
883	Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis. 2008 , 177, 506-15	63
882	Disfunci?n er?ctil en el paciente diab?tico. 2008 , 10, 1219-1223	
881	Acute administration of sildenafil enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic patients. 2008 , 38, 1186-93	22
880	The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors. 2008 , 179, 1072-6; discussion 1076	8
879	[Prevalence and severity of erectile dysfunction in a population with coronary insufficiency: monocentric study]. 2008 , 18, 595-600	1
878	Assessment of endothelial function in the patient with erectile dysfunction: an opportunity for the urologist. 2008 , 20, 370-7	16
877	Prognostic factors predicting successful response to sildenafil after radical cystoprostatectomy. 2008 , 42, 110-5	6
876	Textbook of Reconstructive Urologic Surgery. 2008 ,	
875	Sexual dysfunction in chronic hepatitis C virus patients treated with interferon alpha and ribavirin. 2008 , 28, 603-9	14
874	Discovery of NO in the penis. 2008 , 20, 431-6	7
873	Introduction: centrally acting agents in male sexual dysfunction. 2008 , 20 Suppl 1, S1-2	
872	Clinical applications of centrally acting agents in male sexual dysfunction. 2008 , 20 Suppl 1, S17-23	14
871	Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link. 2008 , 20 Suppl 3, S27-32	11
870	Erectile dysfunction in spinal cord-injured men: different treatment options. 2008 , 20, 181-7	32
869	Penile prosthesis implantation: past, present and future. 2008 , 20, 437-44	14
868	Erectile Dysfunction in Diabetes. 2008 , 391-398	
867	Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial. 2008 , 300, 395-404	113

866	Characteristics and expectations of patients with erectile dysfunction: results of the SCORED study. 2008 , 20, 418-24	12
865	The impact of erectile dysfunction on female partners: a qualitative investigation. 2008 , 23, 147-156	24
864	Sexual and marital aspects of old age: an update. 2008 , 23, 161-169	4
863	Tadalafil in the treatment of lower urinary tract symptoms and erectile dysfunction. 2008 , 5, 355-365	2
862	Research priorities for continence care and urogenital health: URGENT recommendations. 2008 , 35, 610-6	
861	Role of sildenafil in neurological disorders. 2008 , 31, 353-62	36
860	Effectiveness of treatments of sexual disorders. 691-709	
859	Endocrinology. 2008 , 127-162	1
858	Tadalafil versus sildenafil citrate in the treatment of ED: Italian patients' preferences and explanatory notes. 2008 , 75, 24-31	1
857	Chemical Profile of Sildenafil and Related Compounds. 2008 , 13, 73-82	6
856	Myocardial protection against reperfusion injury: The cGMP pathway. 2009 , 101, 635-642	42
855	Sildenafil (Viagra) in the treatment of male erectile dysfunction in Nairobi. 2000 , 77, 76-9	5
854	Penile rehabilitation and neuromodulation. 2009 , 9, 652-64	10
853	Erection, emission, and ejaculation:. 132-152	
852	Effect of erectile dysfunction medications on coexisting sexual dysfunctions in couples: Partners' Preference Study. 2009 , 24, 316-332	1
851	Sex therapy failures: a crucial, yet ignored, issue. 2009 , 35, 320-9	20
850	Self-help therapies for sexual dysfunction. 2009 , 46, 143-55	24
849	The effects of vasodilators in pulmonary hypertension: pulmonary vascular or peripheral vascular?. 2009 , 2, 145-50	19

848	Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism. 2009 , 331, 842-50	37
847	The scientific and clinical basis for the treatment of Parkinson disease (2009). 2009 , 72, S1-136	547
846	Cerebral blood flow regulation by nitric oxide: recent advances. 2009 , 61, 62-97	263
845	Factors associated with phosphodiesterase type 5 inhibitor treatment satisfactions: results of patient interrogation. 2009 , 12, 58-61	2
844	An early report on the role of nitrates in erectile dysfunction. 2009 , 166, 115	1
843	Review of drug treatment for female sexual dysfunction. 2009 , 20, 671-4	13
842	Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. 2009 , 21, 149-57	12
841	Concordance in the perception of couples recovering from primary surgical treatment of prostate cancer. 2009 , 21, 253-60	4
840	A literature review and case reports series on the use of phosphodiesterase inhibitors in the treatment of female sexual dysfunction. 2009 , 20, 152-7	15
839	Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics. 2009 , 166, 114-5	8
838	Sildenafil citrate for female sexual arousal disorder: a future possibility?. 2009 , 6, 216-22	30
837	Phosphodiesterase inhibitors and the eye. 2009 , 37, 514-23	34
836	Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. 2009 , 6, 553-7	35
835	Sexual function and tunica albuginea wound healing following penile fracture: An 18-year follow-up study of 352 patients from Kermanshah, Iran. 2009 , 6, 1141-1150	66
834	Long-term, multicenter study of the safety and efficacy of topical alprostadil cream in male patients with erectile dysfunction. 2009 , 6, 520-34	37
833	Scoring correspondence in outcomes related to erectile dysfunction treatment on a 4-point scale (SCORE-4). 2009 , 6, 809-19	24
832	Erectile dysfunction in diabetes mellitus. 2009 , 6, 1232-47	247
831	2009 update on phosphodiesterase type 5 inhibitor therapy part 1: Recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). 2009 , 6, 1794-808; quiz 1793, 1809-10	33

830	The role of hedgehog-interacting protein in maintaining cavernous nerve integrity and adult penile morphology. 2009 , 6, 2480-93	14
829	Combination of vacuum erection device and PDE5 inhibitors as salvage therapy in PDE5 inhibitor nonresponders with erectile dysfunction. 2009 , 6, 2561-7	29
828	The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. 2009 , 6, 2547-60	41
827	Sildenafil citrate 100 mg starting dose in men with erectile dysfunction in an international, double-blind, placebo-controlled study: effect on the sexual experience and reducing feelings of anxiety about the next intercourse attempt. 2009 , 6, 2826-35	22
826	2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. 2009 , 6, 2352-64; quiz 2365-6	31
825	Hydrogen sulphide is involved in testosterone vascular effect. 2009 , 56, 378-83	43
824	Editorial comment on: Hydrogen sulphide is involved in testosterone vascular effect. 2009 , 56, 383-4	
823	Simple and sensitive LC-ESI-MS method for the quantitation of sildenafil in plasma samples. 2009 , 32, 3866-70	14
822	[Erectile dysfunction]. 2009 , 159, 529-34	
821	ERG evaluation of daily, high-dose sildenafil usage. 2009 , 118, 225-31	23
820	[Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily Tadalafil]. 2009 , 48, 1318, 1320-9	7
819	Improvement in duration of erection following phosphodiesterase type 5 inhibitor therapy with vardenafil in men with erectile dysfunction: the ENDURANCE study. 2009 , 63, 27-34	18
818	The burden and extent of comorbid conditions in patients with erectile dysfunction. 2009 , 63, 1205-13	42
817	Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. 2010 , 64, 240-55	119
816	Psychosomatic aspects in the diagnosis and treatment of erectile dysfunction. 1999 , 31 Suppl 1, 37-44	5
815	Physiology and pathophysiology of erection: consequences for present medical therapy of erectile dysfunction. 1999 , 31 Suppl 1, 59-64	2
814	Prostaglandin E1 long-term self-injection programme for treatment of erectile dysfunction--a follow-up of at least 5 years. 1999 , 31 Suppl 1, 99-103	4
813	Efficacy of sildenafil on erectile dysfunction of newlyweds. 2009 , 41, 348-51	1

812	Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. 2009 , 103, 1392-5	32
811	Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat-related post-traumatic stress disorder: a double-blind, randomized and placebo-controlled study. 2009 , 104, 376-83	15
810	Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitors. 2009 , 19, 4088-91	21
809	Neurophysiology of the Genitourinary Organs. 2009 , 905-930	
808	Medical Management and Complications of Spinal Cord Injury. 2009 , 18-36	
807	Comparing Sildenafil alone vs. Sildenafil plus brief couple sex therapy on erectile dysfunction and couples' sexual and marital quality of life: a pilot study. 2009 , 35, 122-43	54
806	Likelihood of tadalafil-associated adverse events in integrated multiclinical trial database: classification tree analysis in men with erectile dysfunction. 2009 , 73, 756-61	12
805	Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms. 2009 , 74, 831-836.e8	34
804	A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. 2009 , 147, 811-5	1026
803	Brain effects of melanocortins. 2009 , 59, 13-47	76
802	Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications. 2009 , 10, 1625-44	9
801	Retinal Angiography and Optical Coherence Tomography. 2009 ,	12
800	Diabetes, obesity, and erectile dysfunction. 2009 , 6 Suppl 1, 4-16	49
799	Psychobiosocial versus biomedical models of treatment: semantics or substance. 2009 , 24, 30-37	12
798	Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. 2009 , 181, 899-906	50
797	Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. 2009 , 151, 650-61	137
796	Phosphodiesterase type 5 inhibitors for the management of erectile dysfunction: preference and adherence to treatment. 2009 , 15, 3486-95	16
795	Is there a place for adjuvant therapy in IVF?. 2010 , 65, 260-72	9

794 Update in women's health. **2010**, 25, 363-8

793 Toxicological evaluation of a dietary supplement formulated for male sexual health prior to market release. **2010**, 57, 55-61 9

792 Age-related morphological changes in smooth muscle and collagen content in human corpus cavernosum. **2010**, 7, 2723-8 25

791 Sexual satisfaction in men with erectile dysfunction: correlates and potential predictors. **2010**, 7, 203-15 24

790 Pharmacotherapy for erectile dysfunction. **2010**, 7, 524-40 132

789 Considerations for diagnostic criteria for erectile dysfunction in DSM V. **2010**, 7, 654-60 27

788 Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. **2010**, 7, 1928-36 29

787 Failure of PDE5 inhibitor use: a case of nonresponder? (CME). **2010**, 7, 1321-3 2

786 Understanding the effects of sildenafil treatment on erection maintenance and erection hardness. **2010**, 7, 2184-2191 8

785 The impact of sexual orientation on sexuality and sexual practices in North American medical students. **2010**, 7, 2391-400 58

784 Patient expectations prior to coloplast titan penile prosthesis implant predicts postoperative satisfaction. **2010**, 7, 2261-2266 30

783 Angiogenesis therapy for the treatment of erectile dysfunction. **2010**, 7, 2554-63 12

782 A survey of erectile dysfunction in Taiwan: use of the erection hardness score and quality of erection questionnaire. **2010**, 7, 2817-24 26

781 Chronic administration of sildenafil modified the impaired VEGF system and improved the erectile function in rats with diabetic erectile dysfunction. **2010**, 7, 3868-78 34

780 Erectile dysfunction in the community: trends over time in incidence, prevalence, GP consultation and medication use--the Krimpen study: trends in ED. **2010**, 7, 2547-53 22

779 Interrelationship of sildenafil treatment effects on the physiological and psychosocial aspects of erectile dysfunction of mixed or organic etiology. **2010**, 7, 3170-8 24

778 Efficacy and safety of oral mirodenafil in the treatment of erectile dysfunction in diabetic men in Korea: a multicenter, randomized, double-blind, placebo-controlled clinical trial. **2010**, 7, 2842-50 25

777 Intracavernous delivery of synthetic angiopoietin-1 protein as a novel therapeutic strategy for erectile dysfunction in the type II diabetic db/db mouse. **2010**, 7, 3635-46 35

776	Recreational use of phosphodiesterase type 5 inhibitors by healthy young men. 2010 , 7, 3736-42	45
775	The use of Butea superba (Roxb.) compared to sildenafil for treating erectile dysfunction. 2010 , 105, 225-8	10
774	Repercussões cardiovasculares, com e sem fármaco, do carbonato de lodenafila, um novo inibidor da PDE5. 2010 , 94, 160-167	4
773	Male Sexual Dysfunction. 2010 , 408-413	1
772	Effect of sildenafil on erectile dysfunction in spinal cord injured patients. 2009 , 43, 132-4	1
771	Retinal toxicity of systemic and topical medications. 2010 , 104-121	2
770	Sexual Disorders and Sexual Dysfunction. 2010 , 323-335	1
769	Efficacy and Safety of Tadalafil 5 mg Administered Once Daily in Korean Men with Erectile Dysfunction: A Prospective, Multicenter Study. 2010 , 51, 647-52	13
768	PHOSPHODIESTERASE-5 INHIBITORS USE IN PATIENTS WITH ERECTILE DYSFUNCTION AND CARDIOVASCULAR DISEASE IN CLINICAL PRACTICE. 2010 , 6, 691-696	
767	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. 2010 , 4, 61-70	28
766	An integrated dataset for in silico drug discovery. 2010 , 7,	17
765	Thyroid hormone: the modulator of erectile function in the rabbit. 2006 , 21, 83-9	3
764	A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway. 2010 , 30, 1315-24	51
763	The relation between sexual interest and personality characteristics in men: an eye-tracking study. 2010 , 22, 185-9	6
762	Chemical validation of phosphodiesterase C as a chemotherapeutic target in Trypanosoma cruzi, the etiological agent of Chagas' disease. 2010 , 54, 3738-45	29
761	Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. 2010 , 22, 68-76	19
760	ACceptance of therapy in vardenafil-treated patients with Erectile dysfunction (ACTIVE): A noninterventional study in Germany. 2010 , 22, 61-7	2
759	Prevalence of erectile dysfunction among Chinese men with type 2 diabetes mellitus. 2010 , 22, 310-7	29

758	Management of Erectile Dysfunction With Hypogonadism. 2010 , 21, 113-117	1
757	Effects of tetrandrine on cAMP and cGMP levels in rabbit corpus cavernosum in vitro. 2010 , 24, 1095-103	5
756	Evaluation of self-esteem in males with erectile dysfunction treated with viagra. Analysis of a Spanish patients group selected from a multicenter, international study. 2010 , 34, 699-707	6
755	Determinants of erectile dysfunction in type 2 diabetes. 2010 , 22, 204-9	112
754	A multifaceted approach to maximize erectile function and vascular health. 2010 , 94, 2514-20	27
753	Classics of urology: a half century history of the most frequently cited articles (1955-2009). 2010 , 75, 1261-8	45
752	Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. 2010 , 23, 456-64	25
751	Working interactively using a systemic sex therapy model for common sexual problems within a modern health service setting. 2010 , 19, 196-201	
750	Inhibidores de la fosfodiesterasa 5: calidad de la erección y repercusión emocional en los varones con disfunción eréctil y sus parejas. 2010 , 8, 155-164	2
749	Evaluación de la autoestima en varones con disfunción eréctil tratados con sildenafil. Análisis de un grupo de pacientes españoles procedentes de un estudio multicéntrico internacional. 2010 , 34, 699-707	1
748	Muscle Pain: Understanding the Mechanisms. 2010 ,	29
747	Sex therapy: advances in paradigms, nomenclature, and treatment. 2010 , 34, 390-6	5
746	New Technologies in Urology. 2010 ,	3
745	Intracavernosal administration of sodium nitrite as an erectile pharmacotherapy. 2010 , 88, 770-6	10
744	Tunica albuginea reefing: a novel technique for the treatment of erectile dysfunction. 2011 , 24, 44-8	3
743	Pathophysiology and therapy of cardiac dysfunction in Duchenne muscular dystrophy. 2011 , 11, 287-94	64
742	Penile prosthesis implantation in the era of medical treatment for erectile dysfunction. 2011 , 38, 217-25	36
741	Medical implications of erectile dysfunction. 2011 , 95, 213-21	13

740	Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial. 2011 , 74, 556-62	11
739	Newer phosphodiesterase inhibitors: comparison with established agents. 2011 , 38, 155-63	10
738	Old friends in new guise: repositioning of known drugs with structural bioinformatics. 2011 , 12, 312-26	106
737	The Future of Drug Repositioning: Old Drugs, New Opportunities. 2011 , 46, 385-401	23
736	Management of bladder and sexual dysfunction in multiple sclerosis. 676-695	
735	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. 2011 , 21, 820-8	12
734	Promoting the sexual health of the older couple. 2011 , 7, 681-693	
733	Sexual evaluation and treatment of ageing males with haemophilia. 2011 , 17, 875-83	9
732	Prevalence and detection rate of underlying disease in men with erectile dysfunction receiving phosphodiesterase type 5 inhibitors in the United Kingdom: a retrospective database study. 2011 , 65, 797-806	13
731	Patients' preference in the treatment of erectile dysfunction: a critical review of the literature. 2011 , 23, 1-8	17
730	Effect of corticotropin-releasing factor receptor antagonist on psychologically suppressed masculine sexual behavior in rats. 2011 , 8, 688-95	6
729	Coloplast titan inflatable penile prosthesis with one-touch release pump: review of 100 cases and comparison with genesis pump. 2011 , 8, 310-4	12
728	Satisfaction profiles in men using intracavernosal injection therapy. 2011 , 8, 512-7	18
727	Linguistic and psychometric validation of the Erection Hardness Score to Spanish. 2011 , 8, 470-4	6
726	Combination of testosterone and vardenafil increases female sexual functioning in sub-primed rats. 2011 , 8, 989-1001	8
725	The Subjective Sexual Arousal Scale for Men (SSASM): preliminary development and psychometric validation of a multidimensional measure of subjective male sexual arousal. 2011 , 8, 2255-68	3
724	Erectile response to type 5 phosphodiesterase inhibitor could be preserved with the addition of simvastatin to conventional insulin treatment in rat model of diabetes. 2011 , 34, e468-74	9
723	Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. 2011 , 60, 1010-6	242

722	Recreational use of erectile dysfunction medications in undergraduate men in the United States: characteristics and associated risk factors. 2011 , 40, 597-606	33
721	What is the role of unripe <i>Rubus coreanus</i> extract on penile erection?. 2011 , 25, 1046-53	13
720	The role of the lignan constituents in the effect of <i>Schisandra chinensis</i> fruit extract on penile erection. 2011 , 25, 1776-82	17
719	A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases. 2011 , 12, 1341-1348	11
718	Erectile dysfunction and cardiovascular disease. 2011 , 123, 7-16	11
717	Is bigger better? An argument for very low starting doses. 2011 , 183, 65-9	20
716	Men's experience of erectile dysfunction after treatment for colorectal cancer: qualitative interview study. 2011 , 343, d5824	23
715	Autonomic dysfunction in older people. 2011 , 21, 28-44	7
714	Metabolic syndrome and sexual dysfunction. 2011 , 21, 514-8	25
713	The association between Erection Hardness Grading Scale and International Index of Erectile Function in men with erectile dysfunction treated with sildenafil citrate. 2011 , 86, 434-8	4
712	Pulmonary hypertension in heart failure with preserved ejection fraction: a target for therapy?. 2011 , 124, 133-5	8
711	Therapeutic effect of combination of alagebrium (ALT-711) and sildenafil on erectile function in diabetic rats. 2012 , 24, 114-21	9
710	Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. 2012 , 2012, 627278	44
709	Despite some comprehension problems the International Index of Erectile Function is a reliable questionnaire in erectile dysfunction. 2012 , 88, 170-6	7
708	Considerations in the design of clinical trials for erectile dysfunction. 2012 , 2, 733-745	0
707	The HelpED study: agreement and impact of the erection hardness score on sexual function and psychosocial outcomes in men with erectile dysfunction and their partners. 2012 , 9, 2652-63	7
706	New insights into an old debate: Investigating the temporal sequence of commitment and performance at the business unit level. 2012 , 85, 503-522	16
705	Cystic fibrosis: insight into CFTR pathophysiology and pharmacotherapy. 2012 , 45, 1132-44	91

704	Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. 2012 , 187, 1769-75	169
703	The relaxation effect and mechanism of action of higenamine in the rat corpus cavernosum. 2012 , 24, 77-83	6
702	Estudio de la eficacia y preferencia de los pacientes con disfunci3n er3ctil grave despu3s de tomar los 3 inhibidores de la fosfodiesterasa 5. 2012 , 10, 139-146	2
701	Sexual function in men with metabolic syndrome. 2012 , 39, 53-62	13
700	Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. 2012 , 13, 1481-94	15
699	Management of sexual dysfunction due to antipsychotic drug therapy. 2012 , 11, CD003546	19
698	Phoneutria nigriventer spider toxin Tx2-6 causes priapism and death: a histopathological investigation in mice. 2012 , 60, 797-801	16
697	Stamp test delivers message on erectile dysfunction after high-dose intensity-modulated radiotherapy for prostate cancer. 2012 , 80, 337-42	4
696	Usefulness of electromyography of the cavernous corpora (CC EMG) in the diagnosis of arterial erectile dysfunction. 2012 , 24, 165-9	6
695	Delay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 era--an ecological study. 2012 , 9, 3239-46	16
694	Combined effect of sildenafil and guanethidine, propranolol or verapamil on erectile function in rats. 2012 , 64, 1659-66	0
693	Role of hydrogen sulfide in the physiology of penile erection. 2012 , 33, 529-35	19
692	Gene therapy with an erythropoietin enhancer-mediated, hypoxia-inducible gene expression system in the corpus cavernosum of mice with high-cholesterol diet-induced erectile dysfunction. 2012 , 33, 845-53	7
691	Management of erectile dysfunction: great progress, greater promise. 2012 , 33, 1107-10	3
690	Sexual dysfunction in men with type 2 diabetes. 2012 , 88, 152-9	58
689	Sildenafil increases digital skin blood flow during all phases of local cooling in primary Raynaud's phenomenon. 2012 , 91, 813-9	20
688	Challenges and solutions for personalizing medicines. 2012 , 1, 50-57	8
687	Activation of muscarinic receptors inhibits neurogenic nitric oxide in the corpus cavernosum. 2012 , 65, 303-11	10

686 Surgical Treatment for Erectile Dysfunction. **2012**, 121-128

685 Endovascular treatment for erectile dysfunction: an old paradigm revisited. **2012**, 60, 2628-30 11

684 Therapeutic angiogenesis as a potential future treatment strategy for erectile dysfunction. **2012**, 30, 93-8 3

683 The Role Erectile Dysfunction Plays in Cardiovascular Diseases. **2012**,

682 A case of acute pulmonary thromboembolism after taking tadalafil. **2012**, 73, 231-3 1

681 Treatment Effectiveness and Side Effects: A Model of Physician Learning. **2012**,

680 The role of capillarisin from *Artemisia capillaris* on penile erection. **2012**, 26, 800-5 8

679 Combined strategy of mesenchymal stem cell injection with vascular endothelial growth factor gene therapy for the treatment of diabetes-associated erectile dysfunction. **2012**, 33, 37-44 68

678 Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease. **2012**, 29, 775-90 23

677 Rehabilitation interventions in multiple sclerosis: an overview. **2012**, 259, 1994-2008 78

676 Low-intensity extracorporeal shock wave therapy--a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. **2012**, 9, 259-64 99

675 Minimal clinically important differences in the vaginal insertion and successful intercourse items of the sexual encounter profile. **2012**, 9, 169-79 14

674 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. **2012**, 9, 265-70 31

673 Sexual function and distress in women treated for primary headaches in a tertiary university center. **2012**, 9, 761-9 22

672 How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. **2012**, 9, 26-33 24

671 Profiling characteristics of men who use phosphodiesterase type 5 inhibitors based on obtaining patterns: data from the nationwide Japanese population. **2012**, 9, 1649-58 8

670 Recreational use of erectile dysfunction medications and its adverse effects on erectile function in young healthy men: the mediating role of confidence in erectile ability. **2012**, 9, 1852-9 19

669 Tadalafil 5 mg daily treatment for type 1 diabetic premenopausal women affected by sexual genital arousal disorder. **2012**, 9, 2057-65 17

668	PDEI-5 for erectile dysfunction: a potential role in seizure susceptibility. 2012 , 9, 2111-21	12
667	Dropout in the treatment of erectile dysfunction with PDE5: a study on predictors and a qualitative analysis of reasons for discontinuation. 2012 , 9, 2361-9	77
666	Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil. 2012 , 109, 1060-7	14
665	Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial. 2012 , 110, 1801-6	37
664	A phase II, single-blind, randomized, crossover evaluation of the safety and efficacy of avanafil using visual sexual stimulation in patients with mild to moderate erectile dysfunction. 2013 , 111, 137-47	23
663	Pharmacological postconditioning by bolus injection of phosphodiesterase-5 inhibitors vardenafil and sildenafil. 2013 , 379, 43-9	10
662	Low nitric oxide bioavailability is associated with better responses to sildenafil in patients with erectile dysfunction. 2013 , 386, 805-11	15
661	Diabetic neuropathy part 1: overview and symmetric phenotypes. 2013 , 31, 425-45	61
660	[Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors]. 2013 , 52, 204-11	1
659	Lead acetate may cause erectile dysfunction by modulating NO/cGMP pathway in rat corpus cavernosum. 2013 , 29, 355-64	7
658	Sildenafil increases serum testosterone levels by a direct action on the testes. 2013 , 1, 913-8	41
657	PDE5 inhibitors: considerations for preference and long-term adherence. 2013 , 67, 768-80	73
656	Network-based analysis of vaccine-related associations reveals consistent knowledge with the vaccine ontology. 2013 , 4, 33	15
655	Toward personalized sexual medicine (part 2): testosterone combined with a PDE5 inhibitor increases sexual satisfaction in women with HSDD and FSAD, and a low sensitive system for sexual cues. 2013 , 10, 810-23	50
654	Low-Intensity Extracorporeal Shock Wave Therapy in Vascular Disease and Erectile Dysfunction: Theory and Outcomes. 2013 , 1, 83-90	21
653	Psychological and interpersonal dimensions of sexual function and dysfunction in women: An update. 2013 , 11, 299-304	17
652	Erectile function, erection hardness and tolerability in men treated with sildenafil 100 mg vs. 50 mg for erectile dysfunction. 2013 , 67, 1034-9	6
651	Ca ²⁺ -activated K ⁺ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction. 2013 , 169, 449-61	34

650	Experimental evidence for sildenafil's action in the central nervous system: dopamine and serotonin changes in the medial preoptic area and nucleus accumbens during sexual arousal. 2013 , 10, 719-29	25
649	Toward personalized sexual medicine (part 1): integrating the "dual control model" into differential drug treatments for hypoactive sexual desire disorder and female sexual arousal disorder. 2013 , 10, 791-809	40
648	An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. 2013 , 14, 1333-44	72
647	The effect of testosterone on mood and well-being in men with erectile dysfunction in a randomized, placebo-controlled trial. 2013 , 1, 475-82	11
646	Erectile dysfunction. 2013 , 381, 153-65	545
645	The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study. 2013 , 53, 3044-53	28
644	Central serous chorioretinopathy due to tadalafil use. 2013 , 33, 177-80	7
643	La Medicina Sexual en la Historia. Avances y controversias (Parte II). 2013 , 11, 149-157	
642	Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. 2013 , 10, 1592-602	26
641	Primer of Geriatric Urology. 2013 ,	
640	Adjunctive treatment with lodenafil carbonate for erectile dysfunction in outpatients with schizophrenia and spectrum: a randomized, double-blind, crossover, placebo-controlled trial. 2013 , 10, 1136-45	6
639	Modulation of soluble guanylate cyclase for the treatment of erectile dysfunction. 2013 , 28, 262-9	11
638	DEVELOPMENT AND VALIDATION OF BIOANALYTICAL METHOD FOR MATRIX EFFECT CONTROLLED ESTIMATION OF SILDENAFIL AND N-DESMETHYL SILDENAFIL IN HUMAN PLASMA USING LC-MS/MS. 2013 , 150527103729000	
637	Tadalafil significantly reduces ischemia reperfusion injury in skin island flaps. 2013 , 46, 75-81	14
636	Impotence. 2013 , 379-388	
635	Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. 2013 , 2013, 701434	3
634	Treatment Effectiveness and Side Effects: A Model of Physician Learning. 2013 , 59, 1309-1325	37
633	The Histopathological Effect of Sildenafil Citrate on Superior Colliculus of Adult Male Rat. 2013 , 1, 175	2

632	A guanidinylated bio reducible polymer as a novel gene carrier to the corpus cavernosum of mice with high-cholesterol diet-induced erectile dysfunction. 2013 , 1, 216-22	10
631	Sildenafil: two decades of benefits or risks?. 2013 , 16, 85-91	19
630	A web-based survey of erection hardness score and its relationship to aging, sexual behavior, confidence, and risk factors in Japan. 2013 , 1, 76-86	10
629	Managing the difficult penile prosthesis patient. 2013 , 10, 893-906; quiz 907	47
628	Retrospective analysis of the efficacy and safety of once-daily tadalafil in patient subgroups: men with mild vs moderate ED and aged . 2013 , 25, 91-8	2
627	Sexual dysfunction in men with spinal cord injury: a case-control study. 2013 , 25, 133-7	14
626	Longitudinal trajectory of sexual functioning after hematopoietic cell transplantation: impact of chronic graft-versus-host disease and total body irradiation. 2013 , 122, 3973-81	28
625	References. 2013 , 799-844	
624	Sildenafil dilates ophthalmic artery in type 2 diabetic patients. 2013 , 1, 2050312113495195	
623	Drug updates and approvals: 2012 in review. 2013 , 38, 24-42; quiz 42-3	8
622	Rekindling Desire. 2013 ,	2
621	Improvement in erection hardness and intercourse success with first dose of sildenafil citrate 100 mg. 2013 , 6, 849-54	5
620	Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach?. 2013 , 28, 141-8	10
619	Increased cardiac myocyte PDE5 levels in human and murine pressure overload hypertrophy contribute to adverse LV remodeling. 2013 , 8, e58841	22
618	Challenges in translating academic research into therapeutic advancement. 2013 , 4, 123	1
617	Managing erectile dysfunction in heart failure. 2013 , 13, 125-34	13
616	The top 100 cited articles in urology: An update. 2013 , 7, 16	36
615	Routine cardiac assessment is not necessary for all patients with erectile dysfunction. 2013 , 5, 349	

614	A randomized, double-blind, placebo-controlled crossover study of Cappra [®] for the treatment of mild or mild to moderate erectile dysfunction in Thai male. 2013 , 10,	1
613	Mirodenafil for the treatment of erectile dysfunction: a systematic review of the literature. 2014 , 32, 18-27	9
612	Diabetes and sexual dysfunction: current perspectives. 2014 , 7, 95-105	108
611	In-vitro effects of PDE5 inhibitor and statin treatment on the contractile responses of experimental MetS rabbit's cavernous smooth muscle. 2014 , 86, 33-8	2
610	Avanafil for male erectile dysfunction: a systematic review and meta-analysis. 2014 , 16, 472-7	7
609	The prescribing and dispensing of phosphodiesterase type 5 inhibitors in South Korea: a questionnaire survey of patient discomfort. 2014 , 32, 69-75	
608	Chronic kidney disease and erectile dysfunction. 2014 , 3, 220-9	29
607	Management of erectile dysfunction in hypertension: Tips and tricks. 2014 , 6, 908-15	36
606	Multiple sclerosis. 637-654	
605	Men with diabetes may require more aggressive treatment for erectile dysfunction. 2014 , 26, 112-5	16
604	The promotion of data sharing in pharmacoepidemiology. 2014 , 21, 271-96	7
603	Pharmacological profile of a nitric oxide donor spermine NONOate in the mouse corpus cavernosum. 2014 , 44, 569-575	3
602	Alprostadil for the treatment of impotence. 2014 , 15, 421-8	38
601	Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. 2014 , 26, 223-9	12
600	The effect of statins on erectile dysfunction: a systematic review and meta-analysis. 2014 , 11, 1367-75	16
599	Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management: R.E. Scranton, I. Goldstein, and V.J. Stecher. 2014 , 11, 888-890	1
598	Erection hardness score for the evaluation of erectile dysfunction: further psychometric assessment in patients treated by intracavernous prostaglandins injections after radical prostatectomy. 2014 , 11, 2109-18	16
597	Erectile hydraulics: maximizing inflow while minimizing outflow. 2014 , 11, 1208-20	30

596	Cardiovascular outcomes among sildenafil users: results of the International Men's Health Study: M.A. Mittleman, M. Maclure, M.A. Lewis, G.C. Hall, N. Moore, F. Giuliano, H. Porst, H. Hedelin, A. Martin-Morales, R.E. Sobel, R. Reynolds, and D.B. Glasser. 2014 , 11, 880-884	
595	Combination of psychological intervention and phosphodiesterase-5 inhibitors for erectile dysfunction: a narrative review and meta-analysis. 2014 , 11, 1376-91	37
594	Unfair: government-approved sexual medicine treatments only available for men. 2014 , 11, 317-20	0
593	Classic citations in erectile dysfunction. 2014 , 11 Suppl 2, 115-36	
592	Infections Associated with Inflatable Penile Protheses. 2014 , 2, 134-140	8
591	Nonresponse to PDE5 inhibitors in erectile dysfunction. Part 2. 2014 , 4, 45-53	
590	Nutritional and Toxic Optic Neuropathies. 2014 , 177-207	3
589	Total testosterone levels and the effect of sildenafil on type 2 diabetics with erectile dysfunction. 2014 , 29, 46-50	3
588	Sildenafil improves erectile hardness in Chinese men with erectile dysfunction: a real-life study analyzed on age stratification. 2014 , 83, 831-6	5
587	Phosphodiesterase 9: insights from protein structure and role in therapeutics. 2014 , 106, 1-11	16
586	Sexual life of Japanese patients with erectile dysfunction taking phosphodiesterase type 5 inhibitors: an Internet survey using the Psychological and Interpersonal Relationship Scales-Short Form questionnaire. 2014 , 21, 821-5	8
585	Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS. 2014 , 11, 231-41	26
584	Topiramate use does not reduce flares of inflammatory bowel disease. 2014 , 59, 1535-43	20
583	An open-label study to evaluate sildenafil for the treatment of lymphatic malformations. 2014 , 70, 1050-7	60
582	Erectile dysfunction. 2014 , 44, 18-26	45
581	Erectile dysfunction. 2014 , 348, g129	32
580	Platelet-derived growth factor regulation of type-5 phosphodiesterase in human and rat penile smooth muscle cells. 2014 , 11, 1675-84	6
579	Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study. 2014 , 31, 1161-71	72

578	The role of intracavernosal injection therapy and the reasons of withdrawal from therapy in patients with erectile dysfunction in the era of PDE5 inhibitors. 2014 , 2, 45-50	20
577	Sildenafil alters retinal function in mouse carriers of retinitis pigmentosa. 2014 , 128, 43-56	23
576	Blood Pressure and Arterial Wall Mechanics in Cardiovascular Diseases. 2014 ,	16
575	Magnetic solid-phase extraction based on methylcellulose coated-Fe ₃ O ₄ -SiO ₂ -phenyl for HPLC-DAD analysis of sildenafil and its metabolite in biological samples. 2014 , 130, 427-32	31
574	Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. 2014 , 57, 10257-74	2530
573	Optic Nerve Disorders. 2014 ,	3
572	Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors. 2014 , 22, 313-6	2
571	Correlation between erection hardness score and nocturnal penile tumescence measurement. 2014 , 11, 2272-6	12
570	Continuation and effectiveness of tadalafil once daily during a 6-month observational study in erectile dysfunction: the EDATE study. 2014 , 68, 1087-99	15
569	Evaluation of current errors within the administration of phosphodiesterase-5 inhibitors after more than 10 years of use. 2014 , 83, 1334-8	14
568	Medication induced retinal side effects. 2014 , 60, 263-7	3
567	Mexican Traditional Medicine: Traditions of Yesterday and Phytomedicines of Tomorrow. 2015 , 1-37	3
566	Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse. 2015 , 5, 9222	12
565	The association between physical activity and sexual dysfunction in patients with diabetes mellitus of European and South Asian origin: The Oxford Sexual Dysfunction Study. 2015 , 20, 90	4
564	Dynamic Penile Cavernosa Reconstruction Using Bilateral Innervated Gracilis Muscle. 2015 , 136, 75-76	
563	Frequency and determinants of erectile dysfunction in Turkish diabetic men. 2015 , 18, 209-12	5
562	Sildenafil Protects against Myocardial Ischemia-Reperfusion Injury Following Cardiac Arrest in a Porcine Model: Possible Role of the Renin-Angiotensin System. 2015 , 16, 27015-31	14
561	Expectations do not Influence the Response to Phosphodiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction. 2015 , 3, 295-306	

560	Efficacy of sildenafil in a patient with restless legs syndrome/Willis-Ekbom disease. 2015 , 38, 67-8	2
559	[Genetic aspects of erectile dysfunction]. 2015 , 54, 662-7	1
558	Evoluci3n en el tratamiento m3dico de los s3ntomas del tracto urinario bajo en hombres. 2015 , 75, 30-37	
557	Therapy of endocrine disease. Effects of chronic use of phosphodiesterase inhibitors on endothelial markers in type 2 diabetes mellitus: a meta-analysis. 2015 , 172, R103-14	66
556	Evolution of penile prosthetic devices. 2015 , 56, 179-86	37
555	Optimizing in vivo gene transfer into mouse corpus cavernosum by use of surface electroporation. 2015 , 56, 197-204	2
554	Tadalafil 5 mg once daily for the treatment of erectile dysfunction during a 6-month observational study (EDATE): impact of patient characteristics and comorbidities. 2015 , 15, 111	13
553	Symptomatische Therapie. 2015 , 217-265	
552	The effect of pelvic floor muscle training on sexual function in men with lower urinary tract symptoms after stroke. 2015 , 22, 185-93	15
551	The effect of sildenafil on fascia-wrapped diced cartilage grafts. 2015 , 125, E168-72	2
550	Psychological determinants of erectile dysfunction among middle-aged men. 2015 , 27, 63-8	21
549	Treatments for erectile dysfunction in spinal cord patients: alternatives to phosphodiesterase type 5 inhibitors? A review study. 2015 , 53, 849-54	11
548	Sildenafil as a therapeutic option for digital ischemic ulceration: case report. 2015 , 40, 890-3	2
547	Role of sGC-dependent NO signalling and myocardial infarction risk. 2015 , 93, 383-94	22
546	Strategies to increase nitric oxide signalling in cardiovascular disease. 2015 , 14, 623-41	312
545	Additive effects of Artemisia capillaris extract and scopoletin on the relaxation of penile corpus cavernosum smooth muscle. 2015 , 27, 225-32	7
544	Overview of potential molecular targets for hydrogen sulfide: A new strategy for treating erectile dysfunction. 2015 , 50, 65-78	12
543	Long-term phosphodiesterase 5 inhibitor administration reduces inflammatory markers and heat-shock proteins in cavernous tissue of Zucker diabetic fatty rat (ZDF/fa/fa). 2015 , 27, 182-90	10

542	Sexual challenges with aging: integrating the GES approach in an elderly couple. 2015 , 41, 72-82	5
541	The oral microbiome and nitric oxide homeostasis. 2015 , 21, 7-16	89
540	Effect of the novel BKCa channel opener LDD175 on the modulation of corporal smooth muscle tone. 2015 , 12, 29-38	9
539	Results of tadalafil treatment in patients following an open nerve-sparing radical prostatectomy. 2016 , 88, 4-6	1
538	Effects of mirodenafil on the hemodynamics in hypertensive patients taking amlodipine. 2016 , 24, 90	
537	An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction. 2016 , 18, 773-9	10
536	Population pharmacokinetics and inter-laboratory variability of sildenafil and its metabolite after oral administration in Korean healthy male volunteers. 2016 , 24, 105	1
535	Pathophysiology of visual disorders induced by phosphodiesterase inhibitors in the treatment of erectile dysfunction. 2016 , 8, 3407-3413	21
534	Sexual Dysfunction in Men and Women. 2016 , 785-830	1
533	The devil is in the details: an analysis of the subtleties between phosphodiesterase inhibitors for erectile dysfunction. 2016 , 5, 181-6	7
532	Modifying Risk Factors in the Management of Erectile Dysfunction: A Review. 2016 , 34, 89-100	43
531	Sildenafil Improves Functional and Structural Outcome of Retinal Injury Following Term Neonatal Hypoxia-Ischemia. 2016 , 57, 4306-14	4
530	Cardiac safety profile of sildenafil: chronotropic, inotropic and coronary vasodilator effects in the canine isolated, blood-perfused heart preparations. 2016 , 41, 739-744	1
529	Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink. 2016 , 13, e1002037	33
528	PDE5 Exists in Human Neurons and is a Viable Therapeutic Target for Neurologic Disease. 2016 , 52, 295-302	26
527	Successful microsurgical replantation of an amputated penis. 2016 , 49, 99-105	4
526	Management of Sexual Dysfunction in Men and Women. 2016 ,	6
525	Molecular and functional characterization of Kv 7 channels in penile arteries and corpus cavernosum of healthy and metabolic syndrome rats. 2016 , 173, 1478-90	21

524 Drug therapy for erectile dysfunction. **2016**, 172-193

523 Sexual Function in Men and Women with Diabetes. **2016**, 716-730

522 Phosphodiesterase-5 inhibition improves macrocirculation and microcirculation during cardiopulmonary resuscitation. **2016**, 34, 162-6

8

521 Patient-Reported Outcomes and Clinical Trials. **2016**, 13, 1027-8

520 Evolution of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction in Taiwan. **2016**, 27, 66-70

7

519 MicroRNA 146a locally mediates distal axonal growth of dorsal root ganglia neurons under high glucose and sildenafil conditions. **2016**, 329, 43-53

34

518 Serendipity in Cancer Drug Discovery: Rational or Coincidence?. **2016**, 37, 435-450

27

517 Efficacy and Safety of Sildenafil by Age in Men With Erectile Dysfunction. **2016**, 13, 852-9

24

516 Literature-based discovery of new candidates for drug repurposing. **2017**, 18, 488-497

42

515 The quest for an increased genital size drives sex stimulant abuse among male subjects in Calabar, Cross River State, Nigeria. **2016**, 5, 311-316

2

514 Primer of Geriatric Urology. **2016**,

513 Geriatric Sexuality. **2016**, 163-227

512 Impact of aging and comorbidity on the efficacy of low-intensity shock wave therapy for erectile dysfunction. **2016**, 23, 80-4

29

511 A randomized double blinded placebo controlled trial of sildenafil for renoprotection prior to hilar clamping in patients undergoing robotic assisted laparoscopic partial nephrectomy. **2016**, 114, 785-788

4

510 Avanafil for the treatment of erectile dysfunction. **2016**, 9, 1163-70

9

509 Erectile dysfunction. **2016**, 2, 16003

246

508 Comparisons of regular and on-demand regimen of PED5-Is in the treatment of ED after nerve-sparing radical prostatectomy for Prostate Cancer. **2016**, 6, 32853

5

507 Sexual activity as a trigger for intracranial hemorrhage. **2016**, 158, 189-95

4

506	Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. 2016 , 111, 154-62	32
505	Bergamot polyphenolic fraction counteracts erectile dysfunction occurring in patients suffering from type 2 diabetes. 2016 , 4, S41-S46	3
504	PDE5A Polymorphisms Influence on Sildenafil Treatment Success. 2016 , 13, 1104-10	3
503	Cyclic nucleotide phosphodiesterase isoforms in human basophils and mast cells. 2016 , 29, 654-665	6
502	The impact of poor glycaemic control on the prevalence of erectile dysfunction in men with type 2 diabetes mellitus: a systematic review. 2016 , 7, 2054270415622602	27
501	Single dose sublingual testosterone and oral sildenafil vs. a dual route/dual release fixed dose combination tablet: a pharmacokinetic comparison. 2016 , 81, 1091-102	11
500	Finding her voice: first class female sexuality. 2016 , 31, 138-147	3
499	Adjuvant sildenafil therapy in poor responders undergoing in vitro fertilization: A prospective, randomized, double-blind, placebo-controlled trial. 2016 , 21, 175-179	5
498	Erectile Dysfunction Is Not a Predictor of Atrial Fibrillation: A Population-Based Propensity-Score Matched Cohort Study. 2016 , 13, 55-62	2
497	The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. 2016 , 15, 141-52	35
496	Pharmacotherapy for Erectile Dysfunction: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015). 2016 , 13, 465-88	110
495	The role of the sexual partner in managing erectile dysfunction. 2016 , 13, 168-77	33
494	Effect of a novel BKCa opener on BKCa currents and contractility of the rabbit corpus cavernosum. 2016 , 310, C284-92	9
493	Efficacy and safety of phosphodiesterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis. 2016 , 54, 494-501	9
492	Adulterated and Counterfeit Male Enhancement Nutraceuticals and Dietary Supplements Pose a Real Threat to the Management of Erectile Dysfunction: A Global Perspective. 2016 , 13, 660-93	13
491	Sildenafil citrate (Viagra) reduces surface roughness of human erythrocytes: Atomic-force-microscopic study. 2016 , 4, 63-68	
490	The effect of epilepsy and antiepileptic drugs on sexual, reproductive and gonadal health of adults with epilepsy. 2016 , 9, 807-19	31
489	The safety and efficacy of Avanafil, a new 2(nd) generation PDE5i: comprehensive review and meta-analysis. 2016 , 15, 237-47	39

488	The efficacy of udenafil in end-stage renal disease patients undergoing hemodialysis. 2016 , 38, 357-61	2
487	Pelvic floor muscle training for erectile dysfunction and climacturia 1 year after nerve sparing radical prostatectomy: a randomized controlled trial. 2016 , 28, 9-13	33
486	New Pharmacological Strategies to Increase cGMP. 2016 , 67, 229-43	26
485	Sexual Dysfunction. 2016 , 2154-2162.e3	1
484	Effects of Two Different Dosages of Sildenafil on Patients With Erectile Dysfunction. 2017 , 11, 525-530	2
483	Functional Variations in the NOS3 Gene Are Associated With Erectile Dysfunction Susceptibility, Age of Onset and Severity in a Han Chinese Population. 2017 , 14, 551-557	5
482	Preoperative sexual status of Japanese localized prostate cancer patients: comparison of sexual activity and EPIC scores. 2017 , 20, 261-265	6
481	Network mirroring for drug repositioning. 2017 , 17, 55	11
480	QbD-Driven Development and Validation of Liquid Chromatography Tandem Mass Spectrometric Method for the Quantitation of Sildenafil in Human Plasma. 2017 , 55, 587-594	11
479	[Erectile dysfunction : Current diagnostics and treatment]. 2017 , 56, 519-529	9
478	The Drug Repurposing Hub: a next-generation drug library and information resource. 2017 , 23, 405-408	381
477	A Psychobiosocial Approach to Sex Therapy. 2017 , 190-201	6
476	An Empirical vs Risk-Based Approach Algorithm to Intracavernosal Injection Therapy: A Prospective Study. 2017 , 5, e31-e36	3
475	Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome. 2017 , 49, e12751	9
474	Effect of BKCa Channel Opener LDD175 on Erectile Function in an In Vivo Diabetic Rat Model. 2017 , 14, 59-68	6
473	Quantifying Barriers to Improvement of Treatment Satisfaction in Men With Erectile Dysfunction: Use of Person-Item Maps. 2017 , 14, 152-159	0
472	Treating Sexual Problems in Aging Adults. 2017 , 323-344	1
471	Integrating Sexual Partners into Pharmacological Sex Therapy. 2017 , 453-467	1

- 470 Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease. **2017**, 60, 1351-1364 27
- 469 The role of Ca-activated Cl current in tone generation in the rabbit corpus cavernosum. **2017**, 313, C475-C486 8
- 468 Evaluation and Management of Erectile Dysfunction in the Hypertensive Patient. **2017**, 19, 89 15
- 467 Rapid Detection of Sildenafil Drugs in Liquid Nutraceuticals Based on Surface-Enhanced Raman Spectroscopy Technology. **2017**, 35, 1522-1528 16
- 466 Drug Design: Principles and Applications. **2017**, 3
- 465 Strategies for Tackling Drug Resistance in Tuberculosis. **2017**, 89-112 1
- 464 Manifesto: towards a clinically-oriented psychometrics. **2017**, 15, 83 1
- 463 Erectile dysfunction in young men with type 1 diabetes. **2017**, 29, 17-22 16
- 462 Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. **2017**, 13, 183-192 19
- 461 Sildenafil in the Treatment of Erectile Dysfunction in Parkinson's Disease. **2017**, 4, 412-415 9
- 460 Erectile Dysfunction Associated with Cardiovascular Risk Factors. **2017**,
- 459 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Therapeutic Confirmatory Study to Evaluate the Safety and Efficacy of Avanafil in Korean Patients with Erectile Dysfunction. **2017**, 32, 1016-1023 6
- 458 Medical treatment of erectile dysfunction: too many medical prescriptions?. **2017**, 84, 121-129 3
- 457 Drug repurposing for the treatment of glioblastoma multiforme. **2017**, 36, 169 40
- 456 ERECTILE DYSFUNCTION AND ITS PHARMACOLOGY: AN OVERVIEW. **2017**, 10, 17 1
- 455 Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug. **2017**, 8, 111728-111743 15
- 454 Nitric Oxide Donors and Penile Erectile Function. **2017**, 121-140 2
- 453 Have you had Viagra within the past 24 hours? **2017**, 9, 490-494

452	Erectile dysfunction in the elderly male. 2017 , 43, 247-251	10
451	Administration of Testosterone and its Rationale in the Treatment of Erectile Dysfunction. 2017 , 8, 45-49	
450	Penile prosthesis implant: scientific advances and technological innovations over the last four decades. 2017 , 6, 37-45	32
449	Prevention, identification, and management of post-operative penile implant complications of infection, hematoma, and device malfunction. 2017 , 6, S832-S848	22
448	A 90-day Repeat-Dose Oral Toxicity Study of Yonkenafil Hydrochloride in Beagle Dogs. 2017 , 06,	
447	Xybilun ￼ , actualit�2018�de la dysfonction �ctile. 2018 , 27, 67-71	
446	From gene networks to drugs: systems pharmacology approaches for AUD. 2018 , 235, 1635-1662	11
445	Clinically important difference on the Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire in patients with erectile dysfunction. 2018 , 72, e13073	5
444	PDE5 inhibitors - pharmacology and clinical applications 20�years after sildenafil discovery. 2018 , 175, 2554-2565	170
443	MicroRNA-19a/b-3p protect the heart from hypertension-induced pathological cardiac hypertrophy through PDE5A. 2018 , 36, 1847-1857	21
442	PDE5i and Cardiac Health: Why Are We Still Worried After So Many Years?. 2018 , 15, 428-429	
441	Modern management of esophageal achalasia: From pathophysiology to treatment. 2018 , 55, 10-37	12
440	History of the Treatment of Female Sexual Dysfunction(s). 2018 , 14, 29-54	13
439	Four Decades of Change in Sexual Medicine. 2018 , 6, 171-175	
438	British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction in Men-2017. 2018 , 15, 430-457	67
437	From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndrome. 2018 , 41, 1249-1258	64
436	Empfehlungen zum Management von Sexualst�rungen bei M�nnern. 2018 , 25, 37-39	
435	Sexual habits of men with ED who take phosphodiesterase 5 inhibitors: a survey conducted in 7 countries. 2018 , 72, e13074	6

434	Dynamic Penile Corpora Cavernosa Reconstruction Using Bilateral Innervated Gracilis Muscles: A Preclinical Investigation. 2018 , 6, 162-170	0
433	Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. 2018 , 101, 376-386	4
432	Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. 2018 , 10, 84-92	17
431	Identification of murine phosphodiesterase 5A isoforms and their functional characterization in HL-1 cardiac cell line. 2018 , 233, 325-337	14
430	Erectile Dysfunction. 2018 , 623-629.e2	
429	Update on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction. 2018 , 6, 242-252	53
428	Male Sexual Dysfunction. 2018 , 767-774	0
427	A Case of Central Serous Chorioretinopathy after Tadalafil Treatment. 2018 , 59, 93	1
426	Sexual Problems. 327-342	
425	Value of flaccid penile ultrasound in screening for arteriogenic impotence: a preliminary prospective study. 2018 , 18, 40	4
424	The 100 most influential manuscripts in andrology: a bibliometric analysis. 2018 , 28, 15	9
423	An update on emerging drugs for the treatment of erectile dysfunction. 2018 , 23, 319-330	9
422	A gentle introduction to gasotransmitters with special reference to nitric oxide: biological and chemical implications. 2018 , 38, 193-220	16
421	Diagnostic evaluation of sexual dysfunction in the male partner in the setting of infertility: a committee opinion. 2018 , 110, 833-837	5
420	Drug Repurposing of Metabolic Agents in Malignant Glioma. 2018 , 19,	21
419	Sexual Dysfunctions in Mentally Ill Patients. 2018 ,	1
418	Discovery and development of next generation sGC stimulators with diverse multidimensional pharmacology and broad therapeutic potential. 2018 , 78, 72-80	49
417	20 Jahre Viagra® . 2018 , 31, 156-166	

- 416 Pharmacokinetics of a Novel Sildenafil Orodispersible Film Administered by the Supralingual and the Sublingual Route to Healthy Men. **2018**, 38, 765-772 12
- 415 The 2018 Revision to the Process of Care Model for Management of Erectile Dysfunction. **2018**, 15, 1434-1445 23
- 414 Sexual complications of penile fracture in men who have sex with men. **2018**, 44, 550-554 6
- 413 The sleep and sex survey: Relationships between sexual function and sleep. **2018**, 112, 59-65 14
- 412 Role of Penile Prosthesis in Priapism: A Review. **2018**, 36, 4-14 17
- 411 Management of erectile dysfunction. **2018**, 545-554
- 410 Synthesis of Dihydrooxepino[3,2-c]Pyrazoles via Claisen Rearrangement and Ring-Closing Metathesis from 4-Allyloxy-1H-pyrazoles. **2018**, 23, 5
- 409 History of the International Society for the Study of Women's Sexual Health (ISSWSH). **2018**, 1-5
- 408 Predictors of Erectile Function Normalization in Men With Erectile Dysfunction Treated With Placebo. **2018**, 15, 866-872 7
- 407 Palladium-catalyzed oxidative CC bond cleavage with molecular oxygen: one-pot synthesis of quinazolinones from 2-amino benzamides and alkenes. **2018**, 5, 2734-2738 15
- 406 Sildenafil ameliorates EAE by decreasing apoptosis in the spinal cord of C57BL/6 mice. **2018**, 321, 125-137 17
- 405 Patient's choice of health information and treatment modality for Peyronie's disease: a long term assessment. **2018**, 30, 274-275
- 404 Aqueous extract of improves male menopause by increase of nitric oxide and dihydrotestosterone. **2019**, 28, 253-260
- 403 The pharmacist's role in improving the treatment of erectile dysfunction and its underlying causes. **2019**, 15, 591-599 3
- 402 [S1-Guideline for Diagnosis and Treatment of Erectile Dysfunction]. **2019**, 87, 225-233 4
- 401 Nitric Oxide. **2019**, 117-126 1
- 400 An update on the drug safety of treating erectile dysfunction. **2019**, 18, 965-975 6
- 399 Drug repurposing with network reinforcement. **2019**, 20, 383 9

398	From Impotence to Erectile Dysfunction: Reflections on 50 Years in Male Sexual Medicine. 2019 , 134, 32-38	2
397	The effect of CPAP and PDE5i on erectile function in men with obstructive sleep apnea and erectile dysfunction: A systematic review and meta-analysis. 2019 , 48, 101217	4
396	Precautions and Monitoring of Patients Taking Phosphodiesterase Type 5 Inhibitors Who are at Risk of Increased Intraocular Pressure. 2019 , 36, 991-997	3
395	Erectile Dysfunction: A Primer for in Office Management. 2019 , 7,	
394	Multilevel analyses of on-demand medication data, with an application to the treatment of Female Sexual Interest/Arousal Disorder. 2019 , 14, e0221063	1
393	Phosphodiesterase inhibitors say NO to Alzheimer's disease. 2019 , 134, 110822	33
392	WZ3146 inhibits mast cell Lyn and Fyn to reduce IgE-mediated allergic responses in vitro and in vivo. 2019 , 383, 114763	8
391	[Reflexions on 50 Years of Sexual Medicine in Urology Focusing on Male Sexual Dysfunctions]. 2019 , 50, 248-267	1
390	Carotid artery intima-media thickness can predict the response of patients with erectile dysfunction to phosphodiesterase 5 inhibitors. 2019 , 31, 139-144	5
389	Erectile dysfunction in renal failure and transplant patients. 2019 , 8, 155-163	12
388	Current diagnosis and management of erectile dysfunction. 2019 , 210, 469-476	29
387	The beginning of a new era: treatment of erectile dysfunction by use of physical energies as an alternative to pharmaceuticals. 2019 , 31, 155-161	2
386	Physical Activity, Fitness, and Sexual Dysfunction. 2019 , 373-387	
385	Diagnostic Accuracy of Different Criteria of Pharmaco-penile Duplex Sonography for Venous Erectile Dysfunction. 2019 , 38, 2739-2748	4
384	Sildenafil's impact on male infertility: what has changed in 20 years?. 2019 , 31, 71-73	5
383	Erectile Dysfunction and Premature Ejaculation in Homosexual and Heterosexual Men: A Systematic Review and Meta-Analysis of Comparative Studies. 2019 , 16, 624-632	17
382	Substance-Linked Sex in Heterosexual, Homosexual, and Bisexual Men and Women: An Online, Cross-Sectional "Global Drug Survey" Report. 2019 , 16, 721-732	26
381	Endovascular Therapy for Erectile Dysfunction-Who Benefits Most? Insights From a Single-Center Experience. 2019 , 26, 181-190	14

380	An Active Gene Annotation Corpus and Its Application on Anti-epilepsy Drug Discovery. 2019 ,	3
379	study on identification of novel MALT1 allosteric inhibitors.. 2019 , 9, 39338-39347	3
378	Pharmacodynamics of the agents used for the treatment of erectile dysfunction. 2019 , 15, 121-131	3
377	Targeting the vascular dysfunction: Potential treatments for preeclampsia. 2018 , 26, e12522	2
376	Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again. 2019 , 8, e011343	3 ¹
375	Effect of prolonged treatment with phosphodiesterase-5-inhibitors on endothelial dysfunction in vascular diseases and vascular risk conditions: A systematic review analysis and meta-analysis of randomized double-blind placebo-controlled trials. 2019 , 73, e13296	4
374	The Clinical Effects of Sildenafil for Erection in Patients after Kidney Transplantation: A Meta-Analysis. 2019 , 141, 1-9	4
373	A Systematic Review of the Role of Penile Rehabilitation in Prostate Cancer Patients Receiving Radiotherapy and Androgen Deprivation Therapy. 2019 , 50, 171-178	5
372	The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. 2019 , 7, 115-128	53
371	The Masturbation Erection Index (MEI): validation of a new psychometric tool, derived from the six-item version of the International Index of Erectile Function (IIEF-6) and from the Erection Hardness Score (EHS), for measuring erectile function during masturbation. 2019 , 123, 530-537	13
370	Sexual Dysfunction in Men with Prediabetes. 2020 , 8, 622-634	2
369	Therapeutic Strategies for Erectile Dysfunction With Emphasis on Recent Approaches in Nanomedicine. 2020 , 19, 11-24	1
368	Exploring the Role of Sexual Avoidance in Male Sexual Dysfunction. 2020 , 57, 522-533	3
367	A Small Group Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Daily Pentoxifylline in the Management of Patients With Erectile Dysfunction with Suboptimal Treatment Response to Sildenafil. 2020 , 8, 14-20	4
366	Efficacy and tolerability of sildenafil/l-arginine combination relative to sildenafil alone in patients with organic erectile dysfunction. 2020 , 8, 143-147	10
365	Efficacy and safety of avanafil 200 mg versus sildenafil 100 mg in the treatment of erectile dysfunction after robot-assisted unilateral nerve-sparing prostatectomy: A prospective multicentre study. 2020 , 87, 23-28	2
364	Decreased forced expiratory volume in first second is associated with erectile dysfunction in apparently healthy men. A preliminary study. 2020 , 32, 420-425	0
363	Established and emerging therapeutic uses of PDE type 5 inhibitors in cardiovascular disease. 2020 , 177, 5467-5488	34

362	Soluble guanylate cyclase stimulator praliquat attenuates inflammation, fibrosis, and end-organ damage in the Dahl model of cardiorenal failure. 2020 , 318, F148-F159	15
361	Aging and erectile function. 2020 , 23, 1115-1124	3
360	Sildenafil and tadalafil reduce the risk of contrast-induced nephropathy by modulating the oxidant/antioxidant balance in a murine model. 2020 , 135, 111038	16
359	Multiplicity of Nitric Oxide and Natriuretic Peptide Signaling in Heart Failure. 2020 , 75, 370-384	8
358	Editors' Wish List. 2020 , 423-428	
357	The efficient development of a sildenafil orally disintegrating tablet using a material sparing and expedited approach. 2020 , 589, 119816	5
356	Real-World Assessment of the Impact of Erectile Dysfunction on Sexual Planning Behavior and Health- and Treatment-Related Outcomes Among Men in 8 Countries. 2020 , 8, 338-349	1
355	Role of application of tadalafil 5 mg once-daily (8 months) in men with erectile dysfunction from six randomized controlled trials. 2020 , 9, 1405-1414	1
354	Drug Repurposing Approaches to Combating Viral Infections. 2020 , 9,	9
353	Status epilepticus secondary to a high dose sildenafil intake. 2021 , 157, 356-357	
352	Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease. 2020 , 190, 111311	4
351	Promising role of medicinal plants in the regulation and management of male erectile dysfunction. 2020 , 130, 110555	5
350	Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review. 2020 , 6, 38	5
349	Study on the combination of brief psychodynamic psychotherapy with Viagra in the treatment of non-organic ED. 2020 , 33, e100184	1
348	A new method to quantify penile erection hardness: real-time ultrasonic shear wave elastography. 2020 , 9, 1735-1742	3
347	Evaluation of Serum/Urine Genomic and Metabolomic Profiles to Improve the Adherence to Sildenafil Therapy in Patients with Erectile Dysfunction. 2020 , 11, 602369	1
346	Oral drugs used to treat persistent pulmonary hypertension of the newborn. 2020 , 13, 1295-1308	3
345	Tangeretin ameliorates erectile and testicular dysfunction in a rat model of hypertension. 2020 , 96, 1-10	4

344	Drug repurposing in the era of COVID-19: a call for leadership and government investment. 2020 , 212, 450-452.e1	8
343	Drug delivery options and therapeutic advances in the management of erectile dysfunction. 2020 , 17, 1259-1268	2
342	A review of the evolving landscape between the consumer Internet and men's health. 2020 , 9, S123-S134	5
341	Olfactory Sensitivity Is Related to Erectile Function in Adult Males. 2020 , 8, 93	4
340	Phase II Randomized, Clinical Trial Evaluating 2 Schedules of Low-Intensity Shockwave Therapy for the Treatment of Erectile Dysfunction. 2020 , 8, 214-222	5
339	Lipid abnormality, current diabetes and age affect erectile hardness: An analysis of data from complete medical checkups carried out at a single hospital. 2020 , 27, 339-343	1
338	Monitor recipients of phosphodiesterase type 5 inhibitors for glaucoma, pending more clinical evidence of risk. 2020 , 36, 152-155	
337	Effect of tadalafil on penile nitric oxide synthase and corporal smooth muscle in rats under dutasteride treatment. 2020 , 23, 161-167	1
336	Efficacy and Safety of Common Ingredients in Aphrodisiacs Used for Erectile Dysfunction: A Review. 2020 , 8, 431-442	9
335	Penile prosthesis surgery: indications and penoscrotal approach. 2020 , 44, 377-381	
334	Preparation and operative setup of penile prosthesis surgery. 2020 , 6, 5-5	0
333	Behavioral and hormonal effects of prolonged Sildenafil treatment in a mouse model of chronic social stress. 2020 , 392, 112707	
332	Different Evaluations Exist between Men with Erectile Dysfunction and Their Female Partners When Using Erectile Hardness Model: An Interesting, Observational, and Cross-Sectional Field Survey. 2020 , 2020, 2302348	2
331	[Urology goes electric-electrotherapy : Modern therapies in the treatment of modern diseases-examples from urology]. 2020 , 59, 326-340	0
330	Pharmacology and perspectives in erectile dysfunction in man. 2020 , 208, 107493	17
329	Impotence literature: Scientometric analysis of erectile dysfunction articles between 1975 and 2018. 2020 , 52, e13520	2
328	Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer's disease. 2020 , 176, 113818	24
327	Sudden headache due to perimesencephalic subarachnoid hemorrhage after self-medication with 200 mg sildenafil: Case report and discussion. 2020 , 194, 105844	1

326	A practical guide to secondary pharmacology in drug discovery. 2020 , 105, 106869	8
325	"Doc, if it were you, what would you do?": a survey of Men's Health specialists' personal preferences regarding treatment modalities. 2021 , 33, 303-310	1
324	Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. 2021 , 9, 33-38	26
323	Natural phosphodiesterase 5 (PDE5) inhibitors: a computational approach. 2021 , 35, 1648-1653	10
322	PDE5 inhibition improves cardiac morphology and function in SHR by reducing NHE1 activity: Repurposing Sildenafil for the treatment of hypertensive cardiac hypertrophy. 2021 , 891, 173724	2
321	Impact of antiangiogenic treatment on the erectile function in patients with advanced renal cell carcinoma. 2021 , 53, e13881	
320	Effects of phosphodiesterase-5 inhibitor sildenafil on esophageal secondary peristalsis: Studies with high-resolution manometry. 2021 , 36, 430-435	1
319	Erectile Dysfunction Resistant to Medical Treatment Caused by Cavernovenous Leakage: An Innovative Surgical Approach Combining Pre-operative Work Up, Embolisation, and Open Surgery. 2021 , 61, 510-517	3
318	Effects of "metabolic memory" on erectile function in diabetic men: A retrospective case-control study. 2021 , 9, 288-296	1
317	Sildenafil beyond erectile dysfunction and pulmonary arterial hypertension: Thinking about new indications. 2021 , 35, 235-259	7
316	Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. 2021 , 22, 821-834	3
315	Evaluation of daily avanafil efficacy in improving the endothelial function in Egyptian males with erectile dysfunction. 2021 , 53, e13833	2
314	An application of the mixed-effects model and pattern mixture model to treatment groups with differential missingness suspected not-missing-at-random. 2021 , 20, 93-108	1
313	Perceived Importance and Enjoyment of Sexuality in Late Midlife: Cohort Differences in the Longitudinal Aging Study Amsterdam (LASA). 2021 , 18, 621-635	2
312	State-of-the-art pharmacotherapy for diabetic neuropathy. 2021 , 22, 55-68	7
311	Evaluation of Arterial Erectile Dysfunction Using Shear Wave Elastography: A Feasibility Study. 2021 , 40, 1209-1216	2
310	Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. 2021 , 22, 179-189	8
309	Dynamic erectile responses of a novel penile organ model utilizing TPEM \square 2021 , 104, 875-886	1

308	Comparative effect of administration and discontinuation of sildenafil and/or clomipramine on the hepatic, cardiac and testicular tissues of male rats. 2021 , 53, e13983	1
307	Herbal medicines (Eleutherococcus senticosus, Astragalus membranaceus) used to treat andrological problems: Asia and Indian Subcontinent. 2021 , 113-121	
306	Role of regenerative therapies on erectile dysfunction after radical prostatectomy. 2021 , 33, 488-496	1
305	Combination Therapies for Erectile Dysfunction-A Synergy of Modalities Holds the Key. 2021 , 4, e2037292	1
304	Metal-Free Electrochemical Synthesis of Sulfonamides Directly from (Hetero)arenes, SO ₂ , and Amines. 2021 , 60, 5056-5062	20
303	Endovascular Therapy for Arteriogenic Erectile Dysfunction With a Novel Sirolimus-Eluting Stent. 2021 , 18, 315-326	0
302	Top 100 most influential manuscripts in erectile dysfunction. 2021 , 88, 175-184	0
301	Metallfreie, elektrochemische Synthese von Sulfonamiden direkt aus (Hetero)arenen, SO ₂ und Aminen. 2021 , 133, 5114-5120	4
300	Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. 2021 , 22,	3
299	Alternative strategies in cardiac preclinical research and new clinical trial formats. 2021 ,	3
298	Mycophenolate suppresses inflammation by inhibiting prostaglandin synthases: a study of molecular and experimental drug repurposing. 2021 , 9, e11360	2
297	Sildenafil citrate in healthy and diseased hearts. 2021 , 6, 033-039	0
296	Emergency Management of Patients with Genitourinary Prostheses. 2021 , 235-244	
295	Sexual dysfunctions and short-term glucose variability in young men with type 1 diabetes. 2021 , 20, 475-482	1
294	Assessment of the Rigidity Changes of Corpus Cavernosum Penis in Vascular Erectile Dysfunction (ED) Subtypes by Shear Wave Elastography (SWE). 2021 ,	0
293	Digital Real-world Data Suggest Patient Preference for Tadalafil over Sildenafil in Patients with Erectile Dysfunction. 2021 ,	1
292	Sildenafil in ophthalmology: An update. 2021 ,	3
291	Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment. 2021 , 11, 2135-2190	2

290	Erectile Dysfunction A Prospective Randomized Placebo-Controlled Study Evaluating the Effect of Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) in Men With Erectile Dysfunction Following Radical Prostatectomy. 2021 , 9, 100338	3
289	Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses. 2021 , 11, e047396	3
288	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. 2021 , 9, 484-490	2
287	The Prevalence and Predictors of Penile Pain in Men with Peyronie's Disease. 2021 , 9, 100398	1
286	Efficacy and safety of aildenafil citrate in Chinese men with erectile dysfunction: a multicenter, randomized, double-blind, placebo-controlled crossover trial. 2021 , 10, 3358-3367	0
285	The Solid State Landscape of the Sildenafil Drug. 2021 ,	0
284	PDE5 Inhibition Suppresses Ventricular Arrhythmias by Reducing SR Ca Content. 2021 , 129, 650-665	2
283	The Effect of Phosphodiesterase-type 5 Inhibitors on Erectile Function: An Overview of Systematic Reviews. 2021 , 12, 735708	3
282	Diagnosis and management of erectile dysfunction. 2021 , 12, 12-17	1
281	Status epilepticus secondary to a high dose sildenafil intake. 2021 , 157, 356-356	1
280	Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial. 2021 , 23, 931-938	4
279	Pharmaceutical and Energy-Based Management of Sexual Problems in Women. 2021 , 48, 473-486	
278	Exciting Research in the Field of Sexual Psychopharmacology: Treating Patients with Inside Information. 2021 , 199-210	
277	Sex Behavior. 321	1
276	Sexual Function in Men and Woman with Diabetes. 743-759	1
275	Neurochemistry of Male Sexual Behavior. 2007 , 37-94	5
274	Geriatric Sexuality. 2013 , 143-200	1
273	The Future of Erectile Dysfunction Therapy II: Novel Pharmacotherapy and Innovative Technology. 2016 , 109-121	2

272	Psychosocial Aspects Related to Erectile Dysfunction. 2006 , 105-122	1
271	Erectile Dysfunction: Pharmacological Therapy. 2011 , 675-696	1
270	Practical Guidelines for the Treatment of Erectile Dysfunction and Peyronie's Disease. 2020 , 357-392	1
269	Sex and Natural Sexual Enhancement: Sexual Techniques, Aphrodisiac Foods, and Nutraceuticals. 2017 , 413-432	3
268	Introduction: The Need of Sexual Medicine in Contemporary Psychiatry and the Need of Psychiatry in the Growing Field of Sexual Medicine. 2018 , 1-4	1
267	Central Nervous Mechanisms of Muscle Pain: Ascending Pathways, Central Sensitization, and Pain-Modulating Systems. 2010 , 105-175	2
266	The Role of Nitric Oxide in the Peripheral Nervous System. 2000 , 277-313	3
265	History of Premature Ejaculation. 2013 , 5-24	15
264	3 Wetenschappelijk onderzoek naar seksualiteit. 2009 , 45-67	2
263	Nitroprusside, ACE Inhibitors, and Other Cardiovascular Agents. 2007 , 983-999	1
262	Sexual Dysfunction in Men and Women. 2011 , 778-816	2
261	Acquired Neuropathies. 2002 , 937-1041	8
260	Penile prosthesis surgery: Indications and penoscrotal approach. 2020 , 44, 377-381	0
259	Klinisch-psychologische Aspekte der erektilen Dysfunktion: Die Bedeutung psychosozialer Faktoren. 2001 , 30, 97-103	2
258	A Review of Hypogonadism and Erectile Dysfunction Among HIV-Infected Men During the Pre- and Post-HAART Eras: Diagnosis, Pathogenesis, and Management. 2005 , 19, 869-885	1
257	Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy. 2000 , 320, 69-71	30
256	THE CAUSES OF PATIENT DROPOUT FROM PENILE SELF-INJECTION THERAPY FOR IMPOTENCE. 1999 , 1291-1294	2
255	SILDENAFIL CITRATE AFTER RADICAL RETROPUBIC PROSTATECTOMY. 1999 , 1614	9

254	POTENTIATION OF ERECTILE RESPONSE AND cAMP ACCUMULATION BY COMBINATION OF PROSTAGLANDIN E1 AND ROLIPRAM, A SELECTIVE INHIBITOR OF THE TYPE 4 PHOSPHODIESTERASE (PDE 4). 1999 , 1848	1
253	INCIDENCE OF ERECTILE DYSFUNCTION IN MEN 40 TO 69 YEARS OLD:. 2000 , 460	21
252	EFFECT OF THE PLANT-EXTRACT OSTHOLE ON THE RELAXATION OF RABBIT CORPUS CAVERNOSUM TISSUE IN VITRO. 2000 , 1975-1980	4
251	Switching from intracavernous prostaglandin E1 injections to oral sildenafil citrate in patients with erectile dysfunction: results of a multicenter European study. The Sildenafil Multicenter Study Group. 2000 , 164, 708-11	8
250	Erectile dysfunction in patients with spina bifida is a treatable condition. 2000 , 164, 958-61	18
249	EFFICACY, SAFETY AND PATIENT ACCEPTANCE OF SILDENAFIL CITRATE AS TREATMENT FOR ERECTILE DYSFUNCTION. 2000 , 1192-1196	7
248	EFFECT OF SILDENAFIL CITRATE ON POST-RADICAL PROSTATECTOMY ERECTILE DYSFUNCTION. 2000 , 1935-1938	2
247	CLINICAL EFFICACY OF SILDENAFIL IN PATIENTS ON CHRONIC DIALYSIS. 2001 , 819-821	2
246	IMPROVEMENT IN EMOTIONAL WELL-BEING AND RELATIONSHIPS OF USERS OF SILDENAFIL. 2001 , 1774-1778	1
245	SILDENAFIL VERSUS THE VACUUM ERECTION DEVICE. 2001 , 1779-1781	4
244	Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses. 2002 , 1332-1336	35
243	A Prospective Study Comparing Paroxetine Alone Versus Paroxetine Plus Sildenafil in Patients With Premature Ejaculation. 2002 , 2486-2489	6
242	High prevalence of erectile dysfunction after renal transplantation. 2000 , 69, 2121-4	73
241	Transient renal effects of sildenafil in male kidney transplant recipients. 2001 , 72, 1331-3	10
240	Treatment of multiple sclerosis: recent trials and future perspectives. 1999 , 12, 279-93	44
239	Current concepts in the management of post-radical prostatectomy impotence. 1998 , 8, 535-40	3
238	Pharmacological treatment of erectile dysfunction. 1999 , 9, 547-51	5
237	Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. 2000 , 106, 373-84	186

236	Sildenafil pre-treatment promotes decompression sickness in rats. 2013 , 8, e60639	16
235	Ups and downs of Viagra: revisiting ototoxicity in the mouse model. 2013 , 8, e79226	14
234	Transcriptome-based identification of new anti-inflammatory and vasodilating properties of the n-3 fatty acid docosahexaenoic acid in vascular endothelial cell under proinflammatory conditions [corrected]. 2015 , 10, e0129652	7
233	Impact of Mitochondrial Ca ²⁺ -Sensitive Potassium (mBKCa) Channels in Sildenafil-Induced Cardioprotection in Rats. 2015 , 10, e0144737	34
232	Da impotência à disfunção erétil: destinos da medicalização da sexualidade. 2009 , 19, 637-658	8
231	The GAY MEN Sex Studies: design of an online registration of sexual behaviour of men having sex with men and preliminary results (GAMESSS-study). 2013 , 21, 48-53	7
230	Sildenafil in the treatment of erectile dysfunction: an overview of the clinical evidence. 2006 , 1, 403-14	36
229	Tadalafil in the treatment of erectile dysfunction; an overview of the clinical evidence. 2006 , 1, 439-49	12
228	Repurposing of Existing Statin Drugs for Treatment of Microbial Infections: How Much Promising?. 2019 , 19, 224-237	16
227	Effect of tadalafil on erectile dysfunction in male patients with diabetes mellitus. 2007 , 64, 399-404	5
226	Tadalafil: A Comprehensive Update. 2004 , 2, 225-246	1
225	Sildenafil does not influence hepatic venous pressure gradient in patients with cirrhosis. 2008 , 14, 6208-12	26
224	Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. 2016 , 18, 723-31	8
223	A short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment tool. 2015 , 4, 175-81	11
222	Human tissue kallikrein-1 protects against the development of erectile dysfunction in a rat model of hyperhomocysteinemia. 2019 , 21, 508-515	4
221	A meta-analysis on efficacy and tolerability of sildenafil for erectile dysfunction in patients with diabetes mellitus. 2018 , 39, 1-6	4
220	The Influence of Treatment-emergent Adverse Reactions on Selecting Phosphodiesterase Type 5 Inhibitors. 2006 , 47, 272	1
219	Prevalence of Premature Ejaculation among Patients with Type 2 Diabetes in a Tertiary Health Institution: A Cross-Sectional Study. 2020 , 10, 88-97	1

- 218 Current use of phosphodiesterase inhibitors in urology. **2015**, 41, 88-92 10
- 217 An Efficient and Rapid Synthesis of 1H-Pyrazolo[3,4-d]-pyrimidin-4(5H)-one in Water. **2021**, 41, 3701
- 216 Efficacy of the Orally Disintegrating Strip Sildenafil for the Treatment of Erectile Dysfunction: A Prospective, Randomized Trial. **2021**, 9, 100453 0
- 215 Potential Clinical Impact of Nitric Oxide and Nitric Oxide Inhibitors in the Periphery. **2000**, 327-348
- 214 Andrology. **2000**, 1701-1717
- 213 LACK OF DIAGNOSTIC TOOLS TO PROVE ERECTILE DYSFUNCTION:. **2000**, 91 1
- 212 Sexual Rehabilitation After Therapy for Localized Disease. **2000**, 211-221
- 211 Changes in Men as They Age: The Menopause. **2000**, 111-133
- 210 Plant antecedents of, and analogy to Viagra. **2000**, 87-107
- 209 Vasodilators (Other Agents and Drug Classes). **2000**, 248-272
- 208 Tratamiento de disfunci3n sexual en un paciente esquizofr3nico con citrato de sildenafil (Viagra®). **2000**, 7, 131-133
- 207 SILDENAFIL VERSUS INTRACAVERNOUS INJECTION THERAPY: EFFICACY AND PREFERENCE IN PATIENTS ON INTRACAVERNOUS INJECTION FOR MORE THAN 1 YEAR. **2000**, 1197-1200 2
- 206 Erectile dysfunction: An update of diagnosis and management. **2000**, 2000, 0
- 205 Erectile Dysfunction. **2001**, 343-351
- 204 Erektile Dysfunktion. **2001**, 80-103
- 203 Herzkrankheiten und Sexualit3t – Gef3hrdung des kranken Herzens durch Sexualit3t oder Gef3hrdung der Sexualit3t durch das kranke Herz. **2001**, 177-184
- 202 Psychosoziale Probleme. **2001**, 387-399
- 201 DIRECT EFFECTS OF SELECTIVE TYPE 5 PHOSPHODIESTERASE INHIBITORS ALONE OR WITH OTHER VASODILATORS ON THE ERECTILE RESPONSE IN CATS. **2001**, 1004-1009

- 200 LONG-TERM EFFICACY OF SILDENAFIL AND TACHYPHYLAXIS EFFECT. **2001**, 927-931 1
- 199 Anatomie, Physiologie, Pathophysiologie. **2002**, 13-101
- 198 Pharmaka mit Wirkung auf den glatten Muskel. **2002**, 281-294
- 197 Therapie. **2002**, 129-246
- 196 Management of impotence in diabetes. **2002**, 69-107
- 195 Immunolocalization of Multidrug Resistance Protein 5 in the Human Genitourinary System. **2002**, 2271-2275
- 194 RE: LONG-TERM EFFICACY OF SILDENAFIL AND TACHYPHYLAXIS EFFECT. **2002**, 206
- 193 Diagnostic Steps In The Evaluation Of Patients With Erectile Dysfunction. **2002**, 615-620 1
- 192 Andrologie. **2003**, 487-493
- 191 Metabolic and Toxic Encephalopathies. **2003**, 991-1009 1
- 190 Erectile Dysfunction Due to Aortic Disease. **2003**, 139-141
- 189 Sexualität. **2004**, 259-298
- 188 Sexual Function and Androgens. **2004**, 229-233
- 187 Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease. **2004**, 179-194
- 186 Management of Erectile Dysfunction. **2004**, 65-88
- 185 Treating Psychogenic Erectile Dysfunction. **2004**, 235-240
- 184 Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. **2004**, 159-181
- 183 The phosphodiesterase V inhibitor low responder study (PILRS) in patients with erectile dysfunction: A rationale for a PDE5 inhibitor combination therapy. **2004**, 169-181

182 A Psychiatric Perspective on Psychogenic Erectile Dysfunction. **2004**, 73-86

181 Office Evaluation and Diagnostic Testing for Erectile Dysfunction. **2004**, 27-36

180 Management of Erectile Dysfunction Following Radical Prostatectomy. **2004**, 431-458

179 Hypogonadism in Men With Chronic Renal Failure. **2004**, 227-245

178 Sildenafil Citrate and the Nitric Oxide/Cyclic Guanosine Monophosphate Signaling Pathway. **2004**, 89-116

177 Oral Type 5 Phosphodiesterase Therapy for Male and Female Sexual Dysfunction. **2004**, 107-119

176 Erectile Dysfunction. **2004**, 24-28

175 Molecular processing of sildenafil in endothelial function: potential applications in cardiovascular diseases. **2004**, 129-142

174 Sildenafil, pharmacology of a highly selective PDE5 inhibitor. **2004**, 15-33

2

173 Autonomic Neuropathy.

172 Human sexuality. **2004**, 96-108

171 Middle adulthood: ages 40-54. **2004**, 92-113

170 Neural Mechanisms of Sleep-Related Penile Erections. **2005**, 305-317

1

169 Autonomic Systems to the Urinary Bladder and Sexual Organs. **2005**, 299-322

1

168 Erectile Dysfunction Assessment and Management in Primary Care Practice. **2005**, 149-183

167 Erectile Dysfunction. **2005**, 193-223

166 Sildenafil. **2006**, 3133-3137

165 Erectile Dysfunction due to Aortic Disease. **2006**, 157-159

164 References. **2006**, 811-946

163 Erectile Dysfunction. **2006**, 395-410

162 Pharmacological and Pharmaceutical Profiling. **2006**, 103-134

1

161 Structural Genomics. **2007**, 1-27

160 Treatment of Erectile Dysfunction in Chronic Kidney Disease. **2008**, 783-790

159 Impotence. **2009**, 385-393

158 DRUGS THAT ACT ON THE CEREBRAL AND PERIPHERAL ARTERIAL AND VENOUS CIRCULATIONS. **2009**, 431-448

157 Störungen der Erektion, Kohabitation und Ejakulation. **2009**, 283-324

156 Impact of Androgen Deprivation on Male Sexual Function. **2009**, 163-175

155 Toxic Optic Neuropathies. **2009**, 97-114

154 Effect of Phyto-Extract Fermented Mixture (MP119) on the Sexual Functions and on the Toxicities of Cadmium. **2009**, 38, 1724-1731

153 Tissue Bioengineering. **2010**, 147-154

152 Sexual Dysfunction, Male. 1

151 Erectile Dysfunction. **2010**, 364-368.e1

150 Disorders of Erection, Cohabitation, and Ejaculation. **2010**, 279-321

1

149 Erectile Dysfunction. **2010**, 1205-1213

148 Management of Erectile Dysfunction. 134-145

147 Oral Therapy for Erectile Dysfunction. **2011**, 93-106

0

146 Sexual Disorders. **2010**, 706-710

145 Routine cardiac assessment is not necessary for all patients with erectile dysfunction. **2011**, 5, 349-51

144 Prosthetic Surgery for Erectile Dysfunction. **2012**, 780-791.e2

143 Men's Issues in Sexuality and Aging. **2012**, 199-227

142 Erectile Dysfunction. **2012**, 560-566.e2

141 An unusual adverse effect of sildenafil citrate: acute myocardial infarction in a nitrate-free patient. **2012**, 2012, 4

140 Phosphodiesterase-5 Inhibitors in Cardioprotection. **2013**, 439-458

139 Nitrate: The Ideal Drug Action for Isolated Systolic Hypertension in Elderly?. **2014**, 509-518

138 Geriatric Sexuality. **2014**, 377-415

137 Diabetische Folgeerkrankungen. **2014**, 239-296

136 Assessment of patient satisfaction with a multidisciplinary approach to erectile dysfunction. **1998**, 1, 157-159

135 Sildenafil as a psychological treatment. **1998**, 1, 143-146

134 Nonsurgical Treatments for Erectile Dysfunction: Oral, Topical, Intracavernous, and Vacuum Devices. **1999**, 39-52

133 Sildenafil (Viagra) has been reported to be an effective treatment for erectile dysfunction. **1999**, 46, 357

132 THE EFFECT OF SILDENAFIL ON APOMORPHINE-EVOKED INCREASES IN INTRACAVERNOUS PRESSURE IN THE AWAKE RAT. **1999**, 1707-1712

131 Sildenafil (Viagra) may cause nasal stuffiness. **1999**, 19, 468 1

130 Historical Perspective of Raynaud's Phenomenon. **2015**, 1-11

129 Difference of opinion - Is There a Space to Improve the Treatment of Erectile Dysfunction in the Next Years? Opinion: YES. **2015**, 41, 830-1

- 128 Long-term results of radical retropubic prostatectomy. **2015**, 23, 120 1
- 127 Phosphodiesterase type V inhibitors. **2016**, 734-742
- 126 Kallikrein-kinin system: is it the fountain of youth?. **2017**, 19, 138-139
- 125 Couples Therapy and Counseling. **2016**, 365-370
- 124 Urologic/Clinical Treatment of Erectile Dysfunction. **2016**, 53-63
- 123 Comparative Relaxant Effects of Ataciguat and Zaprinast on Sheep Sphincter of Oddi. **2016**, 33, 453-7
- 122 The Impact of Biotechnology on Reproductive Medicine. **2016**, 4,
- 121 Treating Erectile Dysfunctions. **2017**, 201-225
- 120 Sex and Pharmacological Sexual Enhancement. **2017**, 387-411
- 119 The blue pill (sildenafil) and its descendants: an overview. **2017**, 30, 129-133
- 118 Is there a relation between priapism occurring after penile doppler ultrasonography and international erectile function index score and erection hardness score levels?. **2017**, 43, 439-743 0
- 117 Erektile disfonksiyonlu diabetes mellitus olgularında penil Doppler ultrasonografi bulguları. **2017**, 56, 193-199
- 116 ERECTILE DYSFUNCTION IN HAEMODIALYSIS PATIENTS- A CROSS-SECTIONAL STUDY AT VAATSALYA HOSPITAL, SHIMOGA, INDIA. **2018**, 7, 471-473
- 115 Patient-Reported Outcomes in Sexual Medicine. **2018**, 33-40
- 114 Efficacy and Safety Evaluation of Sildenafil Citrate in the Form of 50 mg Orodispersible Tablets Controlled by Placebo. **2018**, 07, 249-258
- 113 The Phosphodiesterase-5 Inhibitors and Prostate Cancer [What We Rely Know About It?]. **2019**,
- 112 For happy and healthy sexual life of people with spinal cord injury. **2019**, 3, 11-13 1
- 111 Erectile dysfunction: drug treatment. **2019**, 65, 1133-1142 1

- 110 Stories of drug repurposing for pancreatic cancer treatmentPast, present, and future. **2020**, 231-272 1
- 109 Theoretical study on thermodynamic properties of NO gas. **2020**, 69, 053301 2
- 108 Experience of Application of Phosphodiesterase Inhibitor 5 Type Eroton (Sildenafil Citrate) in Therapy Erectile Dysfunction. **2020**, 26-32 1
- 107 Pharmacological management of male sexual dysfunction. **2020**, 63, 356-364
- 106 Determination of The Effectiveness of Sildenafil on Human Smooth Muscle Cells. 1-1
- 105 [Effect of tadalafil 5mg daily treatment on penile haemodynamics in patients with erectile dysfunction]. **2020**, 20, 49-49
- 104 Combination of the Phosphodiesterase Inhibitors Sildenafil and Milrinone Induces Cardioprotection With Various Conditioning Strategies. **2020**, 76, 684-691 0
- 103 Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. **2021**, 19, 301-312 2
- 102 Hypertension and reproductive dysfunction: a possible role of inflammation and inflammation-associated lymphangiogenesis in gonads. **2020**, 134, 3237-3257 2
- 101 Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy. **2021**, 127, 560-566
- 100 Erectile dysfunction medical treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with retinitis pigmentosa and side effects. **2020**, 92,
- 99 Pharmacology of Male Sexual Function. **2020**, 159-174
- 98 E. **2005**, 381-444
- 97 Nutritional and Toxic Optic Neuropathies. **2007**, 150-170
- 96 Angiography in Pharmacologic Retinal Toxicity. **2009**, 199-213
- 95 Penile Prostheses. **2006**, 289-299
- 94 Topical and Intra-Urethral Therapy. **2006**, 303-321
- 93 Vacuum Erection Devices. **2006**, 323-330

92	Gene Therapy for Erectile Dysfunction. 2006 , 467-483	
91	Cardiac Issues Related to Erectile Dysfunction. 2006 , 61-75	
90	Female Sexual Dysfunction: Effective Treatment Strategies for All Ages. 2007 , 106-123	
89	Original Gold Standard Clinical Trial of Sildenafil in ED. 2007 , 45-48	
88	Use of Stem Cells in the Treatment of Erectile Dysfunction. 2021 , 347-365	
87	Sildenafil: from the bench to the bedside. 2000 , 163, 1171-5	6
86	Ocular safety of Viagra, (sildenafil citrate). 1999 , 97, 115-25; discussion 125-8	29
85	Sildenafil: a milestone in the treatment of impotence. 1998 , 169, 112-3	6
84	Systematic review of randomised controlled trials of sildenafil (Viagra) in the treatment of male erectile dysfunction. 2001 , 51, 1004-12	19
83	Randomised controlled trial of pelvic floor muscle exercises and manometric biofeedback for erectile dysfunction. 2004 , 54, 819-25	45
82	Future strategies for treating erectile dysfunction. 2002 , 4 Suppl 3, S48-53	1
81	Four-year review of sildenafil citrate. 2002 , 4 Suppl 3, S26-38	9
80	The effect of sildenafil citrate on uterine and clitoral arterial blood flow in postmenopausal women. 2004 , 6, 51	1
79	Optimizing outcomes of oral therapy for patients with erectile dysfunction. 2003 , 5 Suppl 7, S28-34	2
78	Oral pharmacotherapy and the contemporary evaluation and management of erectile dysfunction. 2003 , 5 Suppl 7, S9-S20	1
77	Viagra and broken hearts. 2000 , 46, 257-9, 267-9	1
76	Relation between intracavernosal dose of prostaglandin Pge 1 and mean duration of erection in men with different underlying causes of erectile dysfunction. 2007 , 48, 76-80	3
75	Viagra! Are we ready?. 1998 , 44, 2103-5	0

- 74 Erectile dysfunction in patients with cardiovascular disease. **2006**, 14, 139-146
- 73 Sildenafil (viagra) and the heart. **2001**, 8, 63-6
- 72 A randomized, double-blind, placebo-controlled crossover study of Captopril for the treatment of mild or mild to moderate erectile dysfunction in Thai male. **2013**, 10, 310-5 3
- 71 Effect of sildenafil on erectile dysfunction and improvement in the quality of sexual life in China: a multi-center study. **2015**, 8, 11539-43 5
- 70 Virginia Johnson-human sexuality pioneer. **2013**, 2, 321-3
- 69 The role of sildenafil in the development of transplant arteriosclerosis in rat aortic grafts. **2017**, 9, 4914-4924
- 68 Post-coital death in chronic sildenafil abuser. **2020**, 17, 169-172
- 67 Gender differences in the association between sexual satisfaction and quality of life. 1-22 1
- 66 The only available certification for sexual medicine: The Fellow of the European Committee Sexual Medicine (FECSM). **2021**, 1
- 65 Erectile dysfunction in renal transplant patient - A prospective observational study. **2021**, 15, 307
- 64 INFLUENCE OF RADIOACTIVE BACKGROUND ON SEXUAL FUNCTION IN MEN FROM DIFFERENT REGIONS OF UKRAINE.. **2021**, 26, 479-497
- 63 Evaluating the quality of asynchronously- versus synchronously-delivered virtual care: Differences in rates of reported medication side effects among patients with erectile dysfunction on a direct-to-consumer telehealth platform.. **2021**, 0
- 62 How do phosphodiesterase-5 inhibitors affect cancer? A focus on glioblastoma multiforme.. **2022**, 1 0
- 61 Chapter 1. Introduction and Historical Overview of Drug Repurposing Opportunities. **2022**, 1-13 2
- 60 Migraine Is Associated With High Risk of Erectile Dysfunction: A Systematic Review and Cumulative Analysis.. **2022**, 0
- 59 Antiviral drug discovery by targeting the SARS-CoV-2 polyprotein processing by inhibition of the main protease.. **2022**, 10, e12929 1
- 58 Pharmacological developments in antihypertensive treatment through nitric oxide- cGMP modulation. **2022**, 1
- 57 Traditional Chinese medicine, Ayurveda, and fertility. **2022**, 209-247

- 56 GLYCAEMIC YEARS RATHER THAN GLYCAEMIC CONTROL CORRELATES WITH ERECTILE DYSFUNCTION. **2022**, 34-35
- 55 Efficacy of phosphodiesterase type 5 inhibitors in patients with erectile dysfunction after nerve-sparing radical prostatectomy: a systematic review and meta-analysis.. **2022**, 11, 124-138 1
- 54 Therapeutic enzymes as non-conventional targets in cardiovascular impairments:A Comprehensive Review.. **2021**, 1
- 53 Recent developments in cGMP research: From mechanisms to medicines and back.. **2022**, 0
- 52 Erectile dysfunction in young patients and elderly patients by sexual encounter profile: A comparative study.. **2022**,
- 51 Clinical outcomes of sildenafil application in patients of poor endometrial development. **2022**, 2, 14-19
- 50 Fast and semiquantitative screening for sildenafil in herbal over-the-counter formulations with atmospheric pressure solid analysis probe (ASAP) to prevent medicinal adulteration.. **2022**, 214, 114720 0
- 49 Enhancing autophagy in Alzheimer's disease through drug repositioning.. **2022**, 237, 108171 4
- 48 HINGRL: predicting drug-disease associations with graph representation learning on heterogeneous information networks. **2021**, 6
- 47 The Effect of Health Literacy on Men Seeking Medical Attention for Erectile Dysfunction.. **2021**, 13, e20424 0
- 46 Drug Repurposing for Influenza Virus Polymerase Acidic (PA) Endonuclease Inhibitor. **2021**, 26, 1
- 45 Use of dental drill handpiece to remove steel nut causing penile strangulation: a case report and review of the literature.. **2022**, 16, 158
- 44 Pharmacotherapy for Erectile Dysfunction in 2021 and Beyond.. **2022**, 49, 209-217 0
- 43 Rehabilitation of dementia. 509-534
- 42 Disease-modifying therapy for multiple sclerosis in clinical practice. 583-603
- 41 table1.docx. **2020**,
- 40 table2.docx. **2020**,
- 39 table3.docx. **2020**,

38	table4.docx. 2020 ,	
37	table5.docx. 2020 ,	
36	table6.docx. 2020 ,	
35	table7.docx. 2020 ,	
34	Signaling cascades in the failing heart and emerging therapeutic strategies.. 2022 , 7, 134	1
33	Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers.. 2022 ,	
32	Bibliographie. 2015 , 147-153	
31	Cardiovascular/Stroke Risk Assessment in Patients with Erectile Dysfunction: A Role of Carotid Wall Arterial Imaging and Plaque Tissue Characterization Using Artificial Intelligence Paradigm: A Narrative Review. 2022 , 12, 1249	0
30	Hotspots and frontiers in pulmonary arterial hypertension research: a bibliometric and visualization analysis from 2011 to 2020. 2022 , 13, 14667-14680	0
29	Sildenafil in Emergency Treatment of Biliary Colic: A pilot randomized controlled trial.	
28	An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022. 2022 , 27, 4964	3
27	Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2.	2
26	Advanced formulations and nanotechnology-based approaches for pulmonary delivery of sildenafil: A scoping review. 2022 , 350, 308-323	0
25	Computational Methods for Drug Repurposing. 2022 , 37-48	0
24	Design, synthesis and chemoinformatic studies of new thiazolopyrimidine derivatives as potent anticancer agents via phosphodiesterase-5 inhibition and apoptotic inducing activity. 2023 , 1272, 134216	2
23	NİTRAKAVERNOSAL SİLİDİNAFİLİN SİANLARDA DUTASTERİD TEDAVİSİ SONRASI GELİR EREKTİL DİSFONKSİYON İZERİNE YARARLI ETKİSİ 908-918	0
22	Alterations in endothelial nitric oxide synthase activity and their relevance to blood pressure. 2022 , 205, 115256	0
21	Erectile Dysfunction: Medical Therapy and Rehabilitation. 2023 , 35-45	0

20	Drug-Disease Association Prediction Using Heterogeneous Networks for Computational Drug Repositioning. 2022 , 12, 1497	0
19	Introduction: History of Sexual Medicine. 2023 , 1-12	0
18	Conservative Non-surgical Options for Erectile Dysfunction.	0
17	Sildenafil in Emergency Treatment of Biliary Colic: A pilot randomized controlled trial.	0
16	Leech-Centipede Granules Suppress EndMT to Improve Erectile Dysfunction in Rats with Diabetes Mellitus via TGF- β /Smad Pathway. 2023 , 29, 28-36	0
15	Comparison of penile doppler ultrasound versus Erection Hardness Score during intracavernous injection test in predicting refractory erectile dysfunction.	0
14	Erectile Dysfunction Caused by Cavernous Leakage.	0
13	The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction.	0
12	Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With Hypoactive Sexual Desire Disorder. 2023 , 6, e2254313	0
11	EFFICACY AND SAFETY OF ORAL SILDENAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION: A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF 329 PATIENTS. 1998 , 52, 375-379	17
10	Advances in S-N bond formation via electrochemistry: a green route utilizing diverse sulfur and nitrogen sources. 2023 , 25, 2524-2540	0
9	Does Testosterone Salvage PDE5i Non-Responders? A Scoping Review. 2023 , 4, 117-127	0
8	Testicular torsion in vivo models: Mechanisms and treatments.	0
7	Management of male erectile dysfunction: From the past to the future. 14,	0
6	Effects of stem cell-derived exosome therapy on erectile dysfunction: a systematic review and meta-analysis of preclinical studies. 2023 , 11,	0
5	Multiple Cerebral Infarctions and Rhabdomyolysis After Sildenafil Citrate (Viagra®) Intoxication: A Case Report. 2023 ,	0
4	The association of genetically proxied sildenafil with fertility, sexual activity, and wellbeing: a Mendelian randomisation study.	0
3	Sildenafil (Viagra) Reaches the parts other drugs cannot reach. 1998 , 52, 359-359	1

- 2 Current trends in pharmacotherapy of erectile dysfunction. **2023**, 37, 5-9 o
- 1 History of penile implants: from implants made of bone to modern inflatable penile implants. o